

## Exhibit 1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

According to P.F. Labs's accounting records in SAP, P.F. Labs (SAP company code 109) earned \$1.7 million in 10% markup from 2008 to 2014 related to Purdue through G/L account 404030 (Sales Commission).

G/L Account Company Code		404030 109	Sales Commission							
DocumentNo	Pstng Date	Doc. Date	Year/month	Type	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/> 100007266	31.03.2009	31.03.2009	2009/03	SA	TS0309_TOT COMM	404030	OXI		16.291,00-	USD
<input type="checkbox"/> 100007486	30.04.2009	30.04.2009	2009/04	SA	TS0409_TOTCOMM	404030	MSG	Totowa Commission	51.277,83-	USD
<input type="checkbox"/> 100007487	30.04.2009	30.04.2009	2009/04	AB	TS0409_TOTCOMM	404030	MSG	Totowa Commission	51.277,83	USD
<input type="checkbox"/> 100007488	30.04.2009	30.04.2009	2009/04	SA	TS0409_TOTCOMM	404030	MSG	Totowa Commission	51.277,83-	USD
<input type="checkbox"/> 100007488	30.04.2009	30.04.2009	2009/04	SA	TS0409_TOTCOMM	404030	OXI	Totowa Commission	22.007,58-	USD
<input type="checkbox"/> 100007682	31.05.2009	31.05.2009	2009/05	SA	TS0509_TOTCOMM	404030	UNI		11.445,82-	USD
<input type="checkbox"/> 100007682	31.05.2009	31.05.2009	2009/05	SA	TS0509_TOTCOMM	404030	OXI		11.190,47-	USD
<input type="checkbox"/> 100007682	31.05.2009	31.05.2009	2009/05	SA	TS0509_TOTCOMM	404030	OXY		32.054,13-	USD
<input type="checkbox"/> 100007872	30.06.2009	30.06.2009	2009/06	SA	TS0609_TOTOCOMM	404030	OXI	Commission	5.559,65-	USD
<input type="checkbox"/> 100007872	30.06.2009	30.06.2009	2009/06	SA	TS0609_TOTOCOMM	404030	UNI	Commission	20.591,10-	USD
<input type="checkbox"/> 100008112	31.08.2009	31.08.2009	2009/08	SA	TS0809_TOTCOMM	404030	OXY		17.558,06-	USD
<input type="checkbox"/> 100008840	31.12.2009	31.12.2009	2009/12	SA	TS1209_COMM CORR	404030	OXY	Correct commission for Aug 09	590,08	USD
<input type="checkbox"/> 100009889	30.09.2010	30.09.2010	2010/09	SA	TS0910_TOTCOMM	404030	ORF		28.609,09-	USD
<input type="checkbox"/> 100010050	31.10.2010	31.10.2010	2010/10	SA	TS1010_TOT COMM	404030	ORF	Totowa commission Oct	93.690,44-	USD
<input type="checkbox"/> 100011127	31.05.2011	31.05.2011	2011/05	SA	TS0511_TOTOWA CO	404030	ORF		32.426,15-	USD
<input type="checkbox"/> 100011920	31.12.2011	31.12.2011	2011/12	SA	TS1211_TOTOWA CO	404030	ORF		34.201,87-	USD
<input type="checkbox"/> 100012627	30.06.2012	05.07.2012	2012/06	SA	JAS20120609	404030	ORF	10% commisson on Totowa June Production	23.791,65-	USD
<input type="checkbox"/> 100013041	31.10.2012	05.11.2012	2012/10	SA	JAS20121006	404030	ORF	10% commisson on Totowa June Production	14.337,76-	USD
<input type="checkbox"/> 100013760	31.05.2013	04.06.2013	2013/05	SA	JAS20130506	404030	ORF	Commission for Totowa May production of ORF	21.744,38-	USD
<input type="checkbox"/> 100015113	30.09.2014	30.09.2014	2014/09	SA	JC0914_TOTOWA CO	404030	ORF	Commission for Totowa Sept production of ORF	27.768,96-	USD
									1.700.907,13-	USD

Note:

- The SAP screenshot does not include all entries – excerpt version shown.

## Exhibit 1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

According to P.F. Labs's accounting records in SAP, transactions related to the CMO services were recognized as follows in P.F. Labs' (SAP company code 109) accounting records (2014 is illustrated below).

Account Number	Account Description	DR	CR
<b>Manufacturing costs:</b>			
503000	Cost of Goods Standard - Manufacturing	\$ 277,690	
404000	Gross Sales - Manufacturing		\$ (277,690)
<b>Sales commissions:</b>			
102208	Purdue Pharma L.P.	\$ 27,769	
404030	Sales Commission		\$ (27,769)
<b>Intercompany recognition:</b>			
102208	Purdue Pharma L.P.	\$ 277,690	
102999	Virtual Company		\$ (277,690)

Note:

- G/L account 102999 – Virtual Company is a pooling account for sweep entries before allocating amounts to specific companies.

## Exhibit 1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

These entries appear in P.F. Labs's accounting records in SAP as follows (2014 is illustrated below, the last year of the manufacturing agreement).

Manufacturing costs:

Doc.Type : ZG ( G/L acct doc Sweep ) Normal document				
Doc. Number	100015097	Company Code	109	Fiscal Year 2014
Doc. Date	02.10.2014	Posting Date	30.09.2014	Period 09
Calculate Tax	<input type="checkbox"/>			
Ref.Doc.	XXX	Overall No.	0100015097109 14	
Doc. Currency	USD			
Doc. Hdr Text	Mfg Sweep Entry 09 2014			

Itm	PK	Account	Account short text	Amount	Text
1	50	501021	Prod Var Reclass	3.855,85-	Mfg Variance-109 Mfg Sweep Entry 09 2014
2	40	102999	Virtual Company	3.855,85	Mfg Variance-109 Mfg Sweep Entry 09 2014
3	40	503000	COGs std MFG	277.689,56	F output to Mfg Mfg Sweep Entry 09 2014
4	50	404000	Gross Sales MFG	277.689,56-	F output to Mfg Mfg Sweep Entry 09 2014

10% markup:

Doc.Type : SA ( G/L account document ) Normal document				
Doc. Number	100015113	Company Code	109	Fiscal Year 2014
Doc. Date	30.09.2014	Posting Date	30.09.2014	Period 09
Calculate Tax	<input type="checkbox"/>			
Ref.Doc.	JC0914_TOTOWA CG	Overall No.	0100138628208 14	
Doc. Currency	USD			
Doc. Hdr Text	Totowa ORF Commission Sep			

Itm	PK	Account	Account short text	Amount	Text
1	50	404030	Sales Commission	27.768,96-	Commission for Totowa Sept production of ORF
2	40	102208	Purdue Pharma L.P.	27.768,96	

Intercompany recognition:

Doc.Type : ZG ( G/L acct doc Sweep ) Normal document				
Doc. Number	100015125	Company Code	109	Fiscal Year 2014
Doc. Date	08.10.2014	Posting Date	30.09.2014	Period 09
Calculate Tax	<input type="checkbox"/>			
Ref.Doc.	XXX	Overall No.	0100027587307 14	
Doc. Currency	USD			
Doc. Hdr Text	Dist Sweep Entry 09 2014			

Itm	PK	Account	Account short text	Amount	Text
1	50	102999	Virtual Company	277.689,56-	QC sample offset Dist Sweep Entry 09 2014
2	40	102208	Purdue Pharma L.P.	277.689,56	QC sample offset Dist Sweep Entry 09 2014

## Exhibit 1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

These entries appear in the P.F. Labs accounting records in SAP as follows (2008, the first payment in the time period reviewed, is illustrated below).

Manufacturing costs:

Doc.Type : ZG ( G/L acct doc Sweep ) Normal document					
Doc. Number	100004430	Company Code	109	Fiscal Year	2008
Doc. Date	04.02.2008	Posting Date	31.01.2008	Period	01
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	XXX	Overall No.	0100004430109 08		
Doc. Currency	USD				
Doc. Hdr Text	Mfg Sweep Entry 01 2008				

Itm	PK	Account	Account short text	Amount	Text
1	40	501021	Prod Var Reclass	109.173,70	Mfg Variance-109 Mfg Sweep Entry 01 2008
2	40	501021	Prod Var Reclass	148,67	Mfg Variance-109 Mfg Sweep Entry 01 2008
3	50	102999	Virtual Company	109.173,70-	Mfg Variance-109 Mfg Sweep Entry 01 2008
4	50	102999	Virtual Company	148,67-	Mfg Variance-109 Mfg Sweep Entry 01 2008
5	40	503000	COGS std MFG	465.830,88	F output to Mfg Mfg Sweep Entry 01 2008
6	40	503000	COGS std MFG	98.132,79	F output to Mfg Mfg Sweep Entry 01 2008
7	50	404000	Gross Sales MFG	465.830,88-	F output to Mfg Mfg Sweep Entry 01 2008
8	50	404000	Gross Sales MFG	98.132,79-	F output to Mfg Mfg Sweep Entry 01 2008

10% markup:

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100004421	Company Code	109	Fiscal Year	2008
Doc. Date	31.01.2008	Posting Date	31.01.2008	Period	01
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	TS0108_TOT 10%	Overall No.	0100032348208 08		
Doc. Currency	USD				
Doc. Hdr Text	Totowa commission				

Itm	PK	Account	Account short text	Tx	Amount	Text
1	50	404030	Sales Commission		46.583,09-	Totowa Commission 0108
2	50	404030	Sales Commission		9.813,28-	Totowa Commission 0108
3	40	102208	Purdue Pharma L.P.		56.396,37	Totowa Commission 0108

Intercompany recognition:

Doc.Type : ZG ( G/L acct doc Sweep ) Normal document					
Doc. Number	100004451	Company Code	109	Fiscal Year	2008
Doc. Date	06.02.2008	Posting Date	31.01.2008	Period	01
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	XXX	Overall No.	0100032410208 08		
Doc. Currency	USD				
Doc. Hdr Text	Dist Sweep Entry 01 2008				

Itm	PK	Account	Account short text	Amount	Text
1	50	102999	Virtual Company	465.830,88-	QC sample offset Dist Sweep Entry 01 2008
2	50	102999	Virtual Company	98.132,79-	QC sample offset Dist Sweep Entry 01 2008
3	40	102208	Purdue Pharma L.P.	465.830,88	QC sample offset Dist Sweep Entry 01 2008
4	40	102208	Purdue Pharma L.P.	98.132,79	QC sample offset Dist Sweep Entry 01 2008



## Exhibit 1E: Intercompany transfers between Purdue and The P.F. Laboratories Inc. for contract manufacturing organization services

The transactions related to CMO services were not settled with individual cash payments.

Based on a preliminary analysis of the intercompany account (102208 Purdue Pharma L.P.) in P.F. Labs's accounting records in SAP (SAP company code 109), the balance of the account appears to have been settled on a regular basis.

Furthermore, there were regular cash payments from PPLP, which were in excess of the charges related to the CMO services.

Account 102208-109	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
Prior Year Cumulative Balance	\$ (13,691,651)	\$ (11,186,932)	\$ (3,919,783)	\$ (4,157,573)	\$ (2,984,902)	\$ 1,552,237	\$ 3,502,008	\$ 6,590,556	\$ 6,150,606	\$ 5,510,519	\$ 6,988,497	\$ (994,878)	
Debits	42,637,294	66,215,261	28,853,185	31,669,646	26,126,457	29,611,533	13,882,859	12,763,040	3,754,677	1,900,759	78,083	997,132	258,489,927
Credits	(40,132,575)	(58,948,112)	(29,090,975)	(30,496,976)	(21,589,318)	(27,661,761)	(10,794,311)	(13,202,991)	(4,394,764)	(422,781)	(8,061,459)	(6,695)	(244,802,718)
Ending Cumulative Balance	\$ (11,186,932)	\$ (3,919,783)	\$ (4,157,573)	\$ (2,984,902)	\$ 1,552,237	\$ 3,502,008	\$ 6,590,556	\$ 6,150,606	\$ 5,510,519	\$ 6,988,497	\$ (994,878)	\$ (4,442)	
CMO Charges	\$ 10,794,832	\$ 3,798,172	\$ 1,222,995	\$ 666,280	\$ 381,294	\$ 217,444	\$ 277,690	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 17,358,707
Shared Services Charges	2,072,026	1,087,225	2,443,501	1,518,498	1,737,076	1,514,823	426,056	-	2,199,788	-	-	-	12,998,994
Intercompany Consolidation Entries	4,281,830	3,926,653	2,262,639	6,776,819	4,249,483	7,405,265	2,302,333	357,900	403,415	1,559,592	3,090	-	33,529,019
Production Variance Entries	21,033,300	25,387,000	20,247,700	18,509,700	19,408,500	20,154,200	9,178,600	-	-	-	-	-	133,919,000
Correcting Entries	-	23,955,950	-	1,450	50	-	-	-	-	-	-	-	23,957,450
Cash to PPLP	503,000	685,000	-	-	-	-	-	-	1,000,000	-	40,093	997,132	3,225,225
Other Debits <sup>1</sup>	3,952,306	7,375,262	2,676,349	4,196,899	350,054	319,801	1,698,180	12,405,140	151,474	341,168	34,900	-	33,501,532
Total Debits	\$ 42,637,294	\$ 66,215,261	\$ 28,853,185	\$ 31,669,646	\$ 26,126,457	\$ 29,611,533	\$ 13,882,859	\$ 12,763,040	\$ 3,754,677	\$ 1,900,759	\$ 78,083	\$ 997,132	\$ 258,489,927
Intercompany Consolidation Entries	\$ (5,002,495)	\$ (3,367,354)	\$ (3,050,393)	\$ (4,154,123)	\$ (1,972,012)	\$ (5,915,669)	\$ (1,228,237)	\$ (468,234)	\$ (415,707)	\$ (39,726)	\$ (3,347)	\$ -	\$ (25,617,298)
Production Variance Entries	(813,000)	-	(2,478,300)	(2,787,400)	(3,647,700)	(4,449,500)	(892,300)	-	-	-	-	-	(15,068,200)
Intercompany Charges / Shared Services	(2,069,871)	(3,905,640)	(3,754,480)	(1,963,387)	(2,944,526)	(3,240,348)	(77,493)	(195,964)	(1,221,429)	(90,827)	(11,433)	-	(19,475,400)
Intercompany Reclassification Entries	-	(24,677,176)	-	-	-	-	-	-	-	-	-	-	(24,677,176)
Cash from PPLP	(25,530,600)	(21,541,046)	(16,887,000)	(16,705,003)	(10,750,000)	(11,768,000)	(6,455,000)	(5,375,000)	(500,000)	-	(6,987,465)	-	(122,499,113)
Other Credits <sup>1</sup>	(6,716,609)	(5,456,896)	(2,920,801)	(4,887,063)	(2,275,080)	(2,288,244)	(2,141,281)	(7,163,793)	(2,257,628)	(292,227)	(1,059,214)	(6,695)	(37,465,531)
Total Credits	\$ (40,132,575)	\$ (58,948,112)	\$ (29,090,975)	\$ (30,496,976)	\$ (21,589,318)	\$ (27,661,761)	\$ (10,794,311)	\$ (13,202,991)	\$ (4,394,764)	\$ (422,781)	\$ (8,061,459)	\$ (6,695)	\$ (244,802,718)

<sup>1</sup> "Other Debits" and "Other Credits" consist of intercompany interest as well as various other journal entries. Analysis of these entries remains ongoing.

## Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

On April 13, 1998, Purdue entered into a service agreement with Terramar for office space. Pursuant to the service agreement, Purdue agreed to pay rent calculated as costs (i.e. "Expenses") plus 10%.

### SERVICE AGREEMENT

SERVICE AGREEMENT, effective as of April 13, 1998  
between The Terramar Foundation, Inc., a Delaware corpora-  
tion ("Terramar"), and Purdue Pharma L.P., a Delaware  
limited partnership ("PPLP"),

### W I T N E S S E T H :

WHEREAS, Terramar desires to provide facilities and  
services to PPLP at Terramar's offices at [REDACTED]  
[REDACTED], New York, New York; and

WHEREAS, PPLP is willing to pay for such facilities  
and services provided by Terramar to PPLP;

NOW, THEREFORE, it is agreed as follows:

1. PPLP will pay for services hereunder in an  
amount equal to Expenses (as defined herein) plus 10% of  
Expenses.

## Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

Pursuant to the service agreement, Expenses included the following:

2. "Expenses" means the costs and expenses incurred by Terramar on behalf of or for PPLP and associated with each of the following:

- (a) salaries of Terramar personnel whose activities include activities undertaken on behalf of PPLP;
- (b) employee benefits, payroll taxes and such other employment taxes as may be applicable with respect to the personnel identified in paragraph 2(a) above;

(c) fees for general legal services and advice specific to the conduct of the activities undertaken by Terramar on behalf of PPLP;

- (d) travel and representation;
- (e) rent and service fees for facilities and equipment;
- (f) telecommunications;
- (g) postage, stationery and supplies;
- (h) financial and trade journals; and
- (i) other office overhead expenses associated with services and facilities provided by Terramar to PPLP; and

(j) all sales, use and occupancy taxes on the above.

## Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

Between January 31, 2008 and July 31, 2018, Purdue Pharma L.P. was charged approximately \$22.2 million in office space rent by Terramar. The agreement terminated as of July 1, 2018.

Year	Charges for		Total
	Costs & Expenses	Service Charge	
2008	\$ 1,443,581	\$ 144,358	\$ 1,587,939
2009	1,671,798	167,180	1,838,978
2010	1,576,459	157,646	1,734,105
2011	1,850,762	185,076	2,035,838
2012	1,788,067	178,807	1,966,874
2013	2,489,028	248,903	2,737,930
2014	2,137,612	213,761	2,351,373
2015	1,998,502	199,850	2,198,353
2016	2,100,172	210,017	2,310,189
2017	2,045,599	204,560	2,250,159
2018	1,077,073	107,575	1,184,648
<b>Total</b>	<b>\$ 20,178,653</b>	<b>\$ 2,017,733</b>	<b>\$ 22,196,386</b>

## Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

According to Terramar's accounting records in SAP, Terramar (SAP company code 504) charged Purdue for office space through G/L account 690100 (InterCo Charges/Credits). The screenshot below illustrates the last few years of rent, including total rent and service charges of \$22.2 million charged to Purdue since 2008.

G/L Account Line Item Display														
G/L Account 690100 InterCo Charges/Credits Company Code 504														
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	Order
<input type="checkbox"/>	504	100003152	30.04.2016	05.05.2016	4	2016/04	SA	2100504	EL 050516 52	690100	GEN	Reclass Terramar expense April 2016	157.736,56-	USD
<input type="checkbox"/>	504	100003177	31.05.2016	06.06.2016	5	2016/05	SA	2100504	EL 060616 40	690100	GEN	Reclass Terramar expense May 2016	248.803,63-	USD
<input type="checkbox"/>	504	100003205	30.06.2016	07.07.2016	6	2016/06	SA	2100504	EL 070716 43	690100	GEN	Reclass Terramar expense June 2016	181.979,34-	USD
<input type="checkbox"/>	504	100003233	31.07.2016	04.08.2016	7	2016/07	SA	2100504	EL 080416 46	690100	GEN	Reclass Terramar expense July 2016	185.604,62-	USD
<input type="checkbox"/>	504	100003257	31.08.2016	07.09.2016	8	2016/08	SA	2100504	EL 090716 46	690100	GEN	Reclass Terramar expense August 2016	187.191,37-	USD
<input type="checkbox"/>	504	100003284	30.09.2016	10.10.2016	9	2016/09	SA	2100504	EL 101016 55	690100	GEN	Reclass Terramar expense Sept 2016	176.158,74-	USD
<input type="checkbox"/>	504	100003311	31.10.2016	03.11.2016	10	2016/10	SA	2100504	EL 110316 41	690100	GEN	Reclass Terramar expense Oct 2016	174.717,98-	USD
<input type="checkbox"/>	504	100003340	30.11.2016	06.12.2016	11	2016/11	SA	2100504	EL 120616 40	690100	GEN	Reclass Terramar expense Nov 2016	177.135,05-	USD
<input type="checkbox"/>	504	100003391	31.12.2016	23.01.2017	12	2016/12	SA	2100504	EL 012317 70	690100	GEN	Reclass Terramar expense Dec 2016	304.468,18-	USD
<input type="checkbox"/>	504	100003416	31.12.2016	16.02.2017	12	2016/12	SA	2100504	EL 021617 83	690100	GEN	Reclass Terramar expense Dec 2016	8.788,70-	USD
<input type="checkbox"/>	504	100003417	31.01.2017	21.02.2017	1	2017/01	SA	2100504	EL 022117 42	690100	GEN	Reclass Terramar expense Jan 2017	145.929,81-	USD
<input type="checkbox"/>	504	100003442	28.02.2017	06.03.2017	2	2017/02	SA	2100504	EL 030617 37	690100	GEN	Reclass Terramar expense Feb 2017	182.954,71-	USD
<input type="checkbox"/>	504	100003471	31.03.2017	06.04.2017	3	2017/03	SA	2100504	EL 040617 48	690100	GEN	Reclass Terramar expense March 2017	159.764,66-	USD
<input type="checkbox"/>	504	100003502	30.04.2017	04.05.2017	4	2017/04	SA	2100504	EL 050417 37	690100	GEN	Reclass Terramar expense April 2017	246.810,27-	USD
<input type="checkbox"/>	504	100003528	31.05.2017	05.06.2017	5	2017/05	SA	2100504	HS 0517	690100	GEN	Reclass Terramar expense May 2017	193.961,33-	USD
<input type="checkbox"/>	504	100003548	30.06.2017	04.07.2017	6	2017/06	SA	2100504	HS 0617	690100	GEN	Reclass Terramar expense June 2017	208.627,57-	USD
<input type="checkbox"/>	504	100003580	31.07.2017	04.08.2017	7	2017/07	SA	2100504	HS 0717	690100	GEN	Reclass Terramar expense July 2017	190.375,70-	USD
<input type="checkbox"/>	504	100003610	31.08.2017	07.09.2017	8	2017/08	SA	2100504	HS 0817	690100	GEN	Reclass Terramar expense August 2017	188.631,41-	USD
<input type="checkbox"/>	504	100003647	30.09.2017	05.10.2017	9	2017/09	SA	2100504	HS 0917	690100	GEN	Reclass Terramar expense September 2017	168.649,99-	USD
<input type="checkbox"/>	504	100003677	31.10.2017	07.11.2017	10	2017/10	SA	2100504	HS 1017	690100	GEN	Reclass Terramar expense October 2017	166.550,69-	USD
<input type="checkbox"/>	504	100003701	30.11.2017	06.12.2017	11	2017/11	SA	2100504	HS 1117	690100	GEN	Reclass Terramar expense November 2017	230.315,31-	USD
<input type="checkbox"/>	504	100003729	31.12.2017	15.01.2018	12	2017/12	SA	2100504	HS 1217	690100	GEN	Reclass Terramar expense December 2017	210.656,41-	USD
<input type="checkbox"/>	504	100003753	31.12.2017	25.01.2018	12	2017/12	SA	2100504	HS 1217	690100	GEN	Reclass Terramar expense December 2017	43.068,52	USD
<input type="checkbox"/>	504	100003791	31.01.2018	23.02.2018	1	2018/01	SA	2100504	HS 0118	690100	GEN	Reclass Terramar expense January 2018	186.564,29-	USD
<input type="checkbox"/>	504	100003814	28.02.2018	06.03.2018	2	2018/02	SA	2100504	HS 0218	690100	GEN	Reclass Terramar expense February 2018	179.388,73-	USD
<input type="checkbox"/>	504	100003841	31.03.2018	06.04.2018	3	2018/03	SA	2100504	HS 0318	690100	GEN	#REF!	195.599,45-	USD
<input type="checkbox"/>	504	100003868	30.04.2018	04.05.2018	4	2018/04	SA	2100504	RB 0418	690100	GEN	Reclass Terramar expense April 2018	186.384,07-	USD
<input type="checkbox"/>	504	100003918	31.05.2018	05.06.2018	5	2018/05	SA	2100504		690100	GEN	Reclass Terramar May 2018	216.856,27-	USD
<input type="checkbox"/>	504	100003947	30.06.2018	10.07.2018	6	2018/06	SA	2100504		690100	GEN	Reclass Terramar June 2018	219.855,89-	USD
*												22.196.386,24-	USD	

## Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

Per Purdue's internal analysis of office space charges, the amount that Terramar charged to Purdue for office space was recorded as cost plus a 10% service charge.

A 2018 internal analysis (shown below) shows \$1.2 million in rent billed from Terramar, which reconciles to SAP.

2018	JAN	FEB	MAR	APRIL	MAY	JUNE	JULY	AUG	SEPT	OCT	NOV	DEC	TOTAL
<b>Terramar (504) To PPLP (208)</b>													
Trial Bal	169,604	163,081	177,817	169,440	197,142	199,989							1,077,073
<b>Less Items not Billed</b>													0
608461 Legal 608461 Corp Litigation	-	-	-	-	-	-	-						0
608470 Legal 608470 Legal Other	-	-	-	-	-	-	-						0
608450 Acct Fees External HS 608450	-	-	-	-	-	-	-						0
640000 Contributions 640000	-	-	-	-	-	-	-						0
611615 Community Rel Supp. 611615	-	-	-	-	-	-	-						0
800400 Federal Taxes 800400	-	-	-	-	-	-	-						0
800401 Federal Taxes current year 800401	-	-	-	-	-	-	-						0
800405 State Taxes 800405	-	-	-	-	-	-	-						0
800407 State Taxes current year 800407	-	-	-	-	-	-	-						0
Prior period adj & Fixed Asset adj													0
<b>Adjusted Total</b>	<b>169,603.90</b>	<b>163,080.66</b>	<b>177,817.00</b>	<b>169,440.00</b>	<b>197,142.00</b>	<b>199,989.00</b>		-	-	-	-	-	<b>1,077,072.56</b>
Mark-Up 10%	16,960.39	16,308.07	17,781.70	16,944.00	19,714.20	19,867.00			0.00	0.00	0.00	0.00	<b>107,575.36</b>
<b>TOTAL BILLING</b>	<b>186,564.29</b>	<b>179,388.73</b>	<b>195,598.70</b>	<b>186,384.00</b>	<b>216,856.20</b>	<b>219,856.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>1,184,648</b>
504-690100-2100504 Credit													
504-102208 Debit													
208-690100-2100208 DEBIT													
208-102504 CREDIT													



## Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

According to SAP, Terramar (SAP company code 504) charged Purdue \$1.6 and \$1.2 million for office space in 2008 and 2018, respectively, through G/L account 690100 (InterCo Charges/Credits).

G/L Account Company Code		690100 504		InterCo Charges/Credits									
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/>	504	100000580	31.01.2008	20.02.2008	1	2008/01	SA	2100504	EL 22008 20	690100	GEN	Reclass Terramar expense to PFLP Jan 08	106.981,85- USD
<input type="checkbox"/>	504	100000601	29.02.2008	06.03.2008	2	2008/02	SA	2100504	CK 030608 TR	690100	GEN	Reclass Terramar expense to PFLP Feb 08	119.786,61- USD
<input type="checkbox"/>	504	100000625	31.03.2008	03.04.2008	3	2008/03	SA	2100504	CK 040308 TR	690100	GEN	Reclass Terramar expense to PFLP Mar 08	138.954,78- USD
<input type="checkbox"/>	504	100000646	30.04.2008	06.05.2008	4	2008/04	SA	2100504	CK 050608 TR	690100	GEN	Reclass Terramar expense to PFLP Apr 08	105.546,68- USD
<input type="checkbox"/>	504	100000665	30.05.2008	03.06.2008	5	2008/05	SA	2100504	CK 060308 TR	690100	GEN	Reclass Terramar expense to PFLP May 08	128.479,16- USD
<input type="checkbox"/>	504	100000666	30.05.2008	03.06.2008	5	2008/05	SA	2100504	CK 060308 TR	690100	GEN	Reclass Terramar expense to PFLP May 08	128.479,16- USD
<input type="checkbox"/>	504	100000667	03.06.2008	03.06.2008	6	2008/06	AB	2100504	CK 060308 TR	690100	GEN	Reclass Terramar expense to PFLP May 08	128.479,16- USD
<input type="checkbox"/>	504	100000668	30.06.2008	03.06.2008	6	2008/06	SA	2100504	CK 060308 TR	690100	GEN	Reclass Terramar expense to PFLP May 08	128.479,16- USD
<input type="checkbox"/>	504	100000669	30.05.2008	03.06.2008	5	2008/05	SA	2100504	CK 060308 TR CR	690100	GEN	Reclass Terramar expense to PFLP May 08	128.479,16- USD
<input type="checkbox"/>	504	100000691	30.06.2008	03.07.2008	6	2008/06	SA	2100504	CK 070308 TR	690100	GEN	Reclass Terramar expense to PFLP June 08	161.849,77- USD
<input type="checkbox"/>	504	100000711	31.07.2008	06.08.2008	7	2008/07	SA	2100504	CK 073108 TR	690100	GEN	Reclass Terramar expense to PFLP July 08	123.835,44- USD
<input type="checkbox"/>	504	100000729	29.08.2008	05.09.2008	8	2008/08	SA	2100504	CK 082908 TR	690100	GEN	Reclass Terramar expense to PFLP Aug 08	129.353,13- USD
<input type="checkbox"/>	504	100000751	30.09.2008	06.10.2008	9	2008/09	SA	2100504	CK 093008 TR	690100	GEN	Reclass Terramar expense to PFLP Sep 08	123.709,92- USD
<input type="checkbox"/>	504	100000765	31.10.2008	05.11.2008	10	2008/10	SA	2100504	CK 103108 TR	690100	GEN	Reclass Terramar expense to PFLP Oct 08	147.334,35- USD
<input type="checkbox"/>	504	100000781	26.11.2008	03.12.2008	11	2008/11	SA	2100504	CK 112608 TR	690100	GEN	Reclass Terramar expense to PFLP Nov 08	124.657,04- USD
<input type="checkbox"/>	504	100000823	31.12.2008	27.01.2009	12	2008/12	SA	2100504	CK 123108 TR	690100	GEN	Reclass Terramar expense to PFLP Dec 08	177.450,66- USD
												1.587.939,39-	USD

### G/L Account Line Item Display

Navigation icons: Back, Forward, Home, Search, Print, etc. Selections Dispute Case

G/L Account		690100		InterCo Charges/Credits											
Company Code		504													
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	Order	
<input type="checkbox"/>	504	100003791	31.01.2018	23.02.2018	1	2018/01	SA	2100504	HS 0118	690100	GEN	Reclass Terramar expense January 2018	186.564,29-	USD	
<input type="checkbox"/>	504	100003814	28.02.2018	06.03.2018	2	2018/02	SA	2100504	HS 0218	690100	GEN	Reclass Terramar expense February 2018	179.388,73-	USD	
<input type="checkbox"/>	504	100003841	31.03.2018	06.04.2018	3	2018/03	SA	2100504	HS 0318	690100	GEN	#REF!	195.599,45-	USD	
<input type="checkbox"/>	504	100003868	30.04.2018	04.05.2018	4	2018/04	SA	2100504	RB 0418	690100	GEN	Reclass Terramar expense April 2018	186.384,07-	USD	
<input type="checkbox"/>	504	100003918	31.05.2018	05.06.2018	5	2018/05	SA	2100504		690100	GEN	Reclass Terramar May 2018	216.856,27-	USD	
<input type="checkbox"/>	504	100003947	30.06.2018	10.07.2018	6	2018/06	SA	2100504		690100	GEN	Reclass Terramar June 2018	219.855,89-	USD	
*												1.184.648,70-	USD		

## **Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space**

Cash payments were recognized as follows on Purdue Pharma L.P.'s books (SAP company code 208). The July 2018 cash payment is illustrated below.


<b>Company</b>	<b>Account Number</b>	<b>Account Description</b>	<b>DR</b>	<b>CR</b>
208	100010	Cash Concentration		\$ (943,039)
208	102504	Terramar Foundation	\$ 943,039	
504	100010	Cash Concentration	\$ 943,039	
504	102208	Purdue Pharma L.P.		\$ (943,039)

208: Purdue Pharma L.P.

504: Terramar Foundation Inc.

## Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

Terramar (SAP company code 504) charged Purdue through G/L account 102208. The balance in the account accrued, but was partially paid off periodically such that the cumulative balance never exceeded \$1 million. The July 2018 cash payment from PPLP to Terramar is illustrated below as it closed all activity relating to office space payments.<sup>1</sup>

Account number	102208	Purdue Pharma L.P.		
Company code	504	Terramar Foundation, Inc.		
Business area				
Fiscal year	2018			
All documents in currency	*	Display currency USD		
<div></div>				
Period	Debit	Credit	Balance	Cumulative balance
Balance Carry...				826.722,45
1	193.199,88	151.460,61	41.739,27	868.461,72
2	182.918,63	139.006,92	43.911,71	912.373,43
3	196.030,31	266.224,39	70.194,08-	842.179,35
4	215.394,49	157.576,44	57.818,05	899.997,40
5	219.251,19	176.209,82	43.041,37	943.038,77
6	908.732,12	1.101.820,66	193.088,54-	749.950,23
7	243.630,39	1.062.752,66	819.122,27-	69.172,04-
8	25.000,00	422.154,81	397.154,81-	466.326,85-
9	41.693,01	21.646,80	20.046,21	446.280,64-
10		14.849,22	14.849,22-	461.129,86-
11		65.269,29	65.269,29-	526.399,15-
12	215.722,64	124.566,54	91.156,10	435.243,05-
13				435.243,05-
14				435.243,05-
15				435.243,05-
16				435.243,05-
Total	2.441.572,66	3.703.538,16	1.261.965,50-	435.243,05-

G/L Account		102208	Purdue Pharma L.P.							
Company Code		504								
tng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.
<input type="checkbox"/> .07.2018	01.06.2018	7	2018/07	RE		060118B	102208	GEN		358,66-
<input type="checkbox"/> .07.2018	06.06.2018	7	2018/07	RE		2313057	102208	GEN		404,73-
<input type="checkbox"/> .07.2018	11.06.2018	7	2018/07	RE		C0045369280	102208	GEN		38,77-
<input type="checkbox"/> .07.2018	30.06.2018	7	2018/07	RE		100750526	102208	GEN		1.693,92-
<input type="checkbox"/> .07.2018	06.07.2018	7	2018/07	RE		S053910061	102208	GEN		1.433,82-
<input type="checkbox"/> .07.2018	09.07.2018	7	2018/07	SA		CWS	102208	GEN		943.038,77-
<input type="checkbox"/> .07.2018	10.07.2018	7	2018/07	RE		C0045447514	102208	GEN		38,77-
<input type="checkbox"/> .07.2018	13.07.2018	7	2018/07	KR		JBS071318	102208	GEN		4.638,62-
<input type="checkbox"/> .07.2018	13.07.2018	7	2018/07	KR		CABRALD071318	102208	GEN		101,92-
<input type="checkbox"/> .07.2018	26.07.2018	7	2018/07	SA		LI 0718	102208	GEN		6.250,00-
<input type="checkbox"/> .07.2018	26.07.2018	7	2018/07	SA		EL 072618 9	102208	GEN		75.000,00-
<input type="checkbox"/> .07.2018	27.07.2018	7	2018/07	SA			102208	GEN		389,00-
<input type="checkbox"/> .07.2018	27.07.2018	7	2018/07	KR		JBS072718	102208	GEN		3.944,83-
<input type="checkbox"/> .07.2018	27.07.2018	7	2018/07	KR		CABRALD072718	102208	GEN		101,92-
<input type="checkbox"/> .07.2018	31.07.2018	7	2018/07	RC			102208	GEN	Reconciliation Posting CO	430,86-
<input type="checkbox"/> .07.2018	31.07.2018	7	2018/07	SA		EXPENSITE EXP	102208	GEN		11.050,38-
<input type="checkbox"/> .07.2018	01.08.2018	7	2018/07	SA		LI 718	102208	GEN	To rec adj for Retirement Admin Fee - July	115,00-
<input type="checkbox"/> .07.2018	02.08.2018	7	2018/07	SA		LMT 718	102208	GEN		7.236,45-
<input type="checkbox"/> .07.2018	26.07.2108	7	2018/07	SA		EL 072618 8	102208	GEN	07/2018 Cigna Medical Charges	4.528,05-
<input type="checkbox"/> .07.2018	26.07.2108	7	2018/07	SA		EL 072618 8	102208	GEN	07/2018 Cigna Dental Charges	635,39-
<input type="checkbox"/> .07.2018	26.07.2108	7	2018/07	SA		EL 072618 8	102208	GEN	07/2018 Cigna Drug Charges	1.322,80-
<input checked="" type="checkbox"/> *										1.062.752,66-

CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy
Itm	PK	Account	Account short text	Assignment			Amount Text
208	100175718	2018	SA	09.07.2018	08.07.2018	CWS	USD
1	50	100010	Cash Concentration	20180709			943.038,77- CORP PAY
2	40	102504	Terramar Foundation	20180709			943.038,77
504	100003945	2018	SA	09.07.2018	08.07.2018	CWS	USD
1	40	100010	Cash Concentration	20180709			943.038,77 CORP PAY
2	40	100010	Cash Concentration	20180709			777,00 00000000932902583 REFOCUS FOUNDATION INC. 15 E 62N
3	50	101040	A/R Clearing (Trade)	20180709			777,00- 00000000932902583 REFOCUS FOUNDATION INC. 15 E 62N
4	50	102208	Purdue Pharma L.P.	20180709			943.038,77-

<sup>1</sup>Per Purdue, PPLP settled to cash partial amounts of the outstanding account activity in June and July 2018 for identical amounts: \$943,038.77

## Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

SAP contains support for the May and June 2018 rent charges to PPLP that was settled as part of the July 2018 payment.

G/L Account		102208		Purdue Pharma L.P.										
Company Code		504												
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	
<input type="checkbox"/>	504	100003911	31.05.2018	31.05.2018	5	2018/05	SA		EXPENSITE EXP	102208	GEN		4.481,37-	USD
<input type="checkbox"/>	504	100003912	31.05.2018	31.05.2018	5	2018/05	RC			102208	GEN	Reconciliation Posting CO	430,86-	USD
<input type="checkbox"/>	504	100003913	31.12.2017	01.06.2018	12	2017/12	SA	RK 1217 33	102208	GEN	LCD 12.31.2017	55.449,46-	USD	
<input type="checkbox"/>	504	100003909	31.05.2018	01.06.2018	5	2018/05	SA	CWS	102208	GEN		77.605,75-	USD	
<input type="checkbox"/>	504	1900005737	01.06.2018	01.06.2018	6	2018/06	KR	JBS060118	102208	GEN		5.069,94-	USD	
<input type="checkbox"/>	504	1900005738	01.06.2018	01.06.2018	6	2018/06	KR	CABRALD060118	102208	GEN		101,92-	USD	
<input type="checkbox"/>	504	100003915	03.06.2018	04.06.2018	6	2018/06	SA	CWS	102208	GEN		1.099,24-	USD	
<input type="checkbox"/>	504	100003917	31.05.2018	05.06.2018	5	2018/05	SA	LMT 518	102208	GEN		2.607,84-	USD	
<input type="checkbox"/>	504	100003918	31.05.2018	05.06.2018	5	2018/05	SA		102208	GEN		216.856,27	USD	
<input type="checkbox"/>	504	100003919	31.01.2018	07.06.2018	1	2018/01	SA	RK 0118 01	102208	GEN	LCD 01.31.2018	73,90	USD	
<input type="checkbox"/>	504	100003919	31.01.2018	07.06.2018	1	2018/01	SA	RK 0118 01	102208	GEN	LCD 01.31.2018	0,76-	USD	
<input type="checkbox"/>	504	100003919	31.01.2018	07.06.2018	1	2018/01	SA	RK 0118 01	102208	GEN	LCD 01.31.2018	26,35-	USD	
<input type="checkbox"/>	504	100003921	10.06.2018	11.06.2018	6	2018/06	SA	CWS	102208	GEN		17,74-	USD	
<input type="checkbox"/>	504	1900005740	15.06.2018	15.06.2018	6	2018/06	KR	JBS061518	102208	GEN		5.039,48-	USD	
<input type="checkbox"/>	504	1900005745	15.06.2018	15.06.2018	6	2018/06	KR	CABRALD061518	102208	GEN		101,92-	USD	
<input type="checkbox"/>	504	100003923	17.06.2018	18.06.2018	6	2018/06	SA	CWS	102208	GEN		27.211,17-	USD	
<input type="checkbox"/>	504	100003925	24.06.2018	25.06.2018	6	2018/06	SA	CWS	102208	GEN		9.910,67-	USD	
<input type="checkbox"/>	504	100003926	30.06.2018	25.06.2018	6	2018/06	SA	EL 062518 4	102208	GEN	06/2018 Cigna Medical Charges	4.528,05-	USD	
<input type="checkbox"/>	504	100003926	30.06.2018	25.06.2018	6	2018/06	SA	EL 062518 4	102208	GEN	06/2018 Cigna Dental Charges	635,39-	USD	
<input type="checkbox"/>	504	100003926	30.06.2018	25.06.2018	6	2018/06	SA	EL 062518 4	102208	GEN	06/2018 Cigna Drug Charges	1.322,80-	USD	
<input type="checkbox"/>	504	100003928	27.06.2018	28.06.2018	6	2018/06	SA	CWS	102208	GEN		651.376,23	USD	
<input type="checkbox"/>	504	100003929	27.06.2018	28.06.2018	6	2018/06	SA	CWS	102208	GEN		943.038,77-	USD	
<input type="checkbox"/>	504	100003930	29.06.2018	29.06.2018	6	2018/06	SA		102208	GEN		389,00-	USD	
<input type="checkbox"/>	504	1900005743	29.06.2018	29.06.2018	6	2018/06	KR	JBS062918	102208	GEN		5.083,62-	USD	
<input type="checkbox"/>	504	1900005744	29.06.2018	29.06.2018	6	2018/06	KR	CABRALD062918	102208	GEN		101,92-	USD	
<input type="checkbox"/>	504	100003936	30.06.2018	30.06.2018	6	2018/06	RC		102208	GEN	Reconciliation Posting CO	430,86-	USD	
<input type="checkbox"/>	504	100003937	30.06.2018	30.06.2018	6	2018/06	SA	EXPENSITE EXP	102208	GEN		803,64-	USD	
<input type="checkbox"/>	504	100003934	30.06.2018	02.07.2018	6	2018/06	SA	CWS	102208	GEN		25.616,88-	USD	
<input type="checkbox"/>	504	100003943	30.06.2018	02.07.2018	6	2018/06	SA	LT 618	102208	GEN	To rec adj for Retirement Admin Fee - June	115,00-	USD	
<input type="checkbox"/>	504	100003938	30.06.2018	03.07.2018	6	2018/06	SA	LMT 618	102208	GEN		32.068,32-	USD	
<input type="checkbox"/>	504	100003947	30.06.2018	10.07.2018	6	2018/06	SA		102208	GEN		219.855,89	USD	
<input type="checkbox"/>	504	100003948	30.06.2018	11.07.2018	6	2018/06	SA	EL 071118 36	102208	GEN		37.500,00-	USD	
<input type="checkbox"/>	504	100003949	30.06.2018	11.07.2018	6	2018/06	SA	EL 071118 37	102208	GEN		37.500,00	USD	
<input type="checkbox"/>	504	1700000042	15.09.2003	05.06.2149	9	2003/09	KA	77	102208	GEN		395,34	USD	
<input type="checkbox"/>	504	1900001022	15.09.2003	05.06.2149	9	2003/09	KR	77	102208	GEN		395,34-	USD	
<input type="checkbox"/>	504	1700000043	01.10.2003	14.08.2151	10	2003/10	KA	10A0465029	102208	GEN		155,04	USD	
<input type="checkbox"/>	504	1900001028	01.10.2003	14.08.2151	10	2003/10	KR	10A0465029	102208	GEN		155,04-	USD	
<input type="checkbox"/>	*											749.950,23	USD	

Note: PPLP also provided cash payments to various entities for charges relating to insurance, fleet expenses, pensions, travel and entertainment, etc. Per discussions with Purdue, no formal agreements exist for these arrangements. Charges/cash payments for these other items represent the remaining portion of the activity in PPLP's account (102208) in Terramar's books (SAP company code 504).

## Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

Rent charges and payments can be observed in the G/L account activity of account 102208 on Terramar's books (SAP company code 504). The debits to the account (consisting mostly of rent charges) are netted by credit entries (consisting mostly of cash payments) that result in a relatively low cumulative account balance.

Account 102208-504	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Totals
Prior Year Cumulative Balance	\$ 260,091	\$ 562,179	\$ 621,822	\$ 710,642	\$ 874,613	\$ 1,041,022	\$ 341,723	\$ 298,964	\$ 544,559	\$ 807,406	\$ 826,722	\$ (435,243)	
Debits	2,200,268	1,898,269	1,795,581	2,133,488	2,172,940	2,914,298	2,561,180	2,303,609	2,626,039	2,443,581	2,441,573	562,783	26,053,609
Credits	(1,898,180)	(1,838,625)	(1,706,761)	(1,969,517)	(2,006,531)	(3,613,597)	(2,603,939)	(2,058,014)	(2,363,192)	(2,424,265)	(3,703,538)	(160,012)	(26,346,172)
Ending Cumulative Balance	\$ 562,179	\$ 621,822	\$ 710,642	\$ 874,613	\$ 1,041,022	\$ 341,723	\$ 298,964	\$ 544,559	\$ 807,406	\$ 826,722	\$ (435,243)	\$ (32,472)	
Rent Charges	\$ 1,587,939	\$ 1,838,978	\$ 1,734,105	\$ 2,035,838	\$ 1,966,874	\$ 2,737,930	\$ 2,351,373	\$ 2,198,353	\$ 2,310,188	\$ 2,250,159	\$ 1,184,649	\$ -	\$ 22,196,386
Other Non-Rent Debits	612,329	59,291	61,476	97,650	206,067	176,368	209,807	105,256	315,851	193,422	1,256,924	562,783	3,857,223
Total Debits	\$ 2,200,268	\$ 1,898,269	\$ 1,795,581	\$ 2,133,488	\$ 2,172,940	\$ 2,914,298	\$ 2,561,180	\$ 2,303,609	\$ 2,626,039	\$ 2,443,581	\$ 2,441,573	\$ 562,783	\$ 26,053,609
Cash Payments	\$ (1,449,529)	\$ (1,468,122)	\$ (1,561,565)	\$ (1,667,668)	\$ (1,695,047)	\$ (3,311,540)	\$ (2,087,735)	\$ (1,586,570)	\$ (1,765,138)	\$ (1,909,534)	\$ (2,661,342)	\$ (5,242)	\$ (21,169,032)
Rent Adjustments/Reversals	(256,958)	-	-	-	-	-	-	-	-	(43,069)	(206,130)	-	(506,157)
Other Non-Cash Credits	(191,692)	(370,503)	(145,196)	(301,849)	(311,485)	(302,057)	(516,204)	(471,444)	(598,055)	(471,662)	(836,066)	(154,770)	(4,670,983)
Total Credits	\$ (1,898,180)	\$ (1,838,625)	\$ (1,706,761)	\$ (1,969,517)	\$ (2,006,531)	\$ (3,613,597)	\$ (2,603,939)	\$ (2,058,014)	\$ (2,363,192)	\$ (2,424,265)	\$ (3,703,538)	\$ (160,012)	\$ (26,346,172)

Note: Other non-rent debits includes items paid by PPLP in the ordinary course of business such as insurance, fleet expenses, pensions, travel and entertainment, etc. Other non-cash credits includes intercompany settlements rather than settlements to cash.

## Exhibit 1F: Intercompany transfers between Purdue and The Terramar Foundation, Inc. for office space

The table below provides further details of the rent charges incurred per year. The majority of the activity between Terramar and PPLP is for rent payments that were settled in cash.

SAP Company Code	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
Terramar (504) To PPLP (208)													
Net Rent Charges Incurred per Year	\$1,587,939	\$1,838,978	\$1,734,105	\$2,035,838	\$1,966,874	\$2,737,930	\$2,351,373	\$2,198,353	\$2,310,188	\$2,250,159	\$1,184,649	\$0	\$22,196,386
YE Cumulative Balance	\$562,179	\$621,822	\$710,642	\$874,613	\$1,041,022	\$341,723	\$298,964	\$544,559	\$807,406	\$826,722	(\$435,243)	(\$32,472)	

Year	Rent Charges	Debits	Chrgs/Dr	Cash Settlement	Credits	Cash/Cr
2008	\$ 1,844,898	\$ 2,200,268	84%	\$ 1,449,529	\$ 1,898,180	76%
2009	1,838,978	1,898,269	97%	1,468,122	1,838,625	80%
2010	1,734,105	1,795,581	97%	1,561,565	1,706,761	91%
2011	2,035,838	2,133,488	95%	1,667,668	1,969,517	85%
2012	1,966,874	2,172,940	91%	1,695,047	2,006,531	84%
2013	2,737,930	2,914,298	94%	3,311,540	3,613,597	92%
2014	2,351,373	2,561,180	92%	2,087,735	2,603,939	80%
2015	2,198,353	2,303,609	95%	1,586,570	2,058,014	77%
2016	2,310,188	2,626,039	88%	1,765,138	2,363,192	75%
2017	2,293,228	2,443,581	94%	1,909,534	2,424,265	79%
2018	1,390,779	2,441,573	57%	2,661,342	3,703,538	72%
2019	-	562,783	0%	5,242	160,012	3%
Total	\$22,702,543	\$26,053,609	87%	\$21,169,032	\$26,346,172	80%
Adj.	(506,157)	(506,157)		-	(506,157)	
Total	\$22,196,386	\$25,547,452	87%	\$21,169,032	\$25,840,015	82%

The table to the left provides further details of the rent charges incurred per year. As shown, the rent charges represent the majority of debits in the account (approximately 87% of activity between 2008-2009). The remaining debit activity includes items paid for by PPLP for goods and services such as insurance, fleet expenses, pensions, travel and entertainment, etc. Likewise, the majority of the credits in the account correspond to settlements to cash (82% of activity between 2008-2019), with the remaining credit activity including intercompany settlements rather than cash settlements.

The adjustment shown reconciles the effect of 2 duplicative entries for the May 2008 \$128,479 rent charge, an incorrect July 2018 \$206,130.39 rent charge that was reversed in August 2018 as well as an adjustment of \$43,069 for December 2017. The adjustment is made in order to match the SAP-verified total sum of rent charges incurred between 2008-2019. The duplicative entries net to zero through intercompany corrections.<sup>1</sup>

<sup>1</sup>As explained in the paragraph above regarding adjustments to the intercompany activity, the following lines reconcile the rent charge amounts:

- \$1,844,897.71 - (\$128,479.16 \* 2) = \$1,587,939.39 (2008)
- \$2,293,227.85 - \$43,068.52 = \$2,250,159.33 (2017)
- \$1,390,779.09 - \$206,130.39 = \$1,184,648.70 (2018)



## **Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services**

On January 1, 2008, Purdue entered into a tax services agreement with TXP, the service provider.

### **TAX SERVICES AGREEMENT**

This Tax Services Agreement (the "Agreement") effective as of January 1, 2008 by and between Purdue Pharma L.P., a Delaware limited partnership ("PPLP"), and TXP Services Inc., a Delaware corporation ("TXP"),

#### W I T N E S S E T H :

WHEREAS, TXP is engaged in the tax services business; and

WHEREAS, PPLP wishes to engage TXP to perform tax services in support of PPLP's business;

NOW, THEREFORE, in consideration of the premises and of the mutual agreements hereinafter contained, the parties hereto agree as follows:

1. Direction of Services. At all times the services provided by TXP to PPLP

## **Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services**

Pursuant to this agreement, Purdue agreed to pay costs and expenses incurred by TXP plus a service charge of 10%.

### **4. Invoices and Payment.**

(a) Within thirty (30) days of the last day of each calendar quarter ending on the last day of each March, June, September and December (each a "Calendar Quarter"), TXP shall submit to PPLP an invoice summarizing the costs and expenses incurred by TXP in providing its services hereunder during such Calendar Quarter and containing a service charge in the amount of ten percent (10%) of such costs and expenses.

## **Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services**

In July 2018, Purdue entered into a new services agreement with TXP on a fixed-fee basis.

**Services Agreement**  
**DCG & T&E, Finance & Accounting Services, Payroll, Taxation, Accounts Payable, Cash**  
**Management and Insurance**

PURDUE PHARMA L.P. AND TXP SERVICES INC.

THIS Services Agreement ("Services Agreement") is effective as of July 1, 2018 ("Effective Date") by and between Purdue Pharma L.P. ("Purdue") and TXP Services Inc. ("TXP").

3. **Compensation:** TXP's fee for services performed under this Services Agreement from July 1, 2018 through December 31, 2018 (the "2018 Fixed Fee") shall be [REDACTED]. TXP's fee for services performed under this Services Agreement in 2019 and thereafter shall comprise:
- (a) A fixed fee representing the amount payable for services provided in a given calendar year (the "Fixed Fee"). The Fixed Fee in 2019 shall be [REDACTED]. The Fixed Fee in 2020 shall be equal to the Fixed Fee for 2019 year increased by [REDACTED]. The Fixed Fee in 2021 and thereafter will be determined in the annual budget process as set forth at the end of this Section 3.

## **Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services**

The July 2018 services agreement was later amended on August 8, 2019 to amend, among other clauses, the fixed fee for 2019 services to be rendered.

### **AMENDMENT TO SERVICES AGREEMENT**

This AMENDMENT TO SERVICES AGREEMENT (this “Amendment”), dated as of August [8], 2019 (the “Effective Date”), is entered into by and between Purdue Pharma L.P., a Delaware limited partnership (“PPLP”), and TXP Services Inc., a Delaware corporation (“TXP”), and amends that certain Services Agreement DCG & T&E, Finance & Accounting Services, Payroll, Taxation, Accounts Payable, Cash Management and Insurance by and between PPLP and TXP effective as of July 1, 2018 (the “Services Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Services Agreement.

3. Compensation. Effective as of the Effective Date, Section 3 of the Services Agreement is hereby amended to:

- (a) delete and replace in its entirety the number “[REDACTED]” in the second sentence of subsection (a) thereof with: “[REDACTED]”;

## Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

From January 1, 2008 to December 31, 2018, Purdue was charged \$18.6 million by TXP pursuant to the tax services agreements (costs and expenses plus service charges), including markups of \$1.4 million.<sup>1</sup> As of September 15, 2019, TXP had charged Purdue \$2.6 million for tax services under the fixed-fee arrangement, plus other amounts due under the July 2018 Services Agreement, as amended.

Year	Cost & Expenses	Markups	Total Charges for Financial & Tax Services
2008	\$ 943,966	\$ 94,397	\$ 1,038,363
2009	883,035	88,304	971,339
2010	1,705,741	170,574	1,876,315
2011	1,735,277	173,528	1,908,805
2012	1,700,502	170,050	1,870,552
2013	1,681,641	168,164	1,849,805
2014	1,148,142	114,841	1,262,983
2015	1,114,770	111,477	1,226,247
2016	1,270,694	117,502	1,388,196
2017	1,413,877	141,388	1,555,265
2018	2,418,975	83,937	2,502,912
2019	2,559,793	-	2,559,793
<b>Total</b>	<b>\$ 18,576,413</b>	<b>\$ 1,434,162</b>	<b>\$ 20,010,575</b>

<sup>1</sup>In addition, beginning in 2018 up to September 15, 2019, TXP received \$787,783 from Rhodes Tech and \$542,778 from Rhodes Pharma. TXP also paid Rhodes Tech \$2,750 between 2009 and 2010. No other payments from TXP to Rhodes entities were observed between January 1, 2008 and September 15, 2019.

## Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

According to PPLP's accounting records in SAP, the "Purdue bank group" of companies<sup>1</sup> was charged through G/L accounts 793160 (TXP Cost Assessment) and 793170 (TXP Mark Up) for financial and tax services. The amounts for 2008 and 2017 are illustrated below.

**CC Comparison w/o Commitments**

Variation: Cost Center

- \* Cost Center Group
  - 2301208 FINANCE 208
  - 2301213 FINANCE 213
  - 2301219 FINANCE 219
  - 2301307 FINANCE 307
  - 2301313 FINANCE 313

Cost Center Comparison Report with Company Code  
 Current Period: 12 2008  
 Plan Version: 0 Purdue Plan/Act - Version  
 Cost Center / Group: \*  
 Company Code: 208, Company code

Date: 06/19/2019  
Time: 17:09:09

Account	Act. Period 12	Plan Period 12	Var Period 12	Var %	Act. Per. 1-12	Plan Per. 1-12	Var. Per.1-12	Var %	200
793160 TXP Cost Assessmt	271,559	0	(271,559)	0	943,966	0	(943,966)	0	
793170 TXP MARK UP	27,156	0	(27,156)	0	94,397	0	(94,397)	0	
* Total	298,715	0	(298,715)	0	1,038,363	0	(1,038,363)	0	

**CC Comparison w/o Commitments**

Variation: Cost Center

- \* Cost Center Group
  - 2301208 FINANCE 208
  - 2301225 FINANCE 225
  - 2301231 FINANCE 231

Cost Center Comparison Report with Company Code  
 Current Period: 12 2017  
 Plan Version: 0 Purdue Plan/Act - Version  
 Cost Center / Group: \*  
 Company Code: 208, Company code

Date: 06/19/2019  
Time: 16:55:58

Account	Act. Period 12	Plan Period 12	Var Period 12	Var %	Act. Per. 1-12	Plan Per. 1-12	Var. Per.1-12	Var %	201
793160 TXP Cost Assessmt	199,116	130,571	(68,545)	(52)	1,413,877	1,230,081	(183,796)	(15)	1
793170 TXP MARK UP	19,912	13,058	(6,854)	(52)	141,388	123,013	(18,375)	(15)	
* Total	219,027	143,629	(75,398)	(52)	1,555,265	1,353,094	(202,171)	(15)	1

<sup>1</sup>The Purdue bank group of companies includes SAP company codes 208, 211, 213, 219, 225, 231, 240, 241, 256, 257, 258, 307, 313, and 318.



## Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

The methodology for allocating costs to Purdue changed in late 2018, necessitating manual journal entries to true-up the amount due from Purdue. The approved tie-out schedules detailing these manual entries is illustrated below (and on the next slide).

TXP Services, Inc. 2018 Actual										Already assessed (Through Old TXP Assessment)	
	2300415 Treasury	2301415 Tax	2305415 Credit & Collections	2331415 Accounting Svc	2333415 Payroll	2334415 Accounts Payable	2350415 Corp. Procurement	Total		Secondaries	
<b>PPLP and Associated Companies:</b>	<b>P(3)</b>	<b>P(5)</b>	<b>P(6)</b>	<b>P(7)</b>	<b>P(9)</b>	<b>P(11)</b>	<b>P(13)</b>				
208	\$ 239,420.84	\$ 583,292.21	\$ 33,032.87	\$ 249,930.54	\$ 167,314.88	\$ 193,757.02	\$ 82,563.96	\$ 1,549,312.31		851,100.37	
211	-	2,000.00	-	-	-	141.17	-	2,141.17		-	
219	-	-	-	-	79,930.13	88,831.77	6,688.14	175,450.04		-	
225	-	2,000.00	-	-	-	282.34	-	2,282.34		713.69	
231	-	2,000.00	-	-	2,500.00	494.10	-	4,994.10		713.69	
241	-	-	-	-	-	3,246.93	-	3,246.93		-	
256 Imbrium Therapeutics L.P.	-	-	-	-	2,816.19	35.29	-	2,851.48		-	
257 Greenfield BioVentures LP	-	-	-	-	2,500.00	-	-	2,500.00		-	
313	-	-	-	-	-	882.32	-	882.32		-	
318	-	-	-	-	22,115.38	37,057.35	2,075.63	61,248.37		-	
418	-	-	-	-	-	-	-	-		-	
Rhodes Balancing Figure <sup>(1)</sup>	35,399.23	177,743.11	66,064.89	21,067.21	79,109.47	131,742.72	15,688.43	526,815.06		1,564,688.81	
Charge to Company 208	274,830.07	767,035.32	99,097.75	270,997.75	356,286.06	456,471.01	107,016.16	2,331,724.13		(85,492.43)	Credit for Tax Services - actuals less than previous assessment
307	-	-	128,168.69	-	2,500.00	34,798.62	-	165,467.31	(2)	1,479,196.38	(A)
Subtotal PPLP	274,820.07	767,035.32	227,266.44	270,997.75	358,786.06	491,269.63	107,016.16	2,497,191.43		1,644,663.68	
										713.71	(B)

<sup>(1)</sup> Chargeback for Rhodes above represent fixed at the 2018 amounts agreed to by Jon Lowne and David Fogel. The "balancing figure" represents the charge to PPLP to cover the charges that would have been charged to Rhodes using the current methodologies for billing.

(A) 1,479,196.38

(B) 713.72

J/E 1,478,482.66 (2)

# Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

Examples from the 2018 cost allocation tie-out (cont.).

Tax  
2301415

		2018 Actuals	2018 L.E.	Favorable (Unfavorable)
603000	Salaries - Exempt	710,592.18	629,886.28	(80,705.90) (1)
604000	Payroll Taxes	50,730.32	53,327.89	2,597.57
605100	Fringe Benefit Other (BI Awards)	2,412.50	-	(2,412.50)
605110	Educational Assistance	8,325.00	5,520.00	(2,805.00)
606000	Annual Bonus	74,485.00	74,485.00	-
606030	Long Term Awards	(103,111.86)	11,443.26	114,555.12 (1)
607700	Emp Dining/Co Events	(421.54)	-	421.54
605115	Fringe Ben Adj Acct	(41,796.43)	-	41,796.43
792000	Fringe Benefits	142,083.48	142,083.48	-
605116	Fleet Adjustment Account	3,956.06	-	(3,956.06)
792010	Fleet Allocation	14,268.31	14,268.31	-
	Subtotal Compensation	861,523.02	931,014.22	69,491.20
606400	Travel Other	105.00	500.00	395.00
606420	Meals and Ent.	211.37	750.00	538.63
606510	Ext. Training Exp	2,530.20	2,600.00	69.80
606800	Office Supplies	126.73	750.00	623.27
608400	Misc Proc. Card	(29.00)	(29.00)	-
607050	Canned Software	63,163.54	100,713.58	37,550.04
607300	Dues	2,369.00	2,000.00	(369.00)
607310	Subscription - Books	314.45	350.00	35.55
608450	External Accounting	20,919.60	20,919.60	-
608640	Outside Services	(3,084.00)	12,000.00	15,084.00
650010	Other Taxes	(399.00)	(221.00)	178.00
	Subtotal Direct Costs	947,750.91	1,071,347.39	123,596.48
607510	Outside Rent	15,831.30	15,831.30	-
690600	Indirect Costs	51,417.28	105,766.04	54,348.76
	Subtotal Indirect Costs	67,248.58	121,597.34	54,348.76
690300	TXP Direct Cost	-	-	-
793160	TXP Direct Cost	(926,206.30)	(1,071,347.39)	(145,141.09)
793170	TXP Mark Up	(92,620.66)	(107,134.74)	(14,514.08)
690400	TXP Mark Up	-	-	-
690500	TXP Indirect Cost	(4,000.00)	(121,597.34)	(117,597.34)
	Subtotal TXP Revenue	(1,022,826.96)	(1,300,079.47)	(277,252.51)
	(Profit)	(7,827.47)	(107,134.74)	(99,307.27)
	Headcount	3.00	3.00	3.00

(1) Credit due to forfeiture of LTRP grant as a result of reduction of 1 FTE in 2018.  
(2) L.E. excluded severance.

Calculation of amount to be assessed out:

Direct Costs	947,750.91
Mark up for direct costs	94,775.09
Rent	15,831.30
Other Indirect costs	51,417.28
Total Indirect Costs	67,248.58
	1,109,774.58 (5)

Treasury  
2300415

		2018 Actuals	2018 LE	Favorable (Unfavorable)
603000	Salaries	165,770.09	164,972.02	(798.07)
604000	Payroll Taxes	14,068.55	13,584.03	(484.52)
605100	BI Awards (E-Points)	500.00	-	(500.00)
606000	Annual Bonus	25,670.00	25,755.93	85.93
606400	Travel Other	1,250.00	-	(1,250.00)
606800	Office Supplies	283.67	141.83	(141.84)
607050	Canned Software	6,179.05	6,179.05	-
792000	Fringe Benefits	40,193.72	40,687.42	493.70
792010	Fleet Benefits	4,305.00	4,305.00	-
Subtotal Direct Costs		258,220.08	255,625.27	(2,594.81)
607510	Outside Rent	10,554.24	10,554.24	-
690600	Indirect Costs	14,008.93	18,459.09	4,450.16
Subtotal Indirect Costs		24,563.17	29,013.33	4,450.16
Total Cost		282,783.25	284,638.60	1,855.35
690300	TXP Direct Cost Assmt	-	(255,625.27)	(255,625.27)
690400	TXP Mark Up Assmt	-	(25,562.53)	(25,562.53)
690500	TXP Indirect Cost Assmt	-	(29,013.33)	(29,013.33)
Subtotal TXP Revenue		-	(310,201.13)	(310,201.13)
(Profit)		282,783.25	(25,562.53)	(308,345.78)
Headcount		2.00	2.00	2.00
FTE		2.50	2.50	2.50

% Allocation:

	T1	T2	1/2 of T3 (2)
PPLP	70%	55%	80%
Mundi - Chargeback to PPLP (3)	15%	10%	0%
PRALP	2%	2%	10%
Coventry	10%	30%	10%
OSR	3%	3%	0%
	100%	100%	100%

(1) Expense on PPLP's books offset by the \$75k per year billed by PPLP to Mundi for Risk Management services.  
(2) Only half of T3s cost is included in Treasury, the other half is included in Accounts Payable.

\$ Allocation:

	2018 Actuals	
208 PPLP	66% (204,287.96)	258,220.08 Direct Costs
208 MundiPharma	11% (35,132.88)	284,042.09 Direct Costs + 10%
208 Rhodes Overage from TXP		24,563.17 Indirect Costs
Subtotal - PPLP and Associated Companies	To P (239,420.84)	308,605.26 Total
230 Coventry	17% (51,777.97)	
230 Rhodes Overage to PPLP		
403 OSR	3% (8,072.45)	
416 PRALP	3% (9,333.99)	
	97% (308,605.26)	


(4)

(3)

## Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

In 2019, according to PPLP’s accounting records in SAP, the “Purdue bank group” was charged through G/L account 690300 (TXP Direct Cost Assessment) for financial and tax services. The amounts for 2019 are illustrated below.

G/L Account Line Item Display



G/L Account690300TXP Direct Cost Assessment

Company Code\*

CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	Order	
<input type="checkbox"/>	208	100178887	02/28/2019	03/12/2019	2	2019/02	SA	2301208	RK 1218 48	690300	GEN	2019 TXP assessment out	240,280.49	USD	
<input type="checkbox"/>	208	100178888	02/28/2019	03/12/2019	2	2019/02	SA	2301208	RK 0219 02	690300	GEN	2019 TXP assessment out	240,280.49	USD	
<input type="checkbox"/>	307	100036836	02/28/2019	03/12/2019	2	2019/02	SA	2301307	RK 1218 48	690300	GEN	2019 TXP assessment out	27,606.42	USD	
<input type="checkbox"/>	307	100036837	02/28/2019	03/12/2019	2	2019/02	SA	2301307	RK 0219 02	690300	GEN	2019 TXP assessment out	27,606.42	USD	
<input type="checkbox"/>	208	100179072	03/31/2019	03/31/2019	3	2019/03	SA	2301208	RK 0319 02	690300	GEN	2019 TXP assessment out	240,280.49	USD	
<input type="checkbox"/>	307	100036866	03/31/2019	03/31/2019	3	2019/03	SA	2996307	RK 0319 02	690300	GEN	2019 TXP assessment out	27,606.42	USD	
<input type="checkbox"/>	208	100179457	04/30/2019	04/30/2019	4	2019/04	SA	2301208	RK 0419	690300	GEN	2019 TXP assessment out	240,280.49	USD	
<input type="checkbox"/>	307	100036958	04/30/2019	04/30/2019	4	2019/04	SA	2996307	RK 0419	690300	GEN	2019 TXP assessment out	27,606.42	USD	
<input type="checkbox"/>	208	100179795	05/31/2019	05/31/2019	5	2019/05	SA	2301208	RK 0519 02	690300	GEN	2019 TXP assessment out	240,280.49	USD	
<input type="checkbox"/>	307	100037028	05/31/2019	05/31/2019	5	2019/05	SA	2996307	RK 0519 02	690300	GEN	2019 TXP assessment out	27,606.42	USD	
<input type="checkbox"/>	208	100180340	06/30/2019	07/08/2019	6	2019/06	SA	2301208	AT 0619 03	690300	GEN	2019 TXP assessment out	240,280.49	USD	
<input type="checkbox"/>	208	100180360	06/30/2019	07/08/2019	6	2019/06	AB	2301208	AT 0619 03	690300	GEN	2019 TXP assessment out	240,280.49	USD	
<input type="checkbox"/>	307	100037152	06/30/2019	07/08/2019	6	2019/06	SA	2996307	AT 0619 03	690300	GEN	2019 TXP assessment out	27,606.42	USD	
<input type="checkbox"/>	307	100037154	06/30/2019	07/08/2019	6	2019/06	AB	2996307	AT 0619 03	690300	GEN	2019 TXP assessment out	27,606.42	USD	
<input type="checkbox"/>	208	100180416	06/30/2019	07/09/2019	6	2019/06	SA	2301208	AT 0619 03A	690300	GEN	2019 TXP assessment out	240,280.49	USD	
<input type="checkbox"/>	307	100037160	06/30/2019	07/09/2019	6	2019/06	SA	2996307	AT 0619 03A	690300	GEN	2019 TXP assessment out	27,606.42	USD	
<input type="checkbox"/>	208	100180666	07/31/2019	08/06/2019	7	2019/07	SA	2301208	TXP 0719	690300	GEN	2019 TXP assessment out	240,280.49	USD	
<input type="checkbox"/>	307	100037224	07/31/2019	08/06/2019	7	2019/07	SA	2996307	TXP 0719	690300	GEN	2019 TXP assessment out	27,606.42	USD	
<input type="checkbox"/>	208	100180932	08/31/2019	09/04/2019	8	2019/08	SA	2301208	TXP 0819	690300	GEN	2019 TXP assessment out	240,280.49	USD	
<input type="checkbox"/>	307	100037280	08/31/2019	09/04/2019	8	2019/08	SA	2996307	TXP 0819	690300	GEN	2019 TXP assessment out	27,606.42	USD	
<input type="checkbox"/>	*											2,143,095.28	USD		



## Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

In 2019, three additional charges (contractually required under the July 2018 service agreement as amended) were paid to TXP, totaling \$416,697. These were accounted for on PPLP's books (SAP company code 208) under account 200010 (Intercompany Accounts Payable) under vendor number 7010066 (TXP), as well as under account 102415 (Intercompany Account – TXP). The invoice and contract excerpt<sup>1</sup> for the two larger payments, as well as their SAP entries, are illustrated below.

**TXP SERVICES, INC.**  
One Stamford Forum, 201 Tresser Blvd; Stamford, CT 06901-3431

BILL TO: Purdue Pharma LP  
One Stamford Forum  
201 Tresser Blvd  
Stamford, CT 06901

SHIP TO:

INVOICE DATE: 6/10/2019

INVOICE NUMBER: TXP-51

TERMS: Due Upon Receipt

Quantity	Description	Price	Total
	Special Fee per Shared Service Agreement		

Document Overview - Display

Doc. Type : ZP ( Payment posting ) Normal document  
Doc. Number : 2000156325 Company Code : 208 Fiscal Year : 2019  
Doc. Date : 06/21/2019 Posting Date : 06/21/2019 Period : 06  
Calculate Tax ☐  
Doc. Currency : USD  
Payment Run ID : 06/21/2019 - PAYS

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	TX	Amount	Text
1	25	7010066	TXP SERVICES INC		GEN				
2	50	100010	Cash Concentration		GEN				

3. Compensation. Effective as of the Effective Date, Section 3 of the Services Agreement is hereby amended to:

(a) delete and replace in its entirety the number [REDACTED] in the second sentence of subsection (a) thereof with: [REDACTED];

(b) add a new subsection (e) after subsection (d) thereof that consists of the following words, numbers and punctuation:

“(e) A special one-time fee of [REDACTED] (the “Second Special Fee”), subject to any refunds owed to Purdue as described below. The Second Special Fee will be invoiced on August 7, 2019 and paid within five (5) business days. The parties agree that the Second Special Fee relates to a specific expense of TXP that is subject to one or more potential refunds. If at any time or from time to time TXP receives one or more refunds in

Document Overview - Display

Doc. Type : SA ( G/L account document ) Normal document  
Doc. Number : 100180759 Company Code : 208 Fiscal Year : 2019  
Doc. Date : 08/15/2019 Posting Date : 08/14/2019 Period : 08  
Calculate Tax ☐  
Ref. Doc. : CMS Overall No. : 0100180759208 19  
Doc. Currency : USD  
Doc. Hdr Text : CTW208 08052019-08142019

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	TX	Amount	Text
72	50	100010	Cash Concentration		GEN			240,280.49	1503221604 TXP SERVICES INC ONE STAMFORD FORUM STA
73	50	100010	Cash Concentration		GEN			[REDACTED]	1503221604 TXP SERVICES INC ONE STAMFORD FORUM STA
173	40	102415	TXP Services		GEN			590,144.99	

<sup>1</sup>Per discussions with Purdue, no invoice was issued for the [REDACTED] “Second Special Fee” payment.

## Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

Individual cash settlements for TXP's services were not performed up until 2014. The first chart below illustrates the cumulative balances, debits, and credits from 2008 to September 15, 2019 in account 102415 (Intercompany Accounts – TXP Services Inc.) across the "Purdue bank group" of companies.<sup>1</sup> The second chart illustrates charges to accounts 793160 (TXP Cost Assessment), 793170 (TXP Mark Up), and 200010 (Intercompany Accounts Payable) under vendor number 7010066 (TXP) for services provided by TXP to Purdue.

Account 102415 <sup>2</sup>	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Totals
Prior Year Cumulative Balance	\$ -	\$ (315,910)	\$ (109,254)	\$ (667,099)	\$ (448,295)	\$ (657,776)	\$ (590,983)	\$ (403,143)	\$ (534,907)	\$ (509,627)	\$ (784,515)	\$ (902,024)	
Debits	1,469,749	1,582,162	8,940,652	2,245,000	1,667,669	3,912,429	2,151,750	1,306,651	2,299,904	2,316,239	11,161,770	6,581,847	45,635,823
Credits	(1,785,659)	(1,375,506)	(9,498,497)	(2,026,196)	(1,877,151)	(3,845,636)	(1,963,911)	(1,438,415)	(2,274,625)	(2,591,126)	(11,279,279)	(4,954,515)	(44,910,515)
Ending Cumulative Balance	\$ (315,910)	\$ (109,254)	\$ (667,099)	\$ (448,295)	\$ (657,776)	\$ (590,983)	\$ (403,143)	\$ (534,907)	\$ (509,627)	\$ (784,515)	\$ (902,024)	\$ 725,308	
Cash Wire Sweep (CWS) Payments	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 600,000	\$ 1,000,000	\$ 1,750,000	\$ 1,125,000	\$ 2,940,669	\$ 3,627,732	\$ 11,043,402
Other Non-CWS Debits	1,469,749	1,582,162	8,940,652	2,245,000	1,667,669	3,912,429	1,551,750	306,651	549,904	1,191,239	8,221,101	2,954,115	34,592,421
Total Debits	\$ 1,469,749	\$ 1,582,162	\$ 8,940,652	\$ 2,245,000	\$ 1,667,669	\$ 3,912,429	\$ 2,151,750	\$ 1,306,651	\$ 2,299,904	\$ 2,316,239	\$ 11,161,770	\$ 6,581,847	\$ 45,635,823
Accounts 793160, 793170, and 200010	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Totals
TXP Assessments and Service Charges	\$ 1,038,363	\$ 971,339	\$ 1,876,315	\$ 1,908,805	\$ 1,870,552	\$ 1,849,805	\$ 1,262,983	\$ 1,226,247	\$ 1,388,196	\$ 1,555,265	\$ 2,502,912	\$ 2,559,793	\$ 20,010,575

<sup>1</sup>PPLP charges TXP for various costs such as pension, software, employee compensation, intercompany interest, etc. Charges and funding for these other items, along with adjusting journal entries (e.g. reclassifications, consolidating entries, etc.) represent the remaining portion of the activity in account 102415 for various SAP company codes which make up the "Purdue bank group" of companies (as defined below). Per discussions with Purdue and TXP, no formal agreements exist for these arrangements prior to July of 2018. Beginning July 1, 2018, the nature and amounts charges for these shared services were defined in the July 2018 services agreement.

<sup>2</sup>Represents the aggregate debits, credits, and balances on account 102415 across SAP company codes 208, 211, 213, 219, 225, 231, 240, 241, 256, 257, 258, 307, 313, and 318.

## Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

The screenshots below illustrate the last few years of cash payments, including the total cash payments of \$11.0 million, and the last payment from September 2019.

G/L Account Line Item Display

</

Document Overview - Display

Doc.Type : SA (9/L account document) | Normal document

Doc. Number 10007242 Company Code 307

Doc. Date 08/15/2019 Posting Date 08/14/2019 Fiscal Year 08

Calculate Tax

Ref. Doc. CMS Overall No. 010007242307 USD

Doc. Currency USD

Doc. Hdr Text CTW307 08052019-08142019

Tax data

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tr	Amount	Text
1	40	100010	Cash Concentration		GEN			35,203.73	CASH CONCENTRATION TRANSFER CREDIT FROM ACCOUNT
2	40	100010	Cash Concentration		GEN		876.21	71,754.54	CASH CONCENTRATION TRANSFER CREDIT FROM ACCOUNT
3	40	100010	Cash Concentration		GEN		761.88	609010177	CASH CONCENTRATION TRANSFER CREDIT FROM ACCOUNT
4	40	100010	Cash Concentration		GEN		88,317.23		CASH CONCENTRATION TRANSFER CREDIT FROM ACCOUNT
5	50	100010	Cash Concentration		GEN			TAX SERVICE 702	CASH CONCENTRATION TRANSFER CREDIT FROM ACCOUNT
7	40	100010	Cash Concentration		GEN		154,824.35		CASH CONCENTRATION TRANSFER CREDIT FROM ACCOUNT
8	40	100010	Cash Concentration		GEN		139,024.78		CASH CONCENTRATION TRANSFER CREDIT FROM ACCOUNT
9	40	100010	Cash Concentration		GEN			27,606.42	CASH CONCENTRATION TRANSFER CREDIT FROM ACCOUNT
10	50	100010	Cash Concentration		GEN		826,448.97		CASH CONCENTRATION TRANSFER CREDIT FROM ACCOUNT
12	50	100050	Misc. Cash Clearing		GEN		7,671.88	609010177	CASH CONCENTRATION TRANSFER CREDIT FROM ACCOUNT
13	40	201180	Payroll Suspense		GEN		96,189.11		TAX SERVICE 702
14	40	100208	Purdue Pharma L.P.		GEN	2,40	27,592.92		
15	40	100245	TRX Services		GEN		27,606.42		



## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

On September 17, 2010, Purdue entered into a research services agreement with Mundipharma Research Limited, the service provider, which replaced the 2003 agreement. The agreement was amended in March 2017 and February 2018, adding and replacing the covered projects listed in Schedule 2 of the agreement. All other terms and conditions remain unchanged.

### RESEARCH SERVICES AGREEMENT

THIS AGREEMENT (this "Agreement") is entered into as of *17 September* 2010 by and between PURDUE PHARMA LP, a limited partnership having its place of business at One Stamford Forum, Stamford, CT 06901-3431, USA ("Customer"), and MUNDIPHARMA RESEARCH LIMITED, company no. 04608592, having its registered office at Cambridge Science Park, Milton Road, Cambridge CB4 0AB ("Service Provider")

#### WHEREAS:

- A. Customer is in the business of distributing pharmaceutical products.
- B. Service Provider is in the business of providing clinical research and development services.
- C. Customer and Service Provider entered into a research services agreement effective 1<sup>st</sup> January 2003 (the "2003 Research Services Agreement") pursuant to which Customer appointed Service Provider to provide it with clinical research and development services.
- D. Customer and Service Provider desire to amend and restate the 2003 Research Services Agreement to set forth revised terms and conditions upon which Service Provider will provide clinical research and development services to the Customer with effect from 1<sup>st</sup> January 2010.

### SCHEDULE 2

#### Product/Projects

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

## **Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services**

Pursuant to the research services agreement, Purdue pays Mundipharma Research Limited i) costs and expenses and ii) [REDACTED] of such costs and expenses as a service charge on a monthly basis.

### **7. INVOICES AND PAYMENT**

- 7.1 Within thirty days of the end of each calendar month, Service Provider shall submit to Customer an invoice showing the actual costs and expenses incurred by Service Provider in providing Services during such calendar month and supported by materials in substantially the same form as set out in Schedule 5 and containing a service charge in the amount of [REDACTED] of such costs and expenses save where research services are provided by an Associate Approved Sub-Contractor in which event the service charge will be in the amount of [REDACTED] of the cost of such Associate Approved-Sub Contractor.

## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

From 2008 through September 15, 2019, Purdue was charged \$80.5 million for the research services provided (costs and expenses plus markups<sup>1</sup>) by Mundipharma Research Limited, through PPLP (SAP company code 208) and two of its subsidiaries: PPPLP (SAP company code 313) and Imbrium Therapeutics L.P. ("Imbrium") (SAP company code 256).

Year	SAP Company Code			Total
	208	313	256	
2008	\$ 15,325,659	\$ -	\$ -	\$ 15,325,659
2009	8,404,405	-	-	8,404,405
2010	5,799,177	-	-	5,799,177
2011	3,333,509	-	-	3,333,509
2012	3,988,844	-	-	3,988,844
2013	3,283,531	-	-	3,283,531
2014	2,528,567	3,795,167	-	6,323,734
2015	1,132,803	5,382,312	-	6,515,115
2016	2,383,248	7,644,617	-	10,027,865
2017	3,865,134	6,796,256	-	10,661,390
2018	5,425,366	373,125	-	5,798,491
2019	563,751	443,998	47,984	1,055,733
<b>Total</b>	<b>\$ 56,033,992</b>	<b>\$ 24,435,476</b>	<b>\$ 47,984</b>	<b>\$ 80,517,452</b>

<sup>1</sup>Per discussion with Purdue, the █████ markups are included in the total invoiced amount, and not as shown as a separate line item. As such, the service charges are not separately discernable in SAP.

## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

According to PPLP's accounting records in SAP, PPLP (SAP company code 208) recognized the vendor payments related to R&D services from Mundipharma Research Limited (vendor ID 1027657) as follows.

Vendor Line Item Display

## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

According to PPPLP's accounting records in SAP, PPPLP (SAP company code 313) recognized the vendor payments related to R&D services from Mundipharma Research Limited (vendor ID 1027657) as follows.

Vendor		1027657							
Company Code		313							
Name		MUNDIPHARMA RESEARCH LTD							
City		CAMBRIDGE							

St	Assignment	DocumentNo	Type	Doc. Date	S	DD	Amount in local cur.	LCurr	Clrng doc.	Text
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003223	RE	10.10.2017			703.176,51-	USD	1500000381	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003246	RE	07.11.2017			446.048,09-	USD	1500000382	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003296	RE	07.12.2017			172.380,80	USD	1500000385	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003319	RE	31.01.2018			11.359,86	USD	1500000385	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003342	RE	08.03.2018			568.200,46-	USD	1500000385	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003407	RE	07.06.2018			170.237,02-	USD	1500000389	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003485	RE	07.06.2018			591.981,44	USD	1500000391	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003486	RE	10.05.2018			121.115,84-	USD	1500000391	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003487	RE	09.04.2018			349.980,08-	USD	1500000391	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003502	RE	07.08.2018			47.376,08-	USD	1500000391	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003553	RE	10.09.2018			47.495,81	USD	1500000391	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003572	RE	07.11.2018			33.762,91	USD	1500000391	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003573	RE	08.10.2018			33.139,86	USD	1500000391	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003614	RE	10.12.2018			6.336,20-	USD	1500000391	Clinical Pharmacology and Research Charges 11-2018
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003630	RE	06.02.2019			26.896,98-	USD	1500000391	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003632	RE	06.02.2019			417.101,13-	USD	1500000391	
* <input checked="" type="checkbox"/>							24.435.475,56-	USD		
** Account 1027657							24.435.475,56-	USD		

## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

According to Imbrium's accounting records in SAP, Imbrium (SAP company code 256) recognized the vendor payments related to R&D services from Mundipharma Research Limited (vendor ID 1027657) as follows.

Vendor	1027657
Company Code	256
Name	MUNDIPHARMA RESEARCH LTD
City	CAMBRIDGE

St	Assignment	DocumentNo	Type	Doc. Date	S	DD	Amount in local cur.	LCurr	Clrng doc.	Text
	<input type="checkbox"/> SCAN	4900000078	RE	31.12.2018			47.984,10-	USD	1500000005	
*	<input type="checkbox"/>						47.984,10-	USD		
** Account 1027657							47.984,10-	USD		



## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

According to PPLP's and PPPLP's accounting records in SAP, PPLP (SAP company code 208) and PPPLP (SAP company code 313) recognized the expenses related to R&D services from Mundipharma Research Limited through G/L account 800100 (Foreign Other Expense). 2018 is illustrated below.<sup>1</sup>

G/L Account Company Code		800100 *		Foreign Other Expense						
CoCd	DocumentNo	Pstng Date	Doc. Date	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.
<input type="checkbox"/> 208	4900123106	15.03.2018	08.03.2018	RE	9005208	MRL18004	800100	GEN		361.843,58
<input type="checkbox"/> 313	4900003342	15.03.2018	08.03.2018	RE	9005313	MRL18010	800100	GEN		568.200,46
<input type="checkbox"/> 208	4900124671	01.05.2018	09.04.2018	RE	9005208	MRL18029	800100	GEN		311.615,79
<input type="checkbox"/> 313	4900003487	19.07.2018	09.04.2018	RE	9005313	MRL18035	800100	GEN		349.980,08
<input type="checkbox"/> 208	4900126214	19.06.2018	10.05.2018	RE	9005208	MRL18049	800100	GEN		166.379,24
<input type="checkbox"/> 313	4900003486	18.07.2018	10.05.2018	RE	9005313	MRL18045	800100	GEN		121.115,84
<input type="checkbox"/> 208	4900126166	18.06.2018	07.06.2018	RE	9005208	MRL18062	800100	GEN		461.648,90
<input type="checkbox"/> 208	4900127170	19.07.2018	07.06.2018	RE	9005208	MRL18077	800100	GEN		446.565,63
<input type="checkbox"/> 313	4900003485	18.07.2018	07.06.2018	RE	9005313	MRL18074	800100	GEN		591.981,44-
<input type="checkbox"/> 313	4900003407	18.06.2018	07.06.2018	RE	9005313	MRL18059	800100	GEN		170.237,02
<input type="checkbox"/> 208	4900127911	16.08.2018	07.08.2018	RE	9005208	MRL18092	800100	GEN		991.911,91
<input type="checkbox"/> 313	4900003502	15.08.2018	07.08.2018	RE	9005313	MRL18089	800100	GEN		47.376,08
<input type="checkbox"/> 208	4900129132	08.10.2018	10.09.2018	RE	9005208	MRL18107	800100	GEN		1.170.529,61
<input type="checkbox"/> 313	4900003553	04.10.2018	10.09.2018	RE	9005313	MRL18113	800100	GEN		47.495,81-
<input type="checkbox"/> 208	4900130233	28.11.2018	08.10.2018	RE	9005208	MRL18124	800100	GEN		5.570,45
<input type="checkbox"/> 313	4900003573	28.11.2018	08.10.2018	RE	9005313	MRL18129	800100	GEN		33.139,86-
<input type="checkbox"/> 208	4900130423	06.12.2018	07.11.2018	RE	9005208	MRL18139	800100	GEN		603.091,01
<input type="checkbox"/> 313	4900003572	28.11.2018	07.11.2018	RE	9005313	MRL18145	800100	GEN		33.762,91-
<input type="checkbox"/> 208	4900130817	14.12.2018	10.12.2018	RE	9005208	MRL18155	800100	GEN	Clinical Pharmacology Research Charges for 11-2018	295.069,49
<input type="checkbox"/> 313	4900003614	14.12.2018	10.12.2018	RE	9005313	MRL18161	800100	GEN	Clinical Pharmacology and Research Charges 11-2018	6.336,20
<input checked="" type="checkbox"/> *										5.773.280,64

Note:

- Several G/L accounts were used to book the research service expenses before 2017. For example: 205110 - Accrued Other / 607330 - Subscriptions-Info Svc / 608640 - Outside Services / 609530 - Nonclinical Outsourcing / 800000 - Misc. Charge/Expense.

<sup>1</sup>In addition to the transactions in account 800100 illustrated in this screenshot, one transaction for \$25,210.13 was recognized in account 607330 in 2018. The sum of these transactions equals \$5,798,491, which ties to the amount for 2018 in the table on slide 135.

## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

Cash payments were recognized in PPLP's accounting records as follows. The final invoice sent to PPLP in 2018 is illustrated below.

Account Number	Account Description	DR	CR
Invoice received:			
800100	Foreign Other Expense	\$ 295,069	
200011	Account Payable Intercompany Foreign		\$ (295,069)
Cash paid:			
200011	Account Payable Intercompany Foreign	\$ 295,069	
700520	Gain/Loss on Exchange (Realized)	\$ 5,737	
100010	Cash Concentration		\$ (300,807)

## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

These entries appears in SAP as follows. The final invoice sent to PPLP in 2018 is illustrated below.

Invoice received:

Doc.Type : RE ( Invoice - gross ) Normal document					
Doc. Number	4900130817	Company Code	208	Fiscal Year	2018
Doc. Date	10.12.2018	Posting Date	14.12.2018	Period	12
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	MRL18155				
Doc. Currency	GBP				
Doc. Hdr Text	ARIBA_P2F				

Vendor	1027657	MUNDIPHARMA RESEARCH LTD	G/L Acc.	200011
Company Code	208	194 CAMBRIDGE SCIENCE PARK		
Purdue Pharma L.P.		CAMBRIDGE		
Doc. no.	4900130817			
Line Item 1 / Invoice / 31				
Amount	233.310,00	GBP	Amount in LC	295.069,49 USD
Tax code	U1			

G/L Acct	CoCd	Long Text
200011	208	Accounts Payable Intercompany Foreign

Itm	PK	Account	Account short text	Amount in LC	Text
1	31	1027657	MUNDIPHARMA RESEARCH	295.069,49	Clinical Pharmacology Research Charges for 11-2018
2	81	800100	Foreign Other Exp.	295.069,49	Clinical Pharmacology Research Charges for 11-2018

Cash paid:

Doc.Type : KZ ( Vendor payment ) Normal document					
Doc. Number	1500012661	Company Code	208	Fiscal Year	2019
Doc. Date	16.01.2019	Posting Date	15.02.2019	Period	02
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	MRL18155				
Doc. Currency	GBP				

Vendor	1027657	MUNDIPHARMA RESEARCH LTD	G/L Acc.	200011
Company Code	208	194 CAMBRIDGE SCIENCE PARK		
Purdue Pharma L.P.		CAMBRIDGE		
Doc. no.	1500012661			
Line Item 2 / Outgoing payment / 25				
Amount	233.310,00	GBP	Amount in LC	295.069,49 USD
Tax code				

Itm	PK	Account	Account short text	Amount in LC	Text
1	50	100010	Cash Concentration	300.806,58-	
2	25	1027657	MUNDIPHARMA RESEARCH	295.069,49	WIRE CLEARING
3	40	700520	Realized FX	5.737,09	

## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

These entries appears in SAP as follows. The first invoice sent to PPLP in 2008 is illustrated below.

Invoice received:

Doc.Type : KR ( Vendor invoice ) Normal document					Vendor	1027657	MUNDIPHARMA RESEARCH LTD	G/L Acc	200000
Doc. Number 1900043101 Company Code 208 Fiscal Year 2008					Company Code	208	194 CAMBRIDGE SCIENCE PARK		
Doc. Date 09.06.2008 Posting Date 14.07.2008 Period 07					Purdue Pharma L.P.		CAMBRIDGE		
Calculate Tax <input checked="" type="checkbox"/>					Line Item 1 / Invoice / 31				
Ref.Doc. MR08060					Amount	975.672,80	USD		
Doc. Currency USD					Tax code	U1			

Itm	PK	Account	Account short text	Amount	Text
1	31	1027657	MUNDIPHARMA RESEARCH	975.672,80-	RESEARCH CHARGES
2	40	205110	Accr. Other	975.672,80	RESEARCH CHARGES

Long Text	CoCd	G/L Acct
Accts Payable Trade	208	200000

Cash paid:

Doc.Type : KZ ( Vendor payment ) Normal document					Vendor	1027657	MUNDIPHARMA RESEARCH LTD	G/L Acc	200000
Doc. Number 1500002068 Company Code 208 Fiscal Year 2008					Company Code	208	194 CAMBRIDGE SCIENCE PARK		
Doc. Date 24.07.2008 Posting Date 25.07.2008 Period 07					Purdue Pharma L.P.		CAMBRIDGE		
Calculate Tax <input type="checkbox"/>					Line Item 3 / Outgoing payment / 25				
Ref.Doc. WIRE TRANSFER					Amount	11.125.443,07	USD		
Doc. Currency USD					Tax code				

Itm	PK	Account	Account short text	Amount	Text
1	50	100010	Cash Concentration	11.110.247,89-	
2	50	700520	Realized FX	15.195,18-	Foreign Exchange - Gain/Loss
3	25	1027657	MUNDIPHARMA RESEARCH	11.125.443,07	


  

Clearing Document	Document Number	Amount	Text
1500002068	1900043101	975,672.80	RESEARCH CHARGES
1500002068	1900043102	57,801.28	RESEARCH CHARGES
1500002068	1900043103	5,679,177.82	RESEARCH CHARGES
1500002068	1900043104	4,412,791.17	RESEARCH CHARGES
Total		11,125,443.07	

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

On January 18, 2013, PPLP entered into a services agreement with Mundipharma EDO GmbH. On the same day, PPPLP entered into a similar services agreement with Mundipharma EDO GmbH.

Below is an excerpt of the agreement between PPLP and Mundipharma EDO GmbH.



THIS AGREEMENT is executed as of June 21, 2013 by and between:-

1. **MUNDIPHARMA EDO GMBH**, a Swiss company whose principal place of business is at St. Alban Rheinweg 74, Basel CH-4052 Switzerland ("**Service Provider**"); and
2. **PURDUE PHARMA L.P.**, a Delaware limited partnership whose principal place of business is at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901, USA ("**Customer**").

NOW, THEREFORE, it is agreed as follows:

1. Definitions and Interpretation

- (a) In this Agreement the following expressions shall have the meanings respectively set against them as follows:
  - (i) "Adjustment" has the meaning given such term in Clause 6(d) below;
  - (ii) "Confidential Information" has the meaning given such term in Clause 9(a) below;
  - (iii) "Document" shall include, in addition to any document in writing, any drawing, map, plan, diagram, design, picture or other image, tape, disk or other device or record embodying information in any form;
  - (iv) "Effective Date" means 18th January 2013;

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

Pursuant to the services agreements, Purdue pays Mundipharma EDO GmbH, i) costs incurred and ii) [REDACTED] of costs as a markup. Per discussion with Purdue, Purdue pays the agreed estimated service fees in advance on a quarterly basis, and reconciles estimated versus actual service fees in the following quarter.

### 6. Price and Payment

- (a) With respect to the Term of this Agreement, the price for the Services provided hereunder from time to time shall be (i) the cost to Service Provider of providing the Services plus a markup in the amount of [REDACTED] of such cost and (ii) any direct costs incurred by Service Provider from a third party on behalf of Customer (together, the "Estimated Service Fees"). The Estimated Service Fees for the Term are set forth in Schedule 2.
- (b) Customer will be invoiced for the Services quarterly in advance and will pay the invoice within thirty (30) days, with payments due in amounts as set forth in Schedule 2 (as the same may be amended from time to time).

### SCHEDULE 2

#### Estimated Service Fees

Total	Q1 2013	Q2 2013	Q3 2013	Q4 2013
CHF 406,500.00	CHF 101,625.00	CHF 101,625.00	CHF 101,625.00	CHF 101,625.00



## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

From 2013 to September 15, 2019, Purdue was charged \$31.5 million (costs and markups<sup>1</sup>) for the research services provided by Mundipharma EDO GmbH, through PPLP (SAP company code 208) and two of its subsidiaries: PPPLP (SAP company code 313) and Imbrium (SAP company code 256).

Year	SAP Company Code			Total
	208	313	256	
2013	\$ 136,089	\$ 136,089	\$ -	\$ 272,178
2014	3,704,765	1,302,119	-	5,006,885
2015	406,205	2,043,446	-	2,449,651
2016	1,410,581	1,265,560	-	2,676,142
2017	3,603,299	2,324,353	-	5,927,652
2018	5,711,158	5,130,079	-	10,841,236
2019	-	5,570,794	(1,227,633)	4,343,161
<b>Total</b>	<b>\$ 14,972,098</b>	<b>\$ 17,772,440</b>	<b>\$ (1,227,633)</b>	<b>\$ 31,516,905</b>

<sup>1</sup>Per discussion with Purdue, the [REDACTED] markups are included in the total invoiced amount, and not shown as a separate line item. As such, the service charges are not separately discernable in SAP.

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

According to PPLP's accounting records in SAP, PPLP (SAP company code 208) recognized the vendor payments related to R&D services from Purdue to Mundipharma EDO GmbH (vendor ID 1032927) as follows.

Vendor		1032927								
Company Code		208								
Name		MUNDIPHARMA EDO GMBH								
City		BASEL								

St	Assignment	DocumentNo	Type	Doc. Date	S	DD	Amount in local cur.	LCurr	Clrng doc.	Text
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900108489	RE	18.01.2017			1.459.911,49-	USD	2000130587	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900119467	RE	11.10.2017			1.489.209,64-	USD	2000135315	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900119468	RE	19.07.2017			1.489.209,64-	USD	2000135315	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900119491	RE	19.07.2017			585.155,34	USD	2000135315	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900119492	RE	11.10.2017			975.449,58	USD	2000135315	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900101796	RE	16.07.2016			650.506,28	USD	2000137730	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900111131	RE	18.04.2017			1.184.070,81	USD	2000137730	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900121988	RE	31.01.2018			34.415,82-	USD	2000137730	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900122005	RE	31.01.2018			1.032.527,66-	USD	2000137730	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900125413	RE	19.04.2018			977.155,76-	USD	2000141703	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900125445	RE	19.04.2018			147.242,45	USD	2000141703	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900127295	RE	03.07.2018			981.061,50-	USD	2000144199	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900127309	RE	03.07.2018			1.482.257,01-	USD	2000144199	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900129126	RE	02.10.2018			981.938,10-	USD	2000147294	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900129318	RE	02.10.2018			369.044,37-	USD	2000147557	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>						14.972.097,84-	USD		
** Account 1032927							14.972.097,84-	USD		

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

According to PPPLP's accounting records in SAP, PPPLP (SAP company code 313) recognized the vendor payments related to R&D services from Purdue to Mundipharma EDO GmbH (vendor ID 1032927) as follows.

Vendor		1032927							
Company Code		313							
Name		MUNDIPHARMA EDO GMBH							
City		BASEL							

St	Assignment	DocumentNo	Type	Doc. Date	S	DD	Amount in local cur.	LCurr	Clrng doc.	Text
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900002870	RE	18.10.2016			564.880,54	USD	1500000378	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900002871	RE	31.12.2016			501.332,77	USD	1500000378	Credit Note No. 816031
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900002874	RE	18.10.2016			892.834,81-	USD	1500000378	Invoice No. 816026
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900002876	RE	18.01.2017			962.872,92-	USD	1500000378	Invoice No. 817001
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900002989	RE	18.04.2017			982.682,28-	USD	1500000380	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900002990	RE	18.04.2017			445.645,02	USD	1500000380	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003247	RE	19.07.2017			396.946,30	USD	2000002983	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003248	RE	19.07.2017			984.150,00-	USD	2000002983	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003249	RE	11.10.2017			571.578,62	USD	2000002983	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003250	RE	11.10.2017			982.196,28-	USD	2000002984	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003320	RE	31.01.2018			38.344,52-	USD	2000002998	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003321	RE	31.01.2018			1.634.658,78-	USD	2000002998	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003398	RE	19.04.2018			1.546.996,08-	USD	2000003017	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003403	RE	19.04.2018			603.433,58	USD	2000003017	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003488	RE	03.07.2018			416.637,75	USD	2000003028	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003490	RE	03.07.2018			1.553.179,50-	USD	2000003028	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003552	RE	02.10.2018			177.596,22	USD	2000003038	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003557	RE	02.10.2018			1.554.567,30-	USD	2000003038	
<input checked="" type="checkbox"/> *	<input checked="" type="checkbox"/>						12.201.646,51-	USD		

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

According to Imbrium’s accounting records in SAP, Imbrium (SAP company code 256) recognized the vendor payments related to R&D services from Purdue to Mundipharma EDO GmbH (vendor ID 1032927) as follows.

**Vendor Line Item Display**

Vendor: 1032927  
Company Code: 256

Name: MUNDIPHARMA EDO GMBH  
City: BASEL

St	Assignment	DocumentNo	Type	Doc. Date	S	DD	Amount in local cur.	LCurr	Clrng doc.	Text
<input type="checkbox"/>	● SCAN	4900000301	RE	08/07/2019		1	1,227,632.73	USD		CREDIT 919016
*	●						1,227,632.73	USD		
<input type="checkbox"/>	■ SCAN	4900000147	RE	04/08/2019			2,761,641.86-	USD	1500000006	
<input type="checkbox"/>	■ SCAN	4900000148	RE	12/31/2018			1,628,878.28-	USD	1500000006	
<input type="checkbox"/>	■ SCAN	4900000149	RE	12/31/2018			139,415.28	USD	1500000006	
<input type="checkbox"/>	■ SCAN	4900000151	RE	04/11/2019			1,319,688.79-	USD	1500000006	
*	■						5,570,793.65-	USD		
** Account 1032927							4,343,160.92-	USD		

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

According to PPLP's and PPPLP's accounting records in SAP, PPLP (SAP company code 208) and PPPLP (SAP company code 313) were charged for R&D service by Mundipharma EDO through G/L account 800000 (Misc. Charge/Expense) and G/L account 690200 (International Charges/Credits). 2018 is illustrated below.

G/L Account Company Code		*								
CoCd	DocumentNo	Pstng Date	Doc. Date	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.
<input type="checkbox"/> 208	4900121988	08.02.2018	31.01.2018	RE	9005208	818008	800000	GEN		34.415,82
<input type="checkbox"/> 208	4900122005	08.02.2018	31.01.2018	RE	9005208	818007	800000	GEN		1.032.527,66
<input type="checkbox"/> 313	4900003320	08.02.2018	31.01.2018	RE	9005313	818010	800000	GEN		38.344,52
<input type="checkbox"/> 313	4900003321	08.02.2018	31.01.2018	RE	9005313	818009	800000	GEN		1.634.658,78
<input type="checkbox"/> 208	4900125413	22.05.2018	19.04.2018	RE	9005208	818017	800000	GEN		977.155,76
<input type="checkbox"/> 208	4900125445	23.05.2018	19.04.2018	RE	9005208	818018	800000	GEN		147.242,45-
<input type="checkbox"/> 313	4900003398	22.05.2018	19.04.2018	RE	9005313	818019	800000	GEN		1.546.996,08
<input type="checkbox"/> 313	4900003403	23.05.2018	19.04.2018	RE	9005313	818020	800000	GEN		603.433,58-
<input type="checkbox"/> 208	4900127295	24.07.2018	03.07.2018	RE	4198EDB	818026	690200	EDB		981.061,50
<input type="checkbox"/> 208	4900127309	24.07.2018	03.07.2018	RE	4198EDB	818025	690200	EDB		1.482.257,01
<input type="checkbox"/> 313	4900003488	19.07.2018	03.07.2018	RE	4198EDS	818028	690200	EDS		416.637,75-
<input type="checkbox"/> 313	4900003490	24.07.2018	03.07.2018	RE	4198EDS	818027	690200	EDS		1.553.179,50
<input type="checkbox"/> 208	4900129126	08.10.2018	02.10.2018	RE	4198EDB	818034	690200	EDB		981.938,10
<input type="checkbox"/> 208	4900129318	16.10.2018	02.10.2018	RE	4198EDB	818039	690200	EDB		369.044,37
<input type="checkbox"/> 313	4900003552	04.10.2018	02.10.2018	RE	4198EDS	818040	690200	EDS		177.596,22-
<input type="checkbox"/> 313	4900003557	08.10.2018	02.10.2018	RE	4198EDS	818035	690200	EDS		1.554.567,30
<input checked="" type="checkbox"/> *										10.841.236,40

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

Cash payments were recognized as follows in PPLP's accounting records in SAP. The Q1 2018 advance payment is illustrated below.

Account Number	Account Description	DR	CR
Invoice received - Advance payment for R&D services:			
800000	Misc. Charges/Expenses	\$ 1,032,528	
200011	Account Payable Intercompany Foreign		\$ (1,032,528)
Cash paid:			
200011	Account Payable Intercompany Foreign - Example	\$ 1,032,528	
200011	Account Payable Intercompany Foreign - Other R&D services related		\$ (371,517)
700520	Gain/Loss on Exchange (Realized)		\$ (35,325)
100010	Cash Concentration		\$ (625,685)

Clearing Document	Document Number	Amount	Text
2000137730	4900122005	1,032,527.66	Agreed advance payment - 1Q2018
2000137730	4900101796	-650,506.28	True-up - 4Q2016
2000137730	4900111131	-1,184,070.81	True-up - 1Q2017
2000137730	1500012124	1,428,643.83	Agreed advance payment - 4Q2017
2000137730	4900121988	34,415.82	Agreed additional payment - 4Q2017

Total:  
\$ - 371,517



## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

These entries appear in SAP in PPLP's accounting records (SAP company code 208) through G/L account 200011 (Accounts Payable Intercompany Foreign). The Q1 2018 advance payment is illustrated below.

Invoice received - Advance payment for R&D services:

Doc.Type : RE ( Invoice - gross ) Normal document					
Doc. Number	4900122005	Company Code	208	Fiscal Year	2018
Doc. Date	31.01.2018	Posting Date	08.02.2018	Period	02
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	818007				
Doc. Currency	CHF				
Doc. Hdr Text	ARIBA_P2P				

Vendor	1032927	MUNDIPHARMA EDO GMBH	G/L Acc	200011
Company Code	208	ST ALBAN RHEINWEG 74		
Purdue Pharma L.P.	BASEL			
Doc. no.	4900122005			

Line Item 1 / Invoice / 31	
Amount	974.000,00 CHF Amount in LC 1.032.527,66 USD
Tax code	U1

G/L Acct	CoCd	Long Text
200011	208	Accounts Payable Intercompany Foreign

Itm	PK	Account	Account short text	Amount in LC	Text
1	31	1032927	MUNDIPHARMA EDO GMBH	1.032.527,66-	
2	81	800000	Misc. Charge/Expense	1.032.527,66	

Cash paid:

Doc.Type : ZP ( Payment posting ) Normal document					
Doc. Number	2000137730	Company Code	208	Fiscal Year	2018
Doc. Date	09.02.2018	Posting Date	09.02.2018	Period	02
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	CHF				
Payment Run ID	09.02.2018 - PAY12				

Vendor	1032927	MUNDIPHARMA EDO GMBH	G/L Acc	200011
Company Code	208	ST ALBAN RHEINWEG 74		
Purdue Pharma L.P.	BASEL			
Doc. no.	2000137730			

Line Item 1 / Outgoing payment / 25	
Amount	585.316,00 CHF Amount in LC 661.010,22 USD
Tax code	

Itm	PK	Account	Account short text	Amount in LC	Text
1	25	1032927	MUNDIPHARMA EDO GMBH	661.010,22	
2	50	100010	Cash Concentration	625.685,24-	
3	50	700520	Realized FX	35.324,98-	

Clearing Document	Document Number	Amount	Text
2000137730	4900122005	1,032,527.66	Agreed advance payment - 1Q2018
2000137730	4900101796	-650,506.28	True-up - 4Q2016
2000137730	4900111131	-1,184,070.81	True-up - 1Q2017
2000137730	1500012124	1,428,643.83	Agreed advance payment - 4Q2017
2000137730	4900121988	34,415.82	Agreed additional payment - 4Q2017
Total		661,010.22	

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

These entries appear in SAP in PPLP's books (SAP company code 208) through G/L account 200011 (Accounts Payable Intercompany Foreign). An example of a Q4 2013 advance payment (the first payment) is shown below.

Invoice received - Advance payment for R&D services:

Doc.Type : KR ( Vendor invoice ) Normal document					
Doc. Number	1900117926	Company Code	208	Fiscal Year	2013
Doc. Date	01.10.2013	Posting Date	07.10.2013	Period	10
Calculate Tax	<input checked="" type="checkbox"/>				
Ref.Doc.	813015A				
Doc. Currency	USD				

Vendor	1032927	MUNDIPHARMA EDO GMBH	G/L Acc	200011
Company Code	208	ST ALBAN RHEINWEG 74		
Purdue Pharma L.P.		BASEL		
Doc. no.	1900117926			

Line Item 1 / Invoice / 31	
Amount	136.089,04 USD
Tax code	

G/L Acct	CoCd	Long Text
200011	208	Accounts Payable Intercompany Foreign

Itm	PK	Account	Account short text	Amount	Text
1	31	1032927	MUNDIPHARMA EDO GMBH	136.089,04-	
2	40	800000	Misc. Charge/Expense	136.089,04	

Cash paid:

Doc.Type : KZ ( Vendor payment ) Normal document					
Doc. Number	1500008494	Company Code	208	Fiscal Year	2013
Doc. Date	09.10.2013	Posting Date	11.10.2013	Period	10
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	WIRE TRANSFER				
Doc. Currency	USD				

Vendor	1032927	MUNDIPHARMA EDO GMBH	G/L Acc	200011
Company Code	208	ST ALBAN RHEINWEG 74		
Purdue Pharma L.P.		BASEL		
Doc. no.	1500008494			

Line Item 3 / Outgoing payment / 25	
Amount	136.089,04 USD
Tax code	

Itm	PK	Account	Account short text	Amount	Text
1	50	100010	Cash Concentration	135.983,84-	
2	50	700520	Realized FX	105,20-	
3	25	1032927	MUNDIPHARMA EDO GMBH	136.089,04	

## Exhibit 1J: Intercompany transfers between Purdue and Mundipharma International UK for consulting and legal services

On July 4, 2012, Purdue entered into a services agreement with Mundipharma International Limited (UK) ("MIL UK"). Based on discussions with Purdue, the services provided included director consulting services (i.e., management consulting and general and administrative services). On January 1, 2015, Purdue entered into a second services agreement with MIL UK which expanded the scope of services provided to Purdue to include legal services.

THIS AGREEMENT is executed as of July 4, 2012 by and between:-

1. **MUNDIPHARMA INTERNATIONAL LIMITED**, a company incorporated in England & Wales (Company number 02763367), whose registered office is at Cambridge Science Park, Milton Road, Cambridge CB4 0AB, England and whose VAT registration number is GB 599 7822 57 ("**Service Provider**"); and
2. **PURDUE PHARMA L.P.**, a Delaware limited partnership, whose principal place of business is at One Stamford Forum, Stamford, Connecticut 06901 ("**Customer**").

2. Range of Services

- (a) Service Provider will provide such of the Services as may be required by Customer.
- (b) Nothing in this Agreement shall prevent Customer from obtaining all or part of the Services from any other service provider or resource.

### SCHEDULE 1

#### Services

1.	Management Consultancy Services.
2.	General and Administration.

THIS AGREEMENT is executed as of January 1, 2015 by and between:

1. **MUNDIPHARMA INTERNATIONAL LIMITED**, a company incorporated in England & Wales (Company number 02763367), whose registered office is at Cambridge Science Park, Milton Road, Cambridge CB4 0AB, England and whose VAT registration number is GB 599 7822 57 ("**Service Provider**"); and
2. **PURDUE PHARMA L.P.**, a Delaware limited partnership, whose principal place of business is at One Stamford Forum, Stamford, Connecticut 06901, United States ("**Customer**").

2. Range of Services

- (a) Service Provider will provide such of the Services as may be required by Customer from time to time.
- (b) Nothing in this Agreement shall prevent Customer from obtaining all or part of the Services from any other service provider or resource.

### SCHEDULE 1

#### Services

1.	Management Consultancy Services.
2.	General and Administration.
3.	Legal Services.

## Exhibit 1J: Intercompany transfers between Purdue and Mundipharma International UK for consulting and legal services

Pursuant to the services agreement, Purdue agreed to pay an amount equal to the cost of the services plus 10%. Estimated payments were due quarterly (subject to change from the agreed-upon amounts listed in Schedule 2), and an annual reconciliation between estimated payments and actual costs following calendar year-end.

6. Price and Payment

- (a) With respect to the Term of this Agreement, the price for the Services provided hereunder from time to time shall be the sum of (i) the cost to Service Provider of providing the Services plus a service fee in the amount of ten percent (10%) of such cost and (ii) the amount of any disbursements (the "Estimated Payments"). The Estimated Payments for the Term are set forth in Schedule 2.
- (b) Customer will be invoiced for the Services quarterly in advance and will pay the invoice within thirty (30) days, with payments due in amounts as set forth in Schedule 2 (as the same may be amended from time to time).
- (c) Unless otherwise agreed each quarterly invoice will be for an amount equal to one quarter of the Estimated Payments. Service Provider will provide a mid-Year update to the Estimated Payments and will adjust each quarterly invoice to reflect such revised estimates.
- (d) On or before March 31st of the Year following the Term or by such date as agreed by the Parties, the Estimated Payments for the Term will be adjusted as follows (the "Adjustment"): (i) in the event that the sum of (a) the cost to Service Provider of providing the Services plus the service fee and (b) the amount of any disbursements, in each case, for the Term (the "Final Costs") is greater than the Estimated Payments for the Term, Service Provider will raise a supplemental invoice after the expiration of the Term to collect the difference between the Final Costs and the Estimated Payments, or (ii) in the event that the Final Costs are less than the Estimated Payments for the Term, Service Provider will raise a supplemental credit invoice after the expiration of the Term and Service Provider will pay Customer such credit amount within thirty (30) days.

**SCHEDULE 2**

**Estimated Payments**

Total	Q1 2012	Q2 2012	Q3 2012	Q4 2012
£104,000	£26,000	£26,000	£26,000	£26,000

## Exhibit 1J: Intercompany transfers between Purdue and Mundipharma International UK for consulting and legal services

From January 1, 2012 to November 21, 2018, Purdue paid \$4.5 million (costs and markups<sup>1</sup>) to Mundipharma pursuant to the consulting and legal services agreement.

Vendor Name	Vendor Number	Invoice Number	Invoice Date	Company Code	GL Account	Cost Center	Payment Date	Invoice Amount (Original Currency)	SAP Invoice Amount (USD) [1]	SAP Payment Amount (USD) [2]	Payment Year	Invoice Description	SAP Invoice Doc	SAP Payment Doc
MUNDIPHARMA INTERNATIONAL LTD	1008569	5204	7/16/2012	208	608660	2100208	8/20/2012	£ 78,000	\$ 121,865	\$ 122,421	2012	Q1-Q3 2012	1900100601	1500007015
MUNDIPHARMA INTERNATIONAL LTD	1008569	5227R	8/14/2012	208	608660	2301208	9/14/2012	€ 920	\$ 1,133	\$ 1,184	2012	Meeting Expense	1900101492	1500007099
MUNDIPHARMA INTERNATIONAL LTD	1008569	5291	10/1/2012	208	608640	2100208	10/31/2012	£ 26,000	\$ 41,909	\$ 41,740	2012	Q4 2012	1900103959	1500007274
MUNDIPHARMA INTERNATIONAL LTD	1008569	5371R	11/30/2012	208	606300	2100208	11/12/2012	€ 1,750	\$ 2,291	\$ 2,271	2012	Meeting Expense	1900106195	1500007494
MUNDIPHARMA INTERNATIONAL LTD	1008569	5667	3/28/2013	208	608660	2100208	4/30/2013	£ 113,184	\$ 172,007	\$ 256,108	2013	2012 Settlement Amount	1900111022	1500007942
MUNDIPHARMA INTERNATIONAL LTD	1008569	5540	1/9/2013	208	608660	2100208	4/4/2013	£ 52,657	\$ 79,526	\$ 79,681	2013	Q1 2013	1900110363	1500007829
MUNDIPHARMA INTERNATIONAL LTD	1008569	5694	4/3/2013	208	608660	2100208	4/30/2013	£ 52,657	\$ 79,761	\$ -	2013	Q2 2013	1900111023	1500007942
MUNDIPHARMA INTERNATIONAL LTD	1008569	3742R	6/19/2013	208	609350	2100208	7/24/2013	€ 69	\$ 91	\$ 91	2013	Meeting Expense	1900113910	1500008204
MUNDIPHARMA INTERNATIONAL LTD	1008569	5772	7/1/2013	208	608660	2100208	7/31/2013	£ 58,788	\$ 89,199	\$ 90,725	2013	Q3 2013	1900114458	1500008257
MUNDIPHARMA INTERNATIONAL LTD	1008569	5920	10/1/2013	208	608660	2100208	11/5/2013	£ 54,701	\$ 87,223	\$ 87,571	2013	Q4 2013	1900118344	1500008577
MUNDIPHARMA INTERNATIONAL LTD	1008569	6085R	12/17/2013	208	608640	2100208	1/31/2014	£ 121	\$ 198	\$ -	2014	Meeting Expense	1900121857	1500008867
MUNDIPHARMA INTERNATIONAL LTD	1008569	6134R	12/17/2013	208	608660	2100208	1/31/2014	£ 888	\$ 1,455	\$ -	2014	Meeting Expense	1900121858	1500008867
MUNDIPHARMA INTERNATIONAL LTD	1008569	10090	3/28/2014	208	608660	2100208	11/26/2014	£ (81,142)	\$ (134,999)	\$ -	2014	2013 Settlement Amount (Credit)	1700002659	1500009667
MUNDIPHARMA INTERNATIONAL LTD	1008569	10027A	1/1/2014	208	205110		1/31/2014	£ 37,364	\$ 61,516	\$ 63,649	2014	Q1 2014	1900121862	1500008867
MUNDIPHARMA INTERNATIONAL LTD	1008569	10119A	4/1/2014	208	608660	2100208	11/26/2014	£ 37,364	\$ 62,067	\$ -	2014	Q2 2014	1900130601	1500009667
MUNDIPHARMA INTERNATIONAL LTD	1008569	10252	6/30/2014	208	608491	9004208	7/29/2014	£ 97,000	\$ 165,974	\$ -	2014	Celltrion HC	1900128922	1500009392
MUNDIPHARMA INTERNATIONAL LTD	1008569	10246	7/1/2014	208	100010		7/31/2014	£ 90,664	\$ 155,554	\$ 318,015	2014	Q3 2014	1900129636	1500009392
MUNDIPHARMA INTERNATIONAL LTD	1008569	10402	10/30/2014	208	608660	9004208	11/26/2014	£ 289,028	\$ 461,608	\$ 385,607	2014	Q4 2014	1900133368	1500009667
MUNDIPHARMA INTERNATIONAL LTD	1008569	10636	6/15/2015	208	608660	2100208	9/4/2015	£ (6,463)	\$ (10,233)	\$ -	2015	2014 Settlement Amount (Credit)	1700002944	1500010339
MUNDIPHARMA INTERNATIONAL LTD	1008569	10597	2/12/2015	208	608660	9004208	3/6/2015	£ 132,910	\$ 204,126	\$ 202,369	2015	Q1 2015	1900137358	1500009909
MUNDIPHARMA INTERNATIONAL LTD	1008569	10628	4/23/2015	208	608660	2100208	5/29/2015	£ 132,910	\$ 204,172	\$ 203,499	2015	Q2 2015	1900141273	1500010119
MUNDIPHARMA INTERNATIONAL LTD	1008569	10773	8/6/2015	208	608660	2301208	9/4/2015	£ 132,910	\$ 205,171	\$ 193,552	2015	Q3 2015	1900144125	1500010339
MUNDIPHARMA INTERNATIONAL LTD	1008569	10943	12/17/2015	208	609350	2301208	2/22/2016	€ 453	\$ 515	\$ 506	2016	Meeting Expense	1900150671	1500010757
MUNDIPHARMA INTERNATIONAL LTD	1008569	10807B	2/12/2016	208	608660	9004208	9/30/2016	£ 177,760	\$ 248,041	\$ 248,041	2016	Q4 2015	1900156524 / 1900150910	1500010758 / 1500011324
MUNDIPHARMA INTERNATIONAL LTD	1008569	011307D	11/23/2016	208	608660	9004208	12/23/2016	£ (75,440)	\$ (95,272)	\$ -	2016	2015 Settlement Amount (Credit)	4900105102	1500011522
MUNDIPHARMA INTERNATIONAL LTD	1008569	11062	2/23/2016	208	608660	9004208	1/27/2017	£ 149,303	\$ 183,035	\$ -	2017	Q1 2016	4900107024	1500011583
MUNDIPHARMA INTERNATIONAL LTD	1008569	11114	4/20/2016	208	608660	9004208	1/27/2017	£ 149,303	\$ 185,066	\$ 374,225	2017	Q2 2016	4900106946	1500011583
MUNDIPHARMA INTERNATIONAL LTD	1008569	11267	8/25/2016	208	608660	9004208	9/28/2016	£ 148,803	\$ 194,615	\$ 192,975	2016	Q3 2016	4900100860	1500011316
MUNDIPHARMA INTERNATIONAL LTD	1008569	11295	11/21/2016	208	608660	9004208	12/23/2016	£ 201,310	\$ 250,041	\$ 154,712	2016	Q4 2016	4900104368	1500011522
MUNDIPHARMA INTERNATIONAL LTD	1008569	11370	11/30/2016	208	608660	9004208	12/1/2017	£ 7,758	\$ 8,064	\$ 8,209	2017	Meeting Expense	4900105817	1500011538
MUNDIPHARMA INTERNATIONAL LTD	1008569	12024	11/3/2017	208	608660	9004208	12/5/2017	£ 158,162	\$ 208,957	\$ 213,803	2017	2016 Settlement	4900118825	1500012077
MUNDIPHARMA INTERNATIONAL LTD	1008569	11637	1/23/2017	208	608660	9004208	2/23/2017	£ 156,741	\$ 197,454	\$ 194,939	2017	Q1 2017	4900107463	1500011642
MUNDIPHARMA INTERNATIONAL LTD	1008569	11776	4/20/2017	208	608660	9004208	5/19/2017	£ 156,741	\$ 201,701	\$ 203,230	2017	Q2 2017	4900110981	1500011794
MUNDIPHARMA INTERNATIONAL LTD	1008569	11860	7/17/2017	208	608660	9004208	11/8/2017	£ (74,994)	\$ (97,690)	\$ -	2017	Q3 2017	4900114074	1500012045
MUNDIPHARMA INTERNATIONAL LTD	1008569	11964	9/26/2017	208	606400	4705208	10/27/2017	£ 1,703	\$ 2,008	\$ 1,993	2017	Meeting Expense	4900117594	1500012038
MUNDIPHARMA INTERNATIONAL LTD	1008569	11991	10/11/2017	208	608660	9004208	11/8/2017	£ 189,307	\$ 251,527	\$ 150,482	2017	Q4 2017	4900117423	1500012045
MUNDIPHARMA INTERNATIONAL LTD	1008569	SI000075	10/29/2018	208	608660	9004208	11/21/2018	£ 54,105	\$ 69,261	\$ -	2018	2017 Settlement	4900129639	1500012585
MUNDIPHARMA INTERNATIONAL LTD	1008569	12247	2/8/2018	208	608660	9004208	3/12/2018	£ 106,663	\$ 147,414	\$ 147,472	2018	Q1 2018	4900122108	1500012230
MUNDIPHARMA INTERNATIONAL LTD	1008569	12273	4/19/2018	208	608660	9004208	5/18/2018	£ 106,663	\$ 149,366	\$ 144,294	2018	Q2 2018	4900124454	1500012335
MUNDIPHARMA INTERNATIONAL LTD	1008569	12307	4/23/2018	208	606510	2130208	4/24/2018	£ 3,393	\$ 4,143	\$ 3,997	2018	Training Expense	4900124475	1500012360
MUNDIPHARMA INTERNATIONAL LTD	1008569	SI000013	8/21/2018	208	608660	9004208	9/20/2018	£ 106,663	\$ 137,285	\$ 140,433	2018	Q3 2018	4900128218	1500012503
MUNDIPHARMA INTERNATIONAL LTD	1008569	SI000056	10/22/2018	208	608660	9004208	11/21/2018	£ 194,783	\$ 249,973	\$ 320,319	2018	Q4 2018	4900129619	1500012585
MUNDIPHARMA INTERNATIONAL LTD	1008569	SC000019	12/31/2018	208	608660	9004208	Pmt Pending	£ (187,035)	\$ (239,337)	Pmt Pending	TBD	2018 credit	4900131285	Pmt Pending
MUNDIPHARMA INTERNATIONAL LTD	1008569	SI000361	1/31/2019	208	608660	9004208	Pmt Pending	£ 48,330	\$ 63,201	Pmt Pending	TBD	Q1 2019	4900131789	Pmt Pending
MUNDIPHARMA INTERNATIONAL LTD	1008569	SI000392	4/11/2019	208	608660	9004208	Pmt Pending	£ 48,330	\$ 63,287	Pmt Pending	TBD	Q2 2019	4900133105	Pmt Pending
MUNDIPHARMA INTERNATIONAL LTD	1008569	SI000458	4/30/2019	208	606400	2413208	Pmt Pending	£ 1,230	\$ 1,601	Pmt Pending	TBD	Meeting Expense	4900133589	Pmt Pending
MUNDIPHARMA INTERNATIONAL LTD	1008569	SC000020	6/28/2019	208	607060	2301208	Pmt Pending	\$ 8,300	\$ 8,300	Pmt Pending	TBD	Credit - IT / End User Charges	4900134484	Pmt Pending
<b>Total</b>										<b>\$ 4,548,110</b>				

<sup>1</sup>Per discussion with Purdue, the 10% markups are included in the total invoiced amount, and not as shown as a separate line item. As such, the service charges are not separately discernable in SAP.



## **Exhibit 1J: Intercompany transfers between Purdue and Mundipharma International UK for consulting and legal services**

Cash payments were recognized as follows in PPLP's accounting records in SAP. The first payment from 2012 is illustrated below.

<b>Account Number</b>	<b>Account Description</b>	<b>DR</b>	<b>CR</b>
608660	Consultants Fees and Expenses - Management	\$ 121,865	
200011	Accounts Payable (Intercompany Foreign)		\$ (121,865)
200011	Accounts Payable (Intercompany Foreign)	\$ 121,865	
700520	Realized FX Gain/Loss on Exchange	\$ 556	
100010	Cash Concentration		\$ (122,421)

## Exhibit 1J: Intercompany transfers between Purdue and Mundipharma International UK for consulting and legal services

These entries appear in SAP as follows:

**Document Overview - Display**

Doc.Type : KR ( Vendor invoice ) Normal document  
 Doc. Number 1900100601 Company Code 208 Fiscal Year 2012  
 Doc. Date 16.07.2012 Posting Date 01.08.2012 Period 08  
 Calculate Tax ☒  
 Ref.Doc. 5204  
 Doc. Currency USD

Itm	FK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1008569	MUNDIPHARMA INTERNAT		GEN			121.864,52-	
2	40	608660	Consultants - Mgmt.	2100208	GEN			121.864,52	

**Document Overview - Display**

Doc.Type : KZ ( Vendor payment ) Normal document  
 Doc. Number 1500007015 Company Code 208 Fiscal Year 2012  
 Doc. Date 15.08.2012 Posting Date 20.08.2012 Period 08  
 Calculate Tax ☐  
 Ref.Doc. WIRE TRANSFER  
 Doc. Currency USD

Itm	FK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			122.421,00-	
2	40	700520	Realized FX	2100208	GEN			556,48	
3	25	1008569	MUNDIPHARMA INTERNAT		GEN			121.864,52	

**Display Document: Line Item 001**

Additional Data

Vendor 1008569 MUNDIPHARMA INTERNATIONAL LTD G/L Acc 200011  
 Company Code 208 194 CAMBRIDGE SCIENCE PARK  
 Purdue Pharma LP. CAMBRIDGE Doc. no. 1900100601

Line Item 1 / Invoice / 31  
 Amount 121.864,52 USD


General Ledger Account (1) 1 Entry found  
 G/L account with delete/lock flag in chart of accounts Key words

Master records

Long Text ChAc DelRl Pstg block Crtn.block Plan.block G/L Acct  
 Accounts Payable Intercompany Foreign PURD ☐ ☐ ☐ ☐ 200011

## Exhibit 1J: Intercompany transfers between Purdue and Mundipharma International UK for consulting and legal services

SAP contains support for all payments until the most recent payment on November 21, 2018.



Purdue Pharma LP  
201 One Stamford Forum  
Tresser Boulevard  
Stamford  
USA

Bill-to Customer No. [REDACTED]

Posting Date 22. October 2018  
Due Date 21. November 2018  
Payment Terms 30 days

**Invoice No. SI000056**  
**Sales - Invoice**  
Page 1 of 1

Mundipharma International Limited  
Unit 196, Cambridge Science Park  
Milton Road  
Cambridge  
Cambridgeshire CB4 0AB

Phone No. 01223 424211  
E-Mail finance@mundipharma.com

Bank [REDACTED]  
Account No. [REDACTED]  
Sort Code [REDACTED]  
SWIFT Code [REDACTED]  
IBAN [REDACTED]  
VAT Registration No. [REDACTED]

Description	Quantity	Unit of Measure	Unit Price	VAT %	Amount
Qtr 4 MINT charges	1		194,783.00		194,783.00
<b>Total GBP</b>					<b>194,783.00</b>

Doc.Type : RE ( Invoice - gross ) Normal document

Doc. Number	4900129619	Company Code	208	Fiscal Year	2018
Doc. Date	22.10.2018	Posting Date	29.10.2018	Period	10
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	SI000056				
Doc. Currency	GBP				
Doc. Hdr Text	ARIBA_P2F				

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1008569	MUNDIPHARMA INTERNAT		GEN		U1	194.783,00-	
2	40	608660	Consultants - Mgmt.	9004208	GEN		U1	207.151,72	
3	50	203150	Use Tax Payable		GEN		U1	2.368,72-	

## **Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States**

On January 1, 2008, Purdue entered into a manufacturer's licensing agreement with Mundipharma A.G., the Licensor, for the right to manufacture and sell MS Contin, a morphine-based pain reliver, in the United States.

### **MANUFACTURER'S LICENCE AGREEMENT**

THIS AGREEMENT is entered with effect from the 1st day of January 2008 by and between **MUNDIPHARMA A.G.** of St. Alban-Rheinweg 74, CH-4006 Basel, Switzerland, **PURDUE PHARMA L.P.** of One Stamford Forum, Stamford, Connecticut 06901-3431, U.S.A., and **PLP ASSOCIATES HOLDINGS L.P.** of One Stamford Forum, Stamford, Connecticut 06901-3431, U.S.A.

### **ANNEX II**

The Preparation as set forth in the annexed Agreement shall consist of a pharmaceutical preparation as specified by Licensor containing as active principle the Product which is marketed in certain countries under the trademark MS CONTIN.

## **Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States**

The MS Contin license agreement granted Purdue the following licenses:

### Grant of Licences

#### **Licence to manufacture, use and sell**

Licensor hereby grants the right to Licensee to manufacture, package, use, distribute, market and sell within the Territory the Preparation under the Know-how, Trademarks and Patents as hereinafter provided.

#### **Licence of Know-how**

Licensor hereby licenses Licensee to use the Know-how for the purpose of manufacturing, packaging, using, distributing, marketing and selling the Preparation in the Territory but for no other purpose whatsoever. Nothing herein contained shall prohibit Licensor from licensing the Know-how or any part thereof to any other party for any purpose whatsoever.

#### **Licence of Trademarks**

Licensor hereby licenses Licensee to use and Licensee shall use the Trademarks in connection with the promotion and sale of the Preparation in the Territory, subject to the provision that such Trademarks shall be used in such manner as Licensor may determine and direct from time to time and provided always that the same are available and further provided that in the event that Licensor serves notice to terminate this Agreement Licensor shall have the right to use the Trademarks in the Territory and/or to

authorise others to use the Trademarks in the Territory following service of such notice.

#### **Licence of Patents**

Licensor hereby exclusively licenses Licensee to use the Patents for the purpose of manufacturing, packaging, using, distributing, marketing and selling the Preparation in the Territory during the life of the Patents or until termination of this Agreement whichever shall be earlier but for no other purpose whatsoever. Nothing herein contained shall prohibit Licensor from licensing the Patents to any other party for any other purpose whatsoever.

## **Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States**

The MS Contin license agreement granted Purdue at least an 8-year term with extensions in 3-year periods.

### **DURATION**

This Agreement shall commence with effect from the 1st January 2008 and shall extend for an initial term of eight (8) years and shall continue thereafter for continuation terms of three (3) years unless either party shall give to the other at least six (6) months notice of intention to terminate prior to the end of the initial or any continuation term, in which event this Agreement shall terminate at the end of the term in which such notice is given.



## **Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States**

Pursuant to the license agreement, Purdue agreed to pay a [REDACTED] royalty to Mundipharma A.G. on net sales for the licenses.

### Amount of Royalty

#### **Sales by Licensee to vendees other than to its Associated Companies and Licensor**

Should Licensee sell the Preparation to vendees other than to its Associated Companies and Licensor there shall accrue to Licensor from Licensee an earned royalty of [REDACTED] on the Net Sales of the Preparation.

#### **Sales by Licensee to its Associated Companies**

Should Licensee sell the Preparation to an Associated Company, or to a related person, firm or corporation (i.e., one which is not dealing at arm's length by reason of some common interest) then the royalties payable hereunder shall be based upon the Net Sales of such Associated Company, person, firm or corporation.

#### **Royalties on Sales of Sublicensee or Distributor**

In the event that Licensee markets the Preparation through a sublicensee or distributor the royalties payable hereunder shall be based upon the Net Sales of such sublicensee or distributor.

## **Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States**

Under a prior version of the MS Contin license agreement, Purdue agreed to pay a [REDACTED] profit share on generic versions of MS Contin in addition to the existing [REDACTED] royalty on branded MS Contin. The [REDACTED] profit share was not explicitly discussed in the MS Contin license agreement; however, based on the prior agreement it was paid from 2008 to 2010.

### **DECISION**

**August 9, 2005**

#### MS Contin® License

Subject to confirmation that the following terms constitute an arms-length deal, it was recommended that the Amended License Agreement for Ms Contin® dated September 30, 1997 among Mundipharma A.G. ("Mundipharma"), PLP Associates Holdings L.P. ("PLP Associates") and Purdue Pharma L.P. ("PPLP") (the "License Agreement") be amended in an effort to handle the authorized generic version of MS Contin® as follows:

1. The License Agreement will be extended until September 30, 2011 to give PPLP time to recover its cost to transfer manufacturing from the Totowa facility to the Wilson facility;
2. [REDACTED] of PPLP's authorized generic profit share on the authorized generic version of MS Contin® will be paid to Mundipharma in addition to the current [REDACTED] royalty on the MS Contin® brand; and
3. Keeping the MS Contin® brand in distribution and launching an authorized generic version of MS Contin® will be agreed to be an appropriate promotion program.

(Recommendation of the Board of Directors of MNP Consulting Limited)

## **Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States**

On October 1, 2016, the MS Contin license agreement was assigned by Purdue to Rhodes Pharma effective May 1, 2017. No consideration was enumerated in the assignment and assumption agreement.

### **ASSIGNMENT AND ASSUMPTION AGREEMENT (MS Contin®)**

This Assignment and Assumption Agreement (the "Agreement") effective October 1, 2016 (the "Effective Date") by and between Purdue Pharma L.P., a Delaware limited partnership ("Assignor"), and Rhodes Pharmaceuticals L.P., a Delaware limited partnership ("Assignee").

#### **2. Assignment; Inventory and Sales; Licenses; Transfer.**

(a) Assignment. Assignor does hereby convey, transfer, assign and deliver to Assignee, and Assignee does hereby accept from Assignor effective as of the Assignment Date all of Assignor's rights, title and interest of whatever kind and nature in and to the Products, including, but not limited to, the Know-How, Manufacturing Instructions, Patents, Specifications and, subject to Section 2(f), the Registrations for the Products (collectively, the "Assets"), to have and to hold the Assets hereby assigned, transferred and conveyed unto Assignee, its successors and assigns, to its and their own use and behalf forever. For the avoidance of doubt, "Assets" do not include the Regulatory Documentation for the Products or the Marks for the Products.

## Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States

From January 1, 2008 to April 28, 2017, Purdue paid \$11.0 million under the MS Contin license agreement to Mundipharma A.G. including royalties and profit share.

Year	Quart	Payment Amount (US\$)	Payor	Payee	Payment Method	Payment Date	Payable Doc No.	Wire Transfer Doc No.	Profit Share (Generic)	Profit Share Royalty (15%)	Net Sales (Quarter)	PPD	Rebates	Net Sales less Discounts & Repates	Net Sales Royalty (10%)	Royalty Adjustment	Total Royalty
2009	1	\$ 583,985	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/22/2009	1900054875	1500002850	\$ 708,181	\$ 106,227	\$ 5,459,807	\$ (109,196)	\$ (573,037)	\$ 4,777,574	\$ 477,757		\$ 583,985
2009	2	453,424	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/22/2009	1900058579	1500003147	681,199	102,180	3,970,428	(79,409)	(378,581)	3,512,439	351,244		453,424
2009	3	481,461	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	11/2/2009	1900062628	1500003480	1,164,407	174,661	2,955,237	(59,105)	(171,864)	3,067,997	306,800		481,461
2009	4	541,452	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	2/9/2010	1900066274	1500003786	865,261	129,789	4,474,499	(89,490)	(268,380)	4,116,629	411,663		541,452
2010	1	604,287	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/30/2010	1900068765	1500004093	1,530,260	229,539	4,042,290	(80,846)	(213,961)	3,747,483	374,748		604,287
2010	2	681,848	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/30/2010	1900072120	1500004387	2,235,339	335,301	3,715,794	(74,316)	(176,010)	3,465,468	346,547		681,848
2010	3	490,553	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	10/29/2010	1900075566	1500004667	1,186,706	178,006	3,354,349	(67,087)	(161,795)	3,125,468	312,547		490,553
2010	4	483,383	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	2/25/2011	1900079849	1500005055	845,985	126,898	3,988,093	(79,762)	(343,475)	3,564,856	356,486		483,383
2011	1	324,695	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/29/2011	1900082304	1500005325	-	-	3,504,254	(86,809)	(170,492)	3,246,953	324,695		324,695
2011	2	254,239	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/28/2011	1900085677	1500005662	-	-	2,806,220	(73,543)	(190,284)	2,542,392	254,239		254,239
2011	3	352,964	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	10/31/2011	1900089494	1500006010	-	-	3,848,582	(88,925)	(230,017)	3,529,641	352,964		352,964
2011	4	289,811	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	1/31/2012	1900093268	1500006336	-	-	3,179,618	(30,835)	(250,675)	2,898,107	289,811		289,811
2012	1	273,340	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	5/4/2012	1900096999	1500006677	-	-	3,063,213	(64,327)	(265,484)	2,733,402	273,340		273,340
2012	2	316,696	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/30/2012	1900100509	1500006971	-	-	3,331,034	(69,952)	(94,125)	3,166,957	316,696		316,696
2012	3	283,599	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	11/13/2012	1900104392	1500007299	-	-	3,153,523	(66,224)	(251,305)	2,835,994	283,599		283,599
2012	4	302,485	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	1/31/2013	1900108145	1500007597	-	-	3,426,111	(103,903)	(297,355)	3,024,854	302,485		302,485
2013	1	209,822	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/30/2013	1900111229	1500007937	-	-	2,441,434	(62,970)	(280,242)	2,098,222	209,822		209,822
2013	2	283,882	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/31/2013	1900115338	1500008249	-	-	3,207,683	(71,028)	(297,832)	2,838,823	283,882		283,882
2013	3	262,170	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	11/8/2013	1900118873	1500008585	-	-	2,978,099	(65,931)	(290,472)	2,621,696	262,170		262,170
2013	4	312,621	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	1/30/2014	1900122293	1500008857	-	-	3,119,264	(76,992)	(83,940)	3,126,212	312,621		312,621
2014	1	234,448	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/30/2014	1900126001	1500009148	-	-	2,540,347	(66,846)	(129,024)	2,344,477	234,448		234,448
2014	2	276,808	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/31/2014	1900129689	1500009384	-	-	2,988,290	(85,011)	(135,198)	2,768,082	276,808		276,808
2014	3	242,002	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	10/31/2014	1900133225	1500009612	-	-	2,624,990	(77,508)	(127,465)	2,420,017	242,002		242,002
2014	4	303,752	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	1/30/2015	1900136894	1500009838	-	-	3,337,080	(91,833)	(207,729)	3,037,518	303,752		303,752
2015	1	176,609	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/30/2015	1900140043	1500010060	-	-	2,368,587	(72,088)	(260,000)	2,036,499	203,650	(27,040)	176,609
2015	2	181,600	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/30/2015	1900143273	1500010249	-	-	2,059,997	(56,386)	(187,614)	1,815,997	181,600		181,600
2015	3	248,300	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	10/31/2015	1900146516	1500010483	-	-	3,052,596	(69,235)	(500,361)	2,482,999	248,300		248,300
2015	4	197,349	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	1/28/2016	1900150078	1500010717	-	-	2,494,413	(57,043)	(463,879)	1,973,491	197,349		197,349
2016	1	263,288	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/28/2016	1900153111	1500010939	-	-	2,745,764	(64,220)	(48,662)	2,632,882	263,288		263,288
2016	2	232,473	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/28/2016	1900154996	1500011153	-	-	2,441,436	(54,570)	(62,140)	2,324,726	232,473		232,473
2016	3	201,854	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	10/28/2016	1900157018	1500011380	-	-	2,124,281	(49,441)	(56,300)	2,018,539	201,854		201,854
2016	4	471,518	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	1/31/2017	1900159411	1500011589	-	-	5,199,186	(56,178)	(427,828)	4,715,180	471,518		471,518
2017	1	187,567	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/28/2017	1900160869	1500011764	-	-	1,973,630	(46,647)	(51,315)	1,875,667	187,567		187,567
Total		\$ 11,004,285							\$ 9,217,340	\$ 1,382,601	\$ 105,970,129	\$ (2,347,656)	\$ (7,135,233)	\$ 96,487,240	\$ 9,648,724	\$ (27,040)	\$ 11,004,285

<sup>1</sup>In 2008, royalty and profit share payments of \$2.1 million were paid to Mundipharma A.G. by PLP Associates Holdings L.P., a limited partner of PRA L.P., the parent company of PPLP.

## Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States

SAP contains invoice support for the royalty payments consistent with the terms of the MS Contin license agreement from the first royalty payment in 1Q2009.

Mundipharma AG  
ST Alban-Vorstadt  
Postfach CH-4006  
Basel, Switzerland

First Quarter 2009  
Per Actual Sales & Rebates

Product	Profit Share	Net Sales	2% Discount	Rebates	Net Sales Less Disc & Rebates	Royalty Rate	Total Royalty
MS Contin	-			\$			477,757.41
MS Contin Generic		-	-	-	-		106,227.15
<b>Grand Totals</b>	\$	\$	\$	\$	\$		\$ 583,984.56

PREPARED BY: [REDACTED]  
SIGNATURE: [REDACTED] DATE: April 10, 2009  
REVIEWED BY: [REDACTED]  
SIGNATURE: [REDACTED] DATE: 4/10/09

1400054875  
1400054875

P:\Finance\Share\Accounting Services\2009 Year End\Intercompany\1Q09\MAG\MAG ROYALTIES 1Q09  
MAG ROYALTIES 1Q09

## Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States

SAP contains invoice support for the royalty payments consistent with the terms of the MS Contin license agreement through the last royalty payment made by Purdue in 1Q2017.

Purdue  
MS Contin Royalty to Mundipharma  
Q1 2017 MS Contin Royalty

	Q1 2017 YTD
Gross Sales	\$ 1,973,629.63
Less: PPD	(46,647.45)
Less: Rebates	(51,315.46)
Net Sales	\$ 1,875,666.72

Royalty @ 10% \$ 187,566.67

Less: Q1 Royalty Payment -  
Less: Q2 Royalty Payment -  
Less: Q3 Royalty Payment -

Royalty Payment Due \$ 187,566.67

Prepared by:

Reviewed/Approved by:



## **Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States**

Cash payments were recognized as follows in PPLP's accounting records in SAP. The last royalty payment from 1Q2017 is illustrated below.

<b>Account Number</b>	<b>Account Description</b>	<b>DR</b>	<b>CR</b>
102710	Intercompany Account - Mundipharma AG, Switzerland	\$ 187,567	
200011	Accounts Payable (Intercompany Foreign)		\$ (187,567)
200011	Accounts Payable (Intercompany Foreign)	\$ 187,567	
100010	Cash Concentration		\$ (187,567)

## Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States

These entries appear in SAP as follows:

**Document Overview - Display**

Doc.Type : KR ( Vendor invoice ) Normal document  
 Doc. Number 1900160869 Company Code 208 Fiscal Year 2017  
 Doc. Date 26.04.2017 Posting Date 27.04.2017 Period 04  
 Calculate Tax ☒  
 Ref.Doc. 042617  
 Doc. Currency USD

Item	FK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1002047	MUNDIPHARMA AG (SW)		GEN		U1	187.566,67-	
2	40	102710	Mundi AG, Switz		GEN			187.566,67	

**Document Overview - Display**

Doc.Type : KZ ( Vendor payment ) Normal document  
 Doc. Number 1500011764 Company Code 208 Fiscal Year 2017  
 Doc. Date 28.04.2017 Posting Date 28.04.2017 Period 04  
 Calculate Tax ☐  
 Ref.Doc. WIRE TRANSFER  
 Doc. Currency USD

Item	FK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			187.566,67-	
2	25	1002047	MUNDIPHARMA AG (SW)		GEN			187.566,67	

**Display Document: Line Item 001**

Vendor 1002047 MUNDIPHARMA AG (SW) G/L Acc 200011  
 Company Code 208 ST ALBAN-RHEINWEG 74  
 Purdue Pharma L.P. BASEL Doc. no. 1900160869

Line Item 1 / Invoice / 31  
 Amount 187.566,67 USD

General Ledger Account (1) 1 Entry found  
 G/L account with delete/lock flag in chart of accounts Key words

Long Text ChAc: DelFI Pstg block Crtn.block Plan.block G/L Acct  
 Accounts Payable Intercompany Foreign PURD 200011

1 Entry found

## Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States

From May 1, 2017 to September 15, 2019, Rhodes Pharma (SAP company code 250) accrued \$1.3 million under the MS Contin license agreement in G/L account 205150 (Accrued Royalty Fees), but did not make any cash payments to Mundipharma A.G. during that time.

G/L Account Line Item Display														
G/L Account		205150		Accrued Royalty Fees										
Company Code		250												
CoCd	DocumentNo	Postng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	Order
<input type="checkbox"/>	250	100027404	28.02.2019	26.03.2019	2	2019/02	ZH	RP190251	205150	GEN	Accrue Profit Share Royalties for Feno	276.979,13	USD	
<input type="checkbox"/>	250	100027522	31.03.2019	02.04.2019	3	2019/03	ZH	RP190229	205150	GEN	Mar 2019 Royalty	208.675,10	USD	
<input type="checkbox"/>	250	100027913	30.04.2019	06.05.2019	4	2019/04	ZH	RP190429	205150	GEN	Apr 2019 Royalty	276.563,98	USD	
<input type="checkbox"/>	250	100027969	30.04.2019	08.05.2019	4	2019/04	SA	RP190429C	205150	GEN	Mar 2019 Feno PS	12.622,26	USD	
<input type="checkbox"/>	250	100027969	30.04.2019	08.05.2019	4	2019/04	SA	RP190429C	205150	GEN	Apr 2019 Feno PS	26.958,75	USD	
<input type="checkbox"/>	250	100027970	30.04.2019	08.05.2019	4	2019/04	SA	RP190429D	205150	GEN	Mar 2019 Paroxetine PS	6.456,87	USD	
<input type="checkbox"/>	250	100027970	30.04.2019	08.05.2019	4	2019/04	SA	RP190429D	205150	GEN	Apr 2019 Paroxetine PS	6.454,39	USD	
<input type="checkbox"/>	250	100027971	30.04.2019	08.05.2019	4	2019/04	SA	RP190429E	205150	GEN	Mar 2019 MS Contin PS	18.373,35	USD	
<input type="checkbox"/>	250	100027971	30.04.2019	08.05.2019	4	2019/04	SA	RP190429E	205150	GEN	Apr 2019 MS Contin PS	25.400,60	USD	
<input type="checkbox"/>	250	100027972	30.04.2019	08.05.2019	4	2019/04	SA	RP190430	205150	GEN	Royalties for Feno	75.336,56	USD	
<input type="checkbox"/>	250	100027973	30.04.2019	08.05.2019	4	2019/04	SA	RP190431	205150	GEN	Paroxetine PS Agreement	59.549,78	USD	
<input type="checkbox"/>	250	100027995	31.12.2017	09.05.2019	12	2017/12	ZH	RP171236C	205150	GEN	Reclass MS Contin Royalty	707.717,00	USD	
<input type="checkbox"/>	250	100027996	31.12.2018	09.05.2019	12	2018/12	ZH	RP181245C	205150	GEN	Reclass MS Contin Royalty	441.814,00	USD	
<input type="checkbox"/>	250	100028347	31.05.2019	06.06.2019	5	2019/05	SA	RP190529D	205150	GEN	May 2019 Paroxetine PS	11.342,47	USD	
<input type="checkbox"/>	250	100028348	31.05.2019	06.06.2019	5	2019/05	SA	RP190529E	205150	GEN	May 2019 MS Contin PS	35.852,35	USD	
<input type="checkbox"/>	250	100028352	31.05.2019	06.06.2019	5	2019/05	SA	RP190529C	205150	GEN	May 2019 Feno PS	20.816,99	USD	
<input type="checkbox"/>	250	100028319	31.05.2019	07.06.2019	5	2019/05	ZH	RP190529	205150	GEN	May 2019 Royalty	239.368,81	USD	
<input type="checkbox"/>	250	100028349	31.05.2019	07.06.2019	5	2019/05	SA	RP190531	205150	GEN	Paroxetine PS Agreement	59.549,78	USD	
<input type="checkbox"/>	250	100028349	31.05.2019	07.06.2019	5	2019/05	SA	RP190531	205150	GEN	Paroxetine PS Agreement Adj	59.549,78	USD	
<input type="checkbox"/>	250	100028326	31.05.2019	10.06.2019	5	2019/05	SA	RP190529F	205150	GEN	MS Contin Royalty reclass from Interco	1.149.531,00	USD	
<input type="checkbox"/>	250	100028381	31.12.2018	12.06.2019	12	2018/12	SA	RP180545CR	205150	GEN	MS Contin Royalty reclass from Interco	1.149.531,00	USD	
<input type="checkbox"/>	250	100028382	31.05.2019	12.06.2019	5	2019/05	SA	RP190529FR	205150	GEN	MS Contin Royalty reclass from Interco	1.149.531,00	USD	
<input type="checkbox"/>	250	100028623	30.06.2019	02.07.2019	6	2019/06	SA	RP190634	205150	GEN	Royalties for Feno	26.750,00	USD	
<input type="checkbox"/>	250	100028660	30.06.2019	02.07.2019	6	2019/06	SA	RP190629C	205150	GEN	June 2019 Feno Caps PS Exp	11.082,85	USD	
<input type="checkbox"/>	250	100028660	30.06.2019	02.07.2019	6	2019/06	SA	RP190629C	205150	GEN	June 2019 Feno Tabs PS Exp	2.280,19	USD	
<input type="checkbox"/>	250	100028661	30.06.2019	02.07.2019	6	2019/06	SA	RP190629D	205150	GEN	June 2019 Paroxetine PS	6.194,45	USD	
<input type="checkbox"/>	250	100028662	30.06.2019	02.07.2019	6	2019/06	SA	RP190629E	205150	GEN	June 2019 MS Contin PS	30.667,15	USD	
<input type="checkbox"/>	250	100028619	30.06.2019	03.07.2019	6	2019/06	ZH	RP190629	205150	GEN	June 2019 Royalty	293.742,78	USD	
<input type="checkbox"/>	250	100028689	30.06.2019	09.07.2019	6	2019/06	ZH	RP190629C	205150	GEN	Butrans AG Reclass to Interco	2.350.333,00	USD	
*												1.316.099,95	USD	

## **Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot**

On November 29, 2006, Purdue Products L.P. (now known as Avrio Health) entered into license agreements with Pharmaceutical Research Associates, Inc. ("PRA Inc."), the Licensor, for the right to use the Betadine and Senokot trademarks.

### AMENDED AND RESTATED LICENSE AGREEMENT (SENOKOT®)

THIS AMENDED AND RESTATED LICENSE AGREEMENT (this "Agreement") is entered with effect from November 29, 2006 (the "Effective Date") by and between Pharmaceutical Research Associates, Inc., a New York corporation ("Licensor"), and Purdue Products L.P., a Delaware limited partnership ("Licensee").

#### W I T N E S S E T H:

WHEREAS, The Purdue Frederick Company, a New York corporation ("Original Licensor"), and Licensee are parties to that certain License Agreement (Senokot®), including related Exhibits thereto, effective April 8, 2003 for the license of Product for human therapy (the "Original Agreement");

WHEREAS, Original Licensor has assigned to the Licensor all of its right, title and interest in and to the Original Agreement;

WHEREAS, Licensor and Licensee desire to amend and restate the Original Agreement to reflect the Original Licensor's foregoing assignment to the Licensor as a party to this Agreement;

### AMENDED AND RESTATED LICENSE AGREEMENT (BETADINE®)

THIS AMENDED AND RESTATED LICENSE AGREEMENT (this "Agreement") is entered with effect from November 29, 2006 (the "Effective Date") by and between Pharmaceutical Research Associates, Inc., a New York corporation ("Licensor"), and Purdue Products L.P., a Delaware limited partnership ("Licensee").

#### W I T N E S S E T H:

WHEREAS, The Purdue Frederick Company, a New York corporation ("Original Licensor"), and Licensee are parties to that certain License Agreement (Betadine®), including related Exhibits thereto, effective April 8, 2003 for the license of Product for human therapy (the "Original Agreement");

WHEREAS, Original Licensor has assigned to the Licensor all of its right, title and interest in and to the Original Agreement;

WHEREAS, Licensor and Licensee desire to amend and restate the Original Agreement to reflect the Original Licensor's foregoing assignment to the Licensor as a party to this Agreement;

## **Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot**

Per the agreements, the terms of licenses were for the commercial life of Betadine and Senokot with a royalty rate of [REDACTED] of Net Sales.

### **SECTION 4. DURATION**

This Agreement commenced with effect from the Effective Date and shall extend for the commercial life of the Product, unless Licensee shall give to Licensor notice of intention to terminate, in which event this Agreement shall terminate thirty (30) days after the date such notice is given.

### **SECTION 5. ROYALTIES**

5.1 Amount of Royalty. For the licenses granted under Section 2, Licensee shall pay to Licensor a royalty of [REDACTED] on the Net Sales of the Product in the Territory. In the event that Licensee distributes the Product through a sublicensee or distributor, the royalties payable hereunder shall be based on the Net Sales of such sublicensee or distributor.

## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

From January 1, 2008 to September 15, 2019, Purdue was charged \$22.8 million by PRA Inc. for the use of the Betadine and Senokot trademarks.

Product Code	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
BET - Betadine	\$ 668,206	\$ 616,099	\$ 742,896	\$ 771,008	\$ 765,972	\$ 907,630	\$ 812,491	\$ -	\$ -	\$ -	\$ 729,439	\$ 582,603	\$ 6,596,344
SEN - Senokot	1,873,809	1,155,397	1,369,662	1,221,731	934,166	1,129,092	973,077	-	-	-	1,238,654	899,801	10,795,390
GEN - General non product spec	-	-	-	-	-	-	-	1,833,050	1,838,701	1,766,378	-	-	5,438,129
<b>Total</b>	<b>\$ 2,542,015</b>	<b>\$ 1,771,497</b>	<b>\$ 2,112,558</b>	<b>\$ 1,992,739</b>	<b>\$ 1,700,138</b>	<b>\$ 2,036,722</b>	<b>\$ 1,785,568</b>	<b>\$ 1,833,050</b>	<b>\$ 1,838,701</b>	<b>\$ 1,766,378</b>	<b>\$ 1,968,093</b>	<b>\$ 1,482,404</b>	<b>\$ 22,829,863</b>



## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

According to Purdue Products L.P.'s (SAP company code 307) accounting records in SAP, charges for royalties to Purdue Products from PRA Inc. were consolidated through G/L account 102190 (Intercompany Account - PRA Inc.). The screenshot below illustrates total royalty charges between January 1, 2008 and September 15, 2019.<sup>1</sup>

G/L Account		102190		PRA									
Company Code		307											
CoCd	DocumentNo	Postng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/>	307	100030385	05/31/2015	06/08/2015	5	2015/05	SA	LMT 0515 100	102190	GEN	BET AND SEN ROYALTY 307 TO 190 2014 True Up	147,911.52-	USD
<input type="checkbox"/>	307	100024989	04/30/2013	05/07/2013	4	2013/04	SA	MG 0413 07	102190	GEN	BET AND SEN ROYALTY 307 TO 190 DEC 2012	147,748.66-	USD
<input type="checkbox"/>	307	100036028	02/28/2018	03/01/2018	2	2018/02	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	147,327.06-	USD
<input type="checkbox"/>	307	100032096	02/29/2016	03/01/2016	2	2016/02	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2015 True Up	147,287.38-	USD
<input type="checkbox"/>	307	100027590	09/30/2014	10/09/2014	9	2014/09	SA	MG 0914 19	102190	GEN	BET AND SEN ROYALTY 307 TO 190 SEPT 2014	147,172.04-	USD
<input type="checkbox"/>	307	100035943	01/31/2018	02/08/2018	1	2018/01	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2017 True Up	147,045.35-	USD
<input type="checkbox"/>	307	100036320	07/31/2018	08/02/2018	7	2018/07	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	146,750.87-	USD
<input type="checkbox"/>	307	100029302	01/31/2015	02/12/2015	1	2015/01	SA	LMT 0115 100	102190	GEN	BET AND SEN ROYALTY 307 TO 190 2014 True Up	146,346.00-	USD
<input type="checkbox"/>	307	100026828	12/31/2013	01/09/2014	12	2013/12	SA	MG 1213 08	102190	GEN	BET AND SEN ROYALTY 307 TO 190 DEC 2013	145,468.81-	USD
<input type="checkbox"/>	307	100035002	07/31/2017	08/02/2017	7	2017/07	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2017 True Up	145,145.79-	USD
<input type="checkbox"/>	307	100026953	02/28/2014	03/04/2014	2	2014/02	SA	MG 0214 01	102190	GEN	BET AND SEN ROYALTY 307 TO 190 JAN 2014	144,475.18-	USD
<input type="checkbox"/>	307	100027010	02/28/2014	03/11/2014	2	2014/02	SA	MG 0214 11	102190	GEN	BET AND SEN ROYALTY 307 TO 190 JAN 2014	144,293.30-	USD
<input type="checkbox"/>	307	100029996	03/31/2015	04/08/2015	3	2015/03	SA	LMT 0315 100	102190	GEN	BET AND SEN ROYALTY 307 TO 190 2014 True Up	142,774.35-	USD
<input type="checkbox"/>	307	100031306	10/31/2015	11/09/2015	10	2015/10	SA	LMT 1015 100	102190	GEN	BET AND SEN ROYALTY 307 TO 190 2015 True Up	142,571.41-	USD
<input type="checkbox"/>	307	100021040	03/31/2012	03/31/2012	3	2012/03	SA	ROYALTY	102190	GEN	ROYALTY BET & SEN MAR-12	141,838.57-	USD
<input type="checkbox"/>	307	100029022	11/30/2014	12/04/2014	11	2014/11	SA	JAS 1114 105	102190	GEN	BET & SEN Royalty OCT 2014 from 307 to 190	141,793.62-	USD
<input type="checkbox"/>	307	100034613	04/30/2017	05/02/2017	4	2017/04	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2017 True Up	141,487.67-	USD
<input type="checkbox"/>	307	100032959	07/31/2016	08/01/2016	7	2016/07	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2016 True Up	140,463.51-	USD
<input type="checkbox"/>	307	100023088	09/30/2012	09/30/2012	9	2012/09	SA	ROYALTY	102190	GEN	BET AND SEN ROYALTY 307 TO 190 SEPT 2012	137,891.33-	USD
<input type="checkbox"/>	307	100035164	11/30/2017	12/01/2017	11	2017/11	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2017 True Up	137,665.70-	USD
<input type="checkbox"/>	307	100032601	05/31/2016	06/02/2016	5	2016/05	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2016 True Up	136,466.53-	USD
<input type="checkbox"/>	307	100025979	09/30/2013	10/04/2013	9	2013/09	SA	MG 0913 08	102190	GEN	BET AND SEN ROYALTY 307 TO 190 SEPT 2013	134,345.25-	USD
<input type="checkbox"/>	307	100029666	02/28/2015	03/10/2015	2	2015/02	SA	LMT 0215 100	102190	GEN	BET AND SEN ROYALTY 307 TO 190 2014 True Up	133,922.48-	USD
<input type="checkbox"/>	307	100017320	10/31/2010	10/31/2010	10	2010/10	SA	OCT10 ROYALTY	102190	GEN	"ROYALTY BET, SEN & XFR 307 TO 190 9/10"	133,919.81-	USD
<input type="checkbox"/>	307	100034250	02/28/2017	03/02/2017	2	2017/02	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2016 True Up	133,449.20-	USD
<input type="checkbox"/>	307	100029070	12/31/2014	01/13/2015	12	2014/12	SA	JAS 1214 109	102190	GEN	BET AND SEN ROYALTY 307 TO 190 Dec 2014	132,006.38-	USD
<input type="checkbox"/>	307	100035199	12/31/2017	01/05/2018	12	2017/12	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2017 True Up	130,630.38-	USD
<input type="checkbox"/>	307	100033937	01/31/2017	02/13/2017	1	2017/01	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2016 True Up	129,363.27-	USD
<input type="checkbox"/>	307	100029071	12/31/2014	01/13/2015	12	2014/12	SA	JAS 1214 110	102190	GEN	BET AND SEN ROYALTY 307 TO 190 2014 True Up	128,223.45-	USD
<input type="checkbox"/>	307	100018032	02/28/2011	02/28/2011	2	2011/02	SA	ROYALTY	102190	GEN	BET AND SEN ROYALTY 307 TO 190	128,006.08-	USD
<input type="checkbox"/>	307	100016088	06/30/2010	06/30/2010	6	2010/06	SA	ROYALTY	102190	GEN	BET AND SEN ROYALTY 307 TO 190	125,904.53-	USD
<input type="checkbox"/>	307	100020866	01/31/2012	01/31/2012	1	2012/01	SA	ROYALTY	102190	GEN	BET AND SEN ROYALTY 307 TO 190 AUG-11	124,908.62-	USD
<input type="checkbox"/>	307	100018500	03/31/2011	03/31/2011	3	2011/03	SA	ROYALTY	102190	GEN	BET AND SEN ROYALTY 307 TO 190	124,332.73-	USD
<input type="checkbox"/>	307	100014606	01/31/2010	01/31/2010	1	2010/01	SA	ROYALTY	102190	GEN	BET AND SEN ROYALTY 307 TO 190	123,639.72-	USD
<input type="checkbox"/>	307	100013173	08/31/2009	08/31/2009	8	2009/08	SA	RECURRING	102190	GEN	BET AND SEN ROYALTY 307 TO 190	122,710.41-	USD
<input type="checkbox"/>	307	100035030	08/31/2017	09/05/2017	8	2017/08	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2017 True Up	119,412.80-	USD
<input type="checkbox"/>	307	100031770	01/31/2016	02/18/2016	1	2016/01	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2015 True Up	118,491.05-	USD
<input type="checkbox"/>	307	100020501	11/30/2011	11/30/2011	11	2011/11	SA	ROYALTY	102190	GEN	BET AND SEN ROYALTY 307 TO 190 AUG-11	91,315.03-	USD
<input type="checkbox"/>	307	100013491	09/30/2009	09/30/2009	9	2009/09	SA	SEPT09 ADJ III	102190	GEN	BET AND SEN ROYALTY 307 TO 190	86,915.54-	USD
<input type="checkbox"/>	307	100013199	08/31/2009	09/02/2009	8	2009/08	SA	AUG09 ADJ I	102190	GEN	BET AND SEN ROYALTY 307 TO 190	73,348.52-	USD
<input type="checkbox"/>	307	100029035	11/30/2014	12/05/2014	11	2014/11	SA	JAS 1114 109	102190	GEN	Correct Error in Sept BET Royalty	3,180.45-	USD
<input type="checkbox"/>	307	100036919	03/31/2019	04/02/2019	3	2019/03	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	1,015.15-	USD
*												22,829,862.63-	USD

<sup>1</sup>Screenshot does not include all entries – abbreviated version shown.

## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

According to Purdue Products L.P.'s (SAP company code 307) accounting records in SAP, charges for royalties to Purdue Products L.P. by PRA Inc. were consolidated through G/L account 102190 (Intercompany account - PRA Inc.). Royalty charges for 2008 are illustrated below.

G/L Account		102190		PRA										
Company Code		307												
	CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/>	307	100007204	29.02.2008	03.03.2008	2	2008/02	SA		BILLING	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	196.432,96-	USD
<input type="checkbox"/>	307	100009133	31.07.2008	06.08.2008	7	2008/07	SA		JULY08 ADJ V	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	285.175,54-	USD
<input type="checkbox"/>	307	100007732	31.03.2008	04.04.2008	3	2008/03	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	172.324,89-	USD
<input type="checkbox"/>	307	100008183	30.04.2008	06.05.2008	4	2008/04	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	226.428,32-	USD
<input type="checkbox"/>	307	100008488	31.05.2008	04.06.2008	5	2008/05	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	226.518,26-	USD
<input type="checkbox"/>	307	100008812	30.06.2008	07.07.2008	6	2008/06	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	164.142,10-	USD
<input type="checkbox"/>	307	100009410	31.08.2008	04.09.2008	8	2008/08	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	200.393,66-	USD
<input type="checkbox"/>	307	100009707	30.09.2008	02.10.2008	9	2008/09	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	167.366,06-	USD
<input type="checkbox"/>	307	100009991	31.10.2008	06.11.2008	10	2008/10	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	293.146,16-	USD
<input type="checkbox"/>	307	100010276	30.11.2008	04.12.2008	11	2008/11	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	191.226,03-	USD
<input type="checkbox"/>	307	100010647	31.12.2008	08.01.2009	12	2008/12	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	226.589,23-	USD
<input type="checkbox"/>	307	100007108	31.01.2008	01.02.2007	1	2008/01	SA		ROYALTY I	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	192.272,13-	USD
<input type="checkbox"/>	*												2.542.015,34-	USD

## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

According to Purdue Products L.P.'s (SAP company code 307) accounting records in SAP, charges for royalties to Purdue Products L.P. by PRA Inc. were consolidated through G/L account 102190 (Intercompany Account - PRA Inc.). Royalty charges for 2019 are illustrated below.

G/L Account		102190		PRA									
Company Code		307											
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/> 307	100036740	01/31/2019	02/13/2019	1	2019/01	SA		LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	160,290.43-	USD
<input type="checkbox"/> 307	100036796	02/28/2019	03/06/2019	2	2019/02	SA		LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	163,381.35-	USD
<input type="checkbox"/> 307	100036884	03/31/2019	04/02/2019	3	2019/03	SA		LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	245,174.50-	USD
<input type="checkbox"/> 307	100036919	03/31/2019	04/02/2019	3	2019/03	SA		LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	1,015.15-	USD
<input type="checkbox"/> 307	100036970	04/30/2019	05/02/2019	4	2019/04	SA		LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	205,243.28-	USD
<input type="checkbox"/> 307	100037054	05/31/2019	06/04/2019	5	2019/05	SA		LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2019 True Up	178,726.36-	USD
<input type="checkbox"/> 307	100037123	06/30/2019	07/01/2019	6	2019/06	SA		LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2019 True Up	190,306.35-	USD
<input type="checkbox"/> 307	100037200	07/31/2019	08/02/2019	7	2019/07	SA		LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2019 True Up	157,754.89-	USD
<input type="checkbox"/> 307	100037277	08/31/2019	09/04/2019	8	2019/08	SA		LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2019 True Up	180,511.50-	USD
*												1,482,403.81-	USD

## **Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot**

Since 2007, royalties owed to PRA Inc. for the use of the Betadine and Senokot trademarks accrued without payment. In August 2018, PPLP paid the cumulative royalties owed to PRA Inc. on behalf of Avrio Health (PPLP's subsidiary).

The September 2018 cash payment from PPLP to PRA Inc. is illustrated below.

<b>Company</b>	<b>Account Number</b>	<b>Account Description</b>	<b>DR</b>	<b>CR</b>
190	100010	Cash Concentration	\$ 34,253,275	
190	102208	Purdue Pharma L.P.		\$ (34,253,275)
208	102190	PRA	\$ 34,253,275	
208	100010	Cash Concentration		\$ (34,253,275)

190: PRA Inc.

208: Purdue Pharma L.P.

## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

These entries appear in SAP as follows:

**G/L Account Balance Display**

Document currency | Document currency | Document currency | Business area | Bus

Account number 102208 Purdue Pharma L.P.  
Company code 190 PRA Inc.  
Business area  
Fiscal year 2018  
All documents in currency \* Display currency USD

Period	Debit	Credit	Balance	Cumulative balance
Balance Carry...				32,946,294.64
1	212,414.31	89.60	212,324.71	33,158,619.35
2	63,925.26		63,925.26	33,222,544.61
3				33,222,544.61
4		125,750.02	125,750.02-	33,096,794.59
5				33,096,794.59
6				33,096,794.59
7				33,096,794.59
8		150,589.55	150,589.55-	32,946,205.04
9	1,471,943.79	34,253,275.48	32,781,331.69-	164,873.35
10	156,622.98		156,622.98	321,496.33
11		156,622.98	156,622.98-	164,873.35
12	225,667.87	237,180.48	11,512.61-	153,360.74
13				153,360.74
14				153,360.74
15				153,360.74
16				153,360.74
Total	2,130,574.21	34,923,508.11	32,792,933.90-	153,360.74

**G/L account document**

Overall No. 0100000926190 18 Doc. Currency USD

CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy
Itm	PK Account	Account short text	Assignment	Tx	Amount	Text	
190	100000926	2018	SA	10/01/2018	09/30/2018	CWS	USD
1 40	100010	Cash Concentration	20181001		34,253,275.48	SENOKOT & BETADINE R	
2 50	102208	Purdue Pharma L.P.	20181001		34,253,275.48-		
208	100176647	2018	SA	10/01/2018	09/30/2018	CWS	USD
1 50	100010	Cash Concentration	20181001		34,253,275.48-	SENOKOT & BETADINE R	
2 40	102190	PRA	20181001		34,253,275.48		

## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

Per an internal analysis and verified in SAP, the \$34.3 million cash payment was composed of accrued royalties, excess cash from intercompany funding, and other items as described below.

Payment Type (\$M)	Amount
Accrued Royalties	\$ 23.3
Excess Cash Paid to PPLP	6.5
Intercompany Interest	2.2
██████████ Royalties	2.4
Other	(0.1)
<b>Total</b>	<b>\$ 34.3</b>

Per an internal analysis and verified in SAP, \$23.3 million in royalties were accrued from January 1, 2007 to August 31, 2018.

Per discussions with Purdue and TXP, from 2007 through 2017, PRA Inc. was part of the "PPLP bank group." PPLP was considered the banker of the group. Accordingly, all entities within the PPLP bank group would maintain a small cash balance. Any funds received by the entities would be sent to PPLP. Entities that needed cash for tax payments, life insurance or other benefit payments, etc. would receive the cash from PPLP. From 2007 through 2017, PRA Inc. sent PPLP \$10.6 million in cash and received \$4.1 million resulting in a net receivable due from PPLP of \$6.5 million.

In 1999, an agreement between The Purdue Frederick Company ("PF") and ██████████ was signed, whereby ██████████ would pay a ██████████ royalty on sales of Betadine Ophthalmic product. These rights were later assigned to PRA Inc. (the parent company of PF) who collected the cash from ██████████. Because this cash was transferred to PPLP (as described above), this created a payable from PPLP to PRA Inc.

Per discussions with Purdue and TXP, items included in the "Other" category are listed as miscellaneous activity.



## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

Based on a preliminary analysis of the intercompany accounts (102190 – PRA Inc. and 102208 - Purdue Pharma L.P.) on Avrio Health’s books (SAP company code 307), it appears the majority of the of the activity in 102190-307 relates to Betadine and Senokot royalties with the entirety or the majority of the balance in 102190-307 being transferred to 102208-307 each year via entries commonly labeled LCD (for “Lowest Common Denominator”). However, there is substantially greater activity in 102208-307 that is not related to Betadine and Senokot royalties.

Account 102190-307	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Totals
Prior Year Cumulative Balance	\$ -	\$ -	\$ -	\$ -	\$ (793,634)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
Debits	2,579,111	1,778,836	2,118,103	2,406,423	2,497,491	3,093,669	1,941,797	1,836,673	1,842,634	1,799,753	2,282,816	2,867,360	27,044,666
Credits	(2,579,111)	(1,778,836)	(2,118,103)	(3,200,057)	(1,703,856)	(3,093,669)	(1,941,797)	(1,836,673)	(1,842,634)	(1,799,753)	(2,282,816)	(2,874,563)	(27,051,869)
Ending Cumulative Balance	\$ -	\$ -	\$ -	\$ -	\$ (793,634)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (7,204)	
LCD Entries to 102208	\$ 2,572,236	\$ 1,778,836	\$ 2,118,103	\$ 2,406,423	\$ 2,497,491	\$ 3,093,485	\$ 1,941,797	\$ 1,836,673	\$ 1,842,326	\$ 1,783,214	\$ 150,590	\$ -	\$ 22,021,173
Other Non-102208 Transfer Debits	6,875	-	-	-	-	184	-	-	308	16,539	2,132,226	2,867,360	5,023,492
Total Debits	\$ 2,579,111	\$ 1,778,836	\$ 2,118,103	\$ 2,406,423	\$ 2,497,491	\$ 3,093,669	\$ 1,941,797	\$ 1,836,673	\$ 1,842,634	\$ 1,799,753	\$ 2,282,816	\$ 2,867,360	\$ 27,044,666
LCD Entries from 102208	\$ -	\$ -	\$ -	\$ (1,202,649)	\$ -	\$ (1,055,991)	\$ (154,920)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (2,413,560)
Royalty Charges	(2,542,015)	(1,771,497)	(2,112,558)	(1,992,739)	(1,700,138)	(2,036,722)	(1,785,568)	(1,833,050)	(1,838,701)	(1,766,378)	(1,968,093)	(1,482,404)	(22,829,863)
Other Non-Royalty or LCD Credits	(37,096)	(7,339)	(5,545)	(4,669)	(3,719)	(956)	(1,309)	(3,623)	(3,932)	(33,376)	(314,723)	(1,392,159)	(1,808,447)
Total Credits	\$ (2,579,111)	\$ (1,778,836)	\$ (2,118,103)	\$ (3,200,057)	\$ (1,703,856)	\$ (3,093,669)	\$ (1,941,797)	\$ (1,836,673)	\$ (1,842,634)	\$ (1,799,753)	\$ (2,282,816)	\$ (2,874,563)	\$ (27,051,869)
Account 102208-307	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Totals
Prior Year Cumulative Balance	\$ 1,746,143	\$ 18,687,138	\$ 16,674,494	\$ 23,861,096	\$ 50,618,477	\$ 40,656,289	\$ 62,904,259	\$ 89,579,199	\$ 113,365,620	\$ 133,602,603	\$ 166,785,884	\$ (0)	
Debits	81,424,260	83,502,270	73,144,419	119,614,681	166,786,371	329,480,485	341,783,455	325,413,596	366,744,336	333,771,623	627,735,698	132,073,312	2,981,474,506
Credits	(64,483,265)	(85,514,914)	(65,957,817)	(92,857,300)	(176,748,559)	(307,232,515)	(315,108,515)	(301,627,175)	(346,507,353)	(300,588,342)	(794,521,582)	(132,073,312)	(2,983,220,649)
Ending Cumulative Balance	\$ 18,687,138	\$ 16,674,494	\$ 23,861,096	\$ 50,618,477	\$ 40,656,289	\$ 62,904,259	\$ 89,579,199	\$ 113,365,620	\$ 133,602,603	\$ 166,785,884	\$ (0)	\$ (0)	
LCD Entries to 102190	\$ -	\$ -	\$ -	\$ (1,202,649)	\$ -	\$ (1,055,991)	\$ (154,920)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (2,413,560)
Other Non-102190 Transfer Credits	81,424,260	83,502,270	73,144,419	120,817,330	166,786,371	330,536,476	341,938,375	325,413,596	366,744,336	333,771,623	627,735,698	132,073,312	2,983,888,066
Total Debits	\$ 81,424,260	\$ 83,502,270	\$ 73,144,419	\$ 119,614,681	\$ 166,786,371	\$ 329,480,485	\$ 341,783,455	\$ 325,413,596	\$ 366,744,336	\$ 333,771,623	\$ 627,735,698	\$ 132,073,312	\$ 2,981,474,506
LCD Entries from 102190	\$ 2,572,236	\$ 1,778,836	\$ 2,118,103	\$ 2,406,423	\$ 2,497,491	\$ 3,093,485	\$ 1,941,797	\$ 1,836,673	\$ 1,842,326	\$ 1,783,214	\$ 150,590	\$ -	\$ 22,021,173
Other Non-102190 Transfer Credits	(67,055,501)	(87,293,750)	(68,075,920)	(95,263,723)	(179,246,050)	(310,326,000)	(317,050,312)	(303,463,848)	(348,349,679)	(302,371,556)	(794,672,171)	(132,073,312)	(3,005,241,822)
Total Credits	\$ (64,483,265)	\$ (85,514,914)	\$ (65,957,817)	\$ (92,857,300)	\$ (176,748,559)	\$ (307,232,515)	\$ (315,108,515)	\$ (301,627,175)	\$ (346,507,353)	\$ (300,588,342)	\$ (794,521,582)	\$ (132,073,312)	\$ (2,983,220,649)

## **Exhibit 1M: Intercompany transfers between Purdue and Purdue Pharma Canada for manufacturing and packaging services**

Effective September 1, 2009, Purdue entered into a supply agreement with Purdue Pharma Canada for manufacturing and packaging services.

**THIS SUPPLY AGREEMENT**, is effective as of September 1, 2009 (the "**Effective Date**"), is by and between Purdue Pharma (Canada) ("Supplier") with a place of business at 575 Granite Court, Pickering, Ontario, Canada L1W 3W8 and Purdue Products L.P. ("PPLP"), with a place of business at One Stamford Forum, Stamford, CT 06901-3431.

### **RECITALS:**

**WHEREAS**, Supplier manufactures and packages pharmaceutical products, including the Products (as hereinafter defined in Section 1.20); and

**WHEREAS**, PPLP markets and distributes prescription and non-prescription medicines, including finished dosage non-prescription medicines; and

**WHEREAS**, PPLP has requested that Supplier manufacture, package and sell the Products to PPLP.

**WHEREAS**, subject to the terms and conditions set forth herein, PPLP wishes to distribute the Products and Supplier is agreeable to manufacturing, packaging and supplying the Products for distribution by PPLP as provided herein.

## Exhibit 1M: Intercompany transfers between Purdue and Purdue Pharma Canada for manufacturing and packaging services

According to the supply agreement, Purdue agreed to pay the prices below subject to annual adjustments.

### US Senokot (Calcium Sennosides) 2010 Prices

Note: All prices are in Canadian dollars

		<u>Cdn\$</u>
SNKT04	Senokot Sample 4s	
SNKT20	Senokot 20s	
SNKT50	Senokot 50s	
SNKT1W	Senokot 100s	
SNKT11	Senokot 100s HUD Blister	
SENS04	Senokot S Sample 4s	
SENS10	Senokot S 10s Blister	
SENS30	Senokot S 30s	
SENS60	Senokot S 60s	
SENS11	Senokot S 100s HUD Blister	

Senokot-S Tablets 10's Bonus Pack (10 + 4 tablets free)

Senokot Tablets 20's Bonus Pack (20 + 4 tablets free)

## **Exhibit 1M: Intercompany transfers between Purdue and Purdue Pharma Canada for manufacturing and packaging services**

From September 1, 2009 to September 15, 2019, Purdue paid \$41.1 million to Purdue Pharma Canada pursuant to the supply agreement.

Year	Payments
2009	\$ 1,794,542
2010	2,466,513
2011	2,307,198
2012	5,409,689
2013	5,243,004
2014	4,518,539
2015	3,727,388
2016	3,271,075
2017	4,037,991
2018	4,293,057
2019	4,023,588
<b>Total</b>	<b>\$ 41,092,586</b>

## Exhibit 1M: Intercompany transfers between Purdue and Purdue Pharma Canada for manufacturing and packaging services

The table below presents Purdue's 2009 and 2019 payments to Purdue Pharma Canada as an example.

Company Code	Document Number	Document Type	Clearing Date	Clearing Document	Amount
409	1500000103	KZ	11/17/2009	1500000103	\$ 143,899
409	1500000104	KZ	11/18/2009	1500000104	1,184,025
409	1500000107	KZ	12/11/2009	1500000107	260,912
409	1500000108	KZ	12/31/2009	1500000108	205,706
<b>Total</b>					<b>\$ 1,794,542</b>

307	2000008871	ZP	1/11/2019	2000008883	\$ 100,764
307	2000008883	ZP	1/11/2019	2000008883	(100,764)
307	2000008895	ZP	1/16/2019	2000008895	100,764
307	2000008964	ZP	2/6/2019	2000008964	394,369
307	2000009015	ZP	2/27/2019	2000009015	177,053
307	2000009112	ZP	3/29/2019	2000009112	268,485
307	2000009119	ZP	4/3/2019	2000009119	383,452
307	2000009198	ZP	4/26/2019	2000009198	67,614
307	2000009211	ZP	5/1/2019	2000009211	231,943
307	2000009240	ZP	5/8/2019	2000009240	304,587
307	2000009288	ZP	5/22/2019	2000009288	304,235
307	2000009318	ZP	5/29/2019	2000009318	81,075
307	2000009349	ZP	6/5/2019	2000009349	68,898
307	2000009407	ZP	6/19/2019	2000009407	288,087
307	2000009456	ZP	7/3/2019	2000009456	461,587
307	2000009538	ZP	7/31/2019	2000009538	26,821
307	2000009590	ZP	8/14/2019	2000009590	141,870
307	2000009647	ZP	8/28/2019	2000009647	217,007
307	2000009691	ZP	9/4/2019	2000009691	89,060
307	2000009747	ZP	9/13/2019	2000009747	416,682
<b>Total</b>					<b>\$ 4,023,588</b>

## Exhibit 1M: Intercompany transfers between Purdue and Purdue Pharma Canada for manufacturing and packaging services

The SAP screenshots below illustrate that Purdue made cash payments to Purdue Pharma Canada for 2009 activity pursuant to the supply agreement.

Vendor 1022943  
Company Code 409  
  
Name PURDUE PHARMA CANADA  
City PICKERING

Account	CoCd	Reference	DocumentNo	Assignment	Type	Doc. Date	Postng Date	Net due dt	Blinc Date	FBk	PmtMthSu	Amount in local cur.	Amount in doc. curr.	Curr.	Clng doc.	Clearing	Text
<input type="checkbox"/> 1022943	409	WIRE TRANSFER	1500000104	WIRE TRANSFER	KZ	11/17/2009	11/18/2009	11/17/2009	11/17/2009			1,184,024.62	1,184,024.62	USD	1500000104	11/18/2009	
<input type="checkbox"/> 1022943	409	WIRE TRANSFER	1500000107	WIRE TRANSFER	KZ	12/10/2009	12/11/2009	12/10/2009	12/10/2009			260,912.48	260,912.48	USD	1500000107	12/11/2009	
<input type="checkbox"/> 1022943	409	WIRE TRANSFER	1500000108	WIRE TRANSFER	KZ	12/24/2009	12/31/2009	12/24/2009	12/24/2009			205,705.59	205,705.59	USD	1500000108	12/31/2009	
<input type="checkbox"/> 1022943	409	WIRE TRANSFER	1500000103	WIRE TRANSFER	KZ	11/16/2009	11/17/2009	11/16/2009	11/16/2009			143,899.26	143,899.26	USD	1500000103	11/17/2009	
												1,794,541.95	1,794,541.95	USD			

Doc.Type : KZ ( Vendor payment ) Normal document  
Doc. Number 1500000104 Company Code 409 Fiscal Year 2009  
Doc. Date 11/17/2009 Posting Date 11/18/2009 Period 11  
Calculate Tax ☐  
Ref.Doc. WIRE TRANSFER  
Doc. Currency USD

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			1,185,005.78-	
2	40	700520	Realized FX	9001409	GEN			981.16	Foreign Exchange - Gain/Loss
3	25	1022943	PURDUE PHARMA CANADA		GEN			1,184,024.62	



## Exhibit 1M: Intercompany transfers between Purdue and Purdue Pharma Canada for manufacturing and packaging services

The SAP screenshots below illustrate that Purdue made cash payments to Purdue Pharma Canada for 2019 activity pursuant to the supply agreement.

Vendor 1022943  
Company Code 307  
  
Name PURDUE PHARMA CANADA  
City PICKERING

Account	CoCd	Reference	DocumentNo	Assignment	Type	Doc. Date	Postng Date	Net due dt	Blinc Date	PBk	FmtMthSu	Amount in local cur.	Amount in doc. curr.	Curr.	Clrng doc.	Clearing	Text
<input type="checkbox"/> 1022943	307		2000009456		ZP	07/03/2019	07/03/2019	07/03/2019	07/03/2019			461,586.72	461,586.72	USD	2000009456	07/03/2019	
<input type="checkbox"/> 1022943	307		2000009747		ZP	09/13/2019	09/13/2019	09/13/2019	09/13/2019			416,682.36	416,682.36	USD	2000009747	09/13/2019	
<input type="checkbox"/> 1022943	307		2000008964		ZP	02/06/2019	02/06/2019	02/06/2019	02/06/2019			394,368.96	394,368.96	USD	2000008964	02/06/2019	
<input type="checkbox"/> 1022943	307		2000009119		ZP	04/03/2019	04/03/2019	04/03/2019	04/03/2019			383,452.20	383,452.20	USD	2000009119	04/03/2019	
<input type="checkbox"/> 1022943	307		2000009240		ZP	05/08/2019	05/08/2019	05/08/2019	05/08/2019			304,586.76	304,586.76	USD	2000009240	05/08/2019	
<input type="checkbox"/> 1022943	307		2000009288		ZP	05/22/2019	05/22/2019	05/22/2019	05/22/2019			304,234.92	304,234.92	USD	2000009288	05/22/2019	
<input type="checkbox"/> 1022943	307		2000009407		ZP	06/19/2019	06/19/2019	06/19/2019	06/19/2019			288,087.00	288,087.00	USD	2000009407	06/19/2019	
<input type="checkbox"/> 1022943	307		2000009112		ZP	03/29/2019	03/29/2019	03/29/2019	03/29/2019			268,484.88	268,484.88	USD	2000009112	03/29/2019	
<input type="checkbox"/> 1022943	307		2000009211		ZP	05/01/2019	05/01/2019	05/01/2019	05/01/2019			231,942.84	231,942.84	USD	2000009211	05/01/2019	
<input type="checkbox"/> 1022943	307		2000009647		ZP	08/28/2019	08/28/2019	08/28/2019	08/28/2019			217,006.80	217,006.80	USD	2000009647	08/28/2019	
<input type="checkbox"/> 1022943	307		2000009015		ZP	02/27/2019	02/27/2019	02/27/2019	02/27/2019			177,053.16	177,053.16	USD	2000009015	02/27/2019	
<input type="checkbox"/> 1022943	307		2000009590		ZP	08/14/2019	08/14/2019	08/14/2019	08/14/2019			141,869.88	141,869.88	USD	2000009590	08/14/2019	
<input type="checkbox"/> 1022943	307		2000008895		ZP	01/16/2019	01/16/2019	01/16/2019	01/16/2019			100,763.53	100,763.53	USD	2000008895	01/16/2019	
<input type="checkbox"/> 1022943	307		2000008871		ZP	01/11/2019	01/11/2019	01/11/2019	01/11/2019			100,763.53	100,763.53	USD	2000008871	01/11/2019	
<input type="checkbox"/> 1022943	307		2000009691		ZP	09/04/2019	09/04/2019	09/04/2019	09/04/2019			89,059.68	89,059.68	USD	2000009691	09/04/2019	
<input type="checkbox"/> 1022943	307		2000009318		ZP	05/29/2019	05/29/2019	05/29/2019	05/29/2019			81,075.36	81,075.36	USD	2000009318	05/29/2019	
<input type="checkbox"/> 1022943	307		2000009349		ZP	06/05/2019	06/05/2019	06/05/2019	06/05/2019			68,897.52	68,897.52	USD	2000009349	06/05/2019	
<input type="checkbox"/> 1022943	307		2000009198		ZP	04/26/2019	04/26/2019	04/26/2019	04/26/2019			67,614.00	67,614.00	USD	2000009198	04/26/2019	
<input type="checkbox"/> 1022943	307		2000009538		ZP	07/31/2019	07/31/2019	07/31/2019	07/31/2019			26,821.41	26,821.41	USD	2000009538	07/31/2019	
<input type="checkbox"/> 1022943	307		2000008883		ZP	01/11/2019	01/11/2019	01/11/2019	01/11/2019			100,763.53	100,763.53	USD	2000008883	01/11/2019	
												4,023,587.98	4,023,587.98	USD			

Doc.Type : ZP ( Payment posting ) Normal document  
 Doc. Number 2000009456 Company Code 307 Fiscal Year 2019  
 Doc. Date 07/03/2019 Posting Date 07/03/2019 Period 07  
 Calculate Tax ☐  
 Doc. Currency USD  
 Payment Run ID 07/03/2019 - PAY9

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	25	1022943	PURDUE PHARMA CANADA		GEN			461,586.72	
2	50	100010	Cash Concentration		GEN			461,586.72-	

## **Exhibit 1N: Transfer of the Adhansia assets from Purdue Pharma Canada to Purdue in 2018**

On October 11, 2018, Purdue entered into an asset purchase agreement with Purdue Pharma Canada for the Adhansia assets.

### **ASSET PURCHASE AGREEMENT**

**THIS ASSET PURCHASE AGREEMENT** (this “Agreement”) is made and entered into this 11<sup>th</sup> day of October, 2018 by and among Purdue Pharma, a Canadian limited partnership (“Seller”), and Purdue Pharma L.P., a Delaware limited partnership (“Buyer”). Seller and Buyer are each a “Party” and, collectively, the “Parties”.

### **WITNESSETH:**

**WHEREAS**, Seller desires to sell, and Buyer desires to acquire, the Business (as defined below);

**WHEREAS**, Seller owns the Transferred Assets (as defined below);

**WHEREAS**, the Parties hereto desire that (a) Seller sells and transfers the Transferred Assets to Buyer, and (b) Buyer assumes the Assumed Liabilities (as defined below), in each case upon the terms and conditions set forth herein.

**NOW, THEREFORE**, in consideration of the premises and the mutual covenants and undertakings contained herein, subject to and on the terms and conditions herein set forth, and intending to be bound hereby, the Parties agree as follows:

## Exhibit 1N: Transfer of the Adhansia assets from Purdue Pharma Canada to Purdue in 2018

According to the asset purchase agreement, Purdue agreed to pay the following:

### 2.6 Purchase Price; Payments.

(a) Buyer shall pay to the account designated by Seller pursuant to this Section 2.6(a):

(i) at the Closing, an amount equal to US\$1,000,000 plus US\$2,421,495 for reimbursement of the FDA filing fee incurred by Seller in respect of the Product plus US\$1,488,071 for reimbursement of the costs Seller has incurred as of August 31, 2018 in respect of the AWE Clinical Trials, such amount in the aggregate totaling US\$4,909,566 (“Closing Payment”);

(ii) an amount equal to the costs Seller incurs in respect of the AWE Clinical Trials after August 31, 2018 in accordance with the terms of the Transition Services Agreement;

(iii) upon the earlier of (x) FDA Approval or (ii) the receipt of Regulatory Approval from the FDA, which, for greater certainty, does not include approval of a label for the Product indicating (sixteen) 16 hours of efficacy (in either case, the “FDA Expense Reimbursement Trigger Event”), an amount equal to US\$3,951,941 (“FDA Expense Reimbursement Amount”);

(iv) upon FDA Approval, an amount equal to US\$5,000,000 (“FDA Approval Payment”); and

(v) upon the First Commercial Sale, an amount equal to US\$4,000,000 (the “First Commercial Sale Payment” and together with the Closing Payment and FDA Approval Payment, the “Purchase Price”).

## Exhibit 1N: Transfer of the Adhansia assets from Purdue Pharma Canada to Purdue in 2018

As of the Petition Date, Purdue paid Purdue Pharma Canada \$20.2 million for the Adhansia assets.

Asset Purchase Agreement Section	Description	Paying Entity	Date	Payment Amount
§2.6.i	Purchase price paid at closing	Purdue Pharma L.P. (208)	12/12/2018	\$4,909,566
2.6.iii and 2.6.iv	FDA expense reimbursement and FDA approval	Adlon Therapeutics L.P. (258)	3/20/2019	8,951,941
§2.6.ii	Costs in respect of the AWE Clinical Trials	Adlon Therapeutics L.P. (258)	4/5/2019	2,386,059
2.6.v	First commercial sale	Adlon Therapeutics L.P. (258)	8/5/2019	4,000,000
<b>Total</b>				<b>\$20,247,566</b>

## Exhibit 1N: Transfer of the Adhansia assets from Purdue Pharma Canada to Purdue in 2018

The SAP screenshots below illustrate the cash payments that Purdue made to Purdue Pharma Canada for the Adhansia assets.

### 2.6.i : Purchase price paid at closing - paid out of Purdue Pharma LP (#208):

Doc.Type : KZ ( Vendor payment ) Normal document					
Doc. Number	1500012597	Company Code	208	Fiscal Year	2018
Doc. Date	12/03/2018	Posting Date	12/12/2018	Period	12
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	WIRE TRANSFER				
Doc. Currency	USD				

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			4,909,566.00-	
2	25	1022943	PURDUE PHARMA CANADA		GEN			4,909,566.00	

### 2.6.iii and 2.6.iv : FDA expense reimbursement and FDA approval payment – paid out of Adlon Therapeutics L.P. (#258)

Doc.Type : ZP ( Payment posting ) Normal document					
Doc. Number	2000000045	Company Code	258	Fiscal Year	2019
Doc. Date	03/20/2019	Posting Date	03/20/2019	Period	03
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Payment Run ID	03/20/2019 - PAY9				

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	25	1022943	PURDUE PHARMA CANADA		GEN			8,951,941.00	
2	50	100010	Cash Concentration		GEN			8,951,941.00-	

## Exhibit 1N: Transfer of the Adhansia assets from Purdue Pharma Canada to Purdue in 2018

The SAP screenshots below illustrate the cash payments that Purdue made to Purdue Pharma Canada for the Adhansia assets.

### 2.6.ii : Costs in respect of the AWE Clinical Trials – paid out of Adlon Therapeutics L.P. (#258)

Doc.Type : ZP ( Payment posting ) Normal document					
Doc. Number	2000000072	Company Code	258	Fiscal Year	2019
Doc. Date	04/05/2019	Posting Date	04/05/2019	Period	04
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Payment Run ID	04/05/2019 - PAY9				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	25	1022943	PURDUE PHARMA CANADA		GEN			2,386,059.32	
2	50	100010	Cash Concentration		GEN			2,386,059.32-	

### 2.6.v : First commercial sale payment – paid out of Adlon Therapeutics L.P. (#258)

Doc.Type : ZP ( Payment posting ) Normal document					
Doc. Number	2000000219	Company Code	258	Fiscal Year	2019
Doc. Date	08/05/2019	Posting Date	08/05/2019	Period	08
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	USD				
Payment Run ID	08/05/2019 - PAY15				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	25	1022943	PURDUE PHARMA CANADA		GEN			4,000,000.00	
2	50	100010	Cash Concentration		GEN			4,000,000.00-	



## **Exhibit 10: Intercompany transfers between E.R.G. Realty Inc. and Purdue pursuant to a loan**

On October 1, 2010, Purdue extended an existing loan from 2000 (the "2000 Loan") with E.R.G. Realty Inc. for \$3.35 million at 3.28% interest. The 2000 Loan had a balance of \$3.45 million at 6% interest as of its maturity date on September 30, 2010.

### **PROMISSORY NOTE**

\$3,350,000

October 1, 2010

FOR VALUE RECEIVED, the undersigned, E.R.G. Realty, Inc., a New York corporation (the "Borrower"), hereby promises to pay to the order of Purdue Pharma L.P., a Delaware limited partnership (the "Lender"), the principal sum of Three Million Three Hundred Fifty Thousand Dollars (\$3,350,000) on September 30, 2020 (the "Maturity Date") as provided herein.

The Borrower also promises to pay interest on the unpaid principal amount hereof from time to time outstanding, from the date hereof until payment in full, at the rate of 3.28% per annum, calculated on the basis of a 365-day year, such interest to be payable quarterly on each March 31st, June 30th, September 30th and December 31st commencing December 31, 2010 (each a "Payment Date").

All accrued and unpaid interest hereon shall be due and payable upon the day that all principal is due and payable (whether on the Maturity Date or otherwise).

## **Exhibit 10: Intercompany transfers between E.R.G. Realty Inc. and Purdue pursuant to a loan**

As part of the loan extension, E.R.G. Realty Inc. notified Purdue of a \$100,000 principal payment that would reduce the outstanding amount from the original \$3.45 million principal balance to \$3.35 million.

---

**From:** [REDACTED]  
**Sent:** Tuesday, August 03, 2010 11:54 AM  
**To:** [REDACTED]  
**Cc:** [REDACTED]  
**Subject:** FW: ERG - Status

Tony,

As per the e-mail below, \$3,350,000.00 will be the balance of loan between ERG Realty Inc. and Purdue Pharma LP on 10/01/2010.

Best regards,  
[REDACTED]

## Exhibit 10: Intercompany transfers between E.R.G. Realty Inc. and Purdue pursuant to a loan

From 2008 to 2018. E.R.G. Realty Inc. paid \$5.1 million in principal and interest to Purdue.

Year	Principal	Interest <sup>1</sup>	Total
2008	\$ 200,000	\$ 227,330	\$ 427,330 <sup>2</sup>
2009	200,000	215,930	415,930 <sup>2</sup>
2010	100,000	137,927	237,927
2011	100,000	134,310	234,310
2012	250,000	106,892	356,892
2013	250,000	98,400	348,400
2014	250,000	90,200	340,200
2015	250,000	82,000	332,000
2016	275,000	74,002	349,002
2017	275,000	64,780	339,780
2018	1,700,009 <sup>3</sup>	59,602	1,759,611
<b>Total</b>	<b>\$3,850,009</b>	<b>\$1,291,373</b>	<b>\$5,141,382</b>

<sup>1</sup>Interest is presented in accordance with the timing of actual cash settlements.

<sup>2</sup>Includes principal and interest payments made in 2008 and 2009 that predate the extension of the 2000 loan.

<sup>3</sup>2018 principal repayment includes the reversal of a misclassified \$9 telephone charge per SAP.

## Exhibit 10: Intercompany transfers between E.R.G. Realty Inc. and Purdue pursuant to a loan

According to PPLP's accounting records in SAP (SAP company code 208), PPLP recorded principal payments from E.R.G. Realty Inc. in G/L account 102512 (Current Assets – Pharma Technologies Inc.) until December 2009 and, afterwards, in G/L account 102550 (Long Term Asset – Due From ERG).

G/L Account		102512		Pharma Technologies Inc.									
Company Code		208											
CoCd	DocumentNo	Fatng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
	208	100001964	31.12.2000	31.12.2000	12	2000/12	SA	HISTORICAL DATA	102512		Historical data load	4.600.000,00	USD
	208	100004643	31.01.2001	31.01.2001	1	2001/01	SA	HISTORICAL DATA	102512	GEN	Historical data load	50.000,00	USD
	208	100004649	31.03.2001	31.03.2001	3	2001/03	SA	HISTORICAL DATA	102512	GEN	Historical data load	50.000,00	USD
	208	100000004	31.12.2001	31.12.2001	12	2001/12	SA	HISTORICAL DATA	102512	GEN	Historical data load	4.500.000,00	USD
	208	100001960	31.12.2001	31.12.2001	12	2001/12	AB	HISTORICAL DATA	102512	GEN	Historical data load	4.500.000,00	USD
	208	100016596	31.10.2002	31.10.2002	10	2002/10	SA	AMF 102002 10	102512	GEN	E.R.G. Realty, Inc; ck #517	50.000,00	USD
	208	100012290	31.07.2003	31.07.2003	7	2003/07	SA	7/03 MISC. BANK	102512	GEN	"ERG Realty, Inc; ck #522"	50.000,00	USD
	208	100059309	23.02.2005	23.02.2005	2	2005/02	SA	BANK DEPOSITS: 0	102512	GEN	E.R.G. Realty LP; ck #536	150.000,00	USD
	208	100065526	31.08.2005	06.09.2005	8	2005/08	SA	8/12/05 BANK DEF	102512	GEN	ERG Realty; ck #541	50.000,00	USD
	208	100069411	31.12.2005	31.12.2005	12	2005/12	SA	12/20/05 BANK DE	102512	GEN	"E.R.G. Realty, Inc; ck #544; loan repayment"	50.000,00	USD
	208	100001707	21.04.2006	21.04.2006	4	2006/04	SA	4/14/06 BANK DEF	102512	GEN	"E.R.G. Realty, Inc; ck #548; return of loan"	50.000,00	USD
	208	100004906	19.06.2006	19.06.2006	6	2006/06	SA	208 DEPOSIT 6/13	102512	GEN	"E.R.G. Realty, Inc; ck #550; return of loan"	25.000,00	USD
	208	100006497	31.07.2006	31.07.2006	7	2006/07	SA	7/18/2006 DEPOSIT	102512	GEN	"E.R.G. Realty, Inc; ck #551; loan repayment"	50.000,00	USD
	208	100010953	31.10.2006	31.10.2006	10	2006/10	SA	10/20/06 DEF; 20	102512	GEN	"ERG Realty, Inc; ck #554; loan repayment"	50.000,00	USD
	208	100015940	29.01.2007	29.01.2007	1	2007/01	SA	1/5/07 MISC. DEF	102512	GEN	"ERG Realty, Inc; ck #561; loan repayment"	25.000,00	USD
	208	100022546	28.06.2007	28.06.2007	6	2007/06	SA	MISC. BANK DEPOS	102512	GEN	"ERG Realty, Inc; ck #571"	50.000,00	USD
	208	100025920	17.09.2007	17.09.2007	9	2007/09	SA	MISC. BANK DEPOS	102512	GEN	"ERG Realty, Inc; ck #677; Loan repayment"	50.000,00	USD
	208	100035311	31.03.2008	31.03.2008	3	2008/03	SA	DEPOSITS	102512	GEN	"ERG Realty, Inc; ck #590"	50.000,00	USD
	208	100039935	18.06.2008	18.06.2008	6	2008/06	SA	6/10/2008 MISC.	102512	GEN	"ERG Realty, Inc; ck #592"	75.000,00	USD
	208	100047412	22.12.2008	22.12.2008	12	2008/12	SA	12/17/2008 BANK	102512	GEN	"ERG Realty, Inc; ck # 1002"	75.000,00	USD
	208	100050283	18.03.2009	18.03.2009	3	2009/03	SA	3/17/2009 MISC.	102512	GEN	"ERG Realty, Inc; ck # 1009; Loan Repayment"	50.000,00	USD
	208	100060161	09.10.2009	09.10.2009	10	2009/10	SA	10/7/2009 BANK D	102512	GEN	"E.R.G. Realty, Inc; ck # 1018; loan repayment"	100.000,00	USD
	208	100063766	31.12.2009	31.12.2009	12	2009/12	SA	12/24/2009 BANK	102512	GEN	"ERG Realty, Inc; ck # 1025; loan repayment"	50.000,00	USD
	208	100065830	31.12.2009	31.12.2009	12	2009/12	SA	DEC09	102512	GEN	TO TRANSFER ERG TO 102550	3.450.000,00	USD
*												0,00	USD
G/L Account		102550		ERG Realty Inc.									
Company Code		208											
CoCd	DocumentNo	Fatng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
	208	100065830	31.12.2009	31.12.2009	12	2009/12	SA	DEC09	102550	GEN	TO TRANSFER ERG TO 102550	3.450.000,00	USD
	208	100073137	15.08.2010	17.08.2010	8	2010/08	SA		102550	GEN	8/9/2010 LOAN REPAYMENT	100.000,00	USD
	208	100089908	08.08.2011	11.08.2011	8	2011/08	SA		102550	GEN	8/2/2011 INTEREST ON INTEREST BEARING LOAN	134.309,92	USD
	208	100089908	08.08.2011	11.08.2011	8	2011/08	SA		102550	GEN	8/3/2011 PRINCIPAL PAYMENT ON INTEREST BEARING LOAN	100.000,00	USD
	208	100090452	31.05.2011	07.09.2011	8	2011/08	SA	EL 090711 22	102550	GEN	Reclass interest to the correct account	134.309,92	USD
	208	100108666	23.08.2012	28.08.2012	8	2012/08	SA		102550	GEN	FUNDING from ERG REALTY, INC.	250.000,00	USD
	208	100126790	31.08.2013	03.09.2013	8	2013/08	SA		102550	GEN	FUNDING from ERG REALTY, INC.	250.000,00	USD
	208	100138185	31.08.2014	03.09.2014	8	2014/08	SA	CTWS50 08252014-	102550	GEN		250.000,00	USD
	208	100151478	31.08.2015	02.09.2015	8	2015/08	SA	CWS	102550	GEN		250.000,00	USD
	208	100157708	30.04.2016	27.04.2016	4	2016/04	SA	CWS	102550	GEN		9,00	USD
	208	100160546	31.08.2016	01.09.2016	8	2016/08	SA	CWS	102550	GEN		275.000,00	USD
	208	100160688	31.08.2016	06.09.2016	8	2016/08	SA	2510.40 ADG JE	102550	GEN		33,16	USD
	208	100163045	30.11.2016	05.12.2016	11	2016/11	SA	EL 120516 25	102550	GEN		33,16	USD
	208	100163910	31.12.2016	13.01.2017	12	2016/12	SA	ERG LOAN	102550	GEN		9,00	USD
	208	100169260	31.08.2017	01.09.2017	8	2017/08	SA	CWS	102550	GEN	Reclass to correct account	275.000,00	USD
	208	100176298	30.11.2017	14.11.2017	11	2017/11	SA	1117	102550	GEN	To correct JE 100163910	9,00	USD
	208	100176306	31.08.2018	04.09.2018	8	2018/08	SA	CWS	102550	GEN		275.000,00	USD
	208	100173118	31.10.2018	05.11.2018	10	2018/10	SA	LT 1018	102550	GEN	To adj for Loan Repayment plus interest	1.425.009,00	USD
*												0,00	USD

## Exhibit 10: Intercompany transfers between E.R.G. Realty Inc. and Purdue pursuant to a loan

According to PPLP's accounting records in SAP (SAP company code 208), PPLP recorded accrued interest payments from E.R.G. Realty Inc. in G/L account 103090 (Accrued Interest Income). Accrued interest from September 2017 to September 2018 is illustrated below (i.e., the amount paid in 2018 per the next slide).

G/L Account Line Item Display										
G/L Account 103090      Accrued Interest Income Company Code 208										
	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/>	9	2017/09	SA		ERG LOAN	103090	GEN	Interest Income ERG Loan Sept 2017	4.583,01	USD
<input type="checkbox"/>	10	2017/10	SA		ERG LOAN	103090	GEN	Interest Income ERG Loan Oct 2017	4.735,78	USD
<input type="checkbox"/>	11	2017/11	SA		ERG LOAN	103090	GEN	Interest Income ERG Loan Nov 2017	4.583,01	USD
<input type="checkbox"/>	12	2017/12	SA		ERG LOAN	103090	GEN	Interest Income ERG Loan Dec 2017	4.735,78	USD
<input type="checkbox"/>	1	2018/01	SA		ERG LOAN	103090	GEN	Interest Income ERG Loan Jan 2018	4.735,78	USD
<input type="checkbox"/>	2	2018/02	SA		ERG LOAN	103090	GEN	Interest Income ERG Loan Feb 2018	4.277,48	USD
<input type="checkbox"/>	3	2018/03	SA		ERG LOAN	103090	GEN	Interest Income ERG Loan March 2018	4.735,78	USD
<input type="checkbox"/>	4	2018/04	SA		ERG LOAN	103090	GEN	Interest Income ERG Loan April 2018	4.583,01	USD
<input type="checkbox"/>	5	2018/05	SA		ERG LOAN	103090	GEN	Interest Income ERG Loan May 2018	4.735,78	USD
<input type="checkbox"/>	6	2018/06	SA		ERG LOAN	103090	GEN	Interest Income ERG Loan June 2018	4.583,01	USD
<input type="checkbox"/>	7	2018/07	SA		ERG LOAN	103090	GEN	Interest Income ERG Loan July 2018	4.735,78	USD
<input type="checkbox"/>	8	2018/08	SA		ERG LOAN	103090	GEN	Interest Income ERG Loan August 2018	4.735,78	USD
<input type="checkbox"/>	9	2018/09	SA		RK 0918 03	103090	GEN	Interest Income ERG Loan 09.2018	3.841,64	USD
*									59.601,62	USD

## Exhibit 10: Intercompany transfers between E.R.G. Realty Inc. and Purdue pursuant to a loan

Cash payments were recognized as follows in PPLP's accounting records in SAP. 2018 principal and interest payments are illustrated below.

Company	Account Number	Account Description	DR	CR
550	100010	Cash Concentration		\$ (1,428,842)
550	200010	Accounts Payable I/C	\$ 1,428,842	
208	100010	Cash Concentration	\$ 1,428,842	
208	103090	Accrued Interest Income		\$ (1,428,842)
Company	Account Number	Account Description	DR	CR
550	100010	Cash Concentration		\$ (275,000)
550	102208	Purdue Pharma L.P.	\$ 275,000	
208	100010	Cash Concentration	\$ 275,000	
208	102550	ERG Realty Inc.		\$ (275,000)
Company	Account Number	Account Description	DR	CR
550	100010	Cash Concentration		\$ (55,760)
550	205080	Accrued Interest	\$ 55,760	
208	100010	Cash Concentration	\$ 55,760	
208	103090	Accrued Interest Income		\$ (55,760)

550: ERG Realty Inc.  
208: Purdue Pharma L.P.

Total interest paid in 2018 equals \$59,602. The discrepancy is due to \$3,841.64 of interest included in the final principal payments per SAP.



## Exhibit 10: Intercompany transfers between E.R.G. Realty Inc. and Purdue pursuant to a loan

The entries for the final 2018 principal payment appear in SAP as follows:

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100176835	Company Code	208	Fiscal Year	2018
Doc. Date	08.10.2018	Posting Date	07.10.2018	Period	10
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	CWS	Overall No.	0100176835208 18		
Doc. Currency	USD				
Doc. Hdr Text	CTW208 10012018-10072018				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
41	40	100010	Cash Concentration		GEN			1.428.841,64	LOAN REPAYMENT PLUS INTEREST 1.425MM PRINCIPAL 384
107	50	103090	Accrued Interest Inc		GEN			1.428.841,64-	LOAN REPAYMENT PLUS INTEREST 1.425MM PRINCIPAL 384

Doc.Type : KZ ( Vendor payment ) Normal document					
Doc. Number	1500000023	Company Code	550	Fiscal Year	2018
Doc. Date	02.10.2018	Posting Date	03.10.2018	Period	10
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	LICEA100218				
Doc. Currency	USD				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			1.428.841,64-	
2	25	7010011	PURDUE PHARMA LP		GEN			1.428.841,64	WIRE CLEARING

Vendor	7010011	<input checked="" type="checkbox"/> PURDUE PHARMA LP	G/L Acc	200010
Company Code	550	ONE STAMFORD FORUM		
ERG Realty Incorporated	STAMFORD	Doc. no.	1500000023	
Line Item 2 / Outgoing payment / 25				
Amount	1.428.841,64	USD		
Tax code				
W.tax base	1.428.841,64	USD	W.tax exempt	0,00
			W.Tax Code	07

## Exhibit 10: Intercompany transfers between E.R.G. Realty Inc. and Purdue pursuant to a loan

The entries for the scheduled 2018 principal and interest payments appear in SAP as follows:

CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy
Itm	PK Account	Account short text	Assignment	Tx	Amount	Text	
208	100176306	2018 SA	04.09.2018	31.08.2018	CWS	USD	
1	40 100010	Cash Concentration	20180904		275.000,00	PARTIAL LOAN REPAYMENT CREDIT REF ATS OF 18/08/28	
2	50 102550	ERG Realty Inc.	20180904		275.000,00-		
504	100003993	2018 SA	04.09.2018	31.08.2018	CWS	USD	
1	50 100010	Cash Concentration	20180904		118.749,99-	CORP PAY	
2	40 102550	ERG Realty Inc.	20180904		118.749,99		
550	100000366	2018 SA	04.09.2018	31.08.2018	CWS	USD	
1	50 100010	Cash Concentration	20180904		275.000,00-	PARTIAL LOAN REPAYMENT CREDIT REF ATS OF 18/08/28	
2	50 100010	Cash Concentration	20180904		55.760,00-	ACCRUED INTEREST PAYMENT CREDIT REF ATS OF 18/08/28	
3	40 100010	Cash Concentration	20180904		118.749,99	CORP PAY	
4	40 205080	Accr. Interest	20180904		55.760,00	ACCRUED INTEREST PAYMENT CREDIT REF ATS OF 18/08/28	
5	40 102208	Purdue Pharma L.P.	20180904		275.000,00		
6	50 102504	Terramar Foundation	20180904		118.749,99-		
208	100176304	2018 SA	04.09.2018	31.08.2018	CWS	USD	
6	40 100010	Cash Concentration	20180904		55.760,00	ACCRUED INTEREST PAYMENT DEBIT REF NONREF	
17	50 100010	Cash Concentration	20180904		21.275,71-	Load # 024734	
18	50 100010	Cash Concentration	20180904		136.605,13-	AC40063014 PURDUE PHARMA LP CIGNA MEDICAL INSUUS	
19	40 100086	Restrict Cash Chase	20180904		203,75	INTEREST PAYMENT	
20	50 100400	Temp. Invest. Chase	20180904		50.000.000,00-	UNITED STATES TREASURY BILLS UNITED S	
21	50 103040	AR Other	20180904		138.657,45-	8612132537	
22	50 103090	Accrued Interest Inc	20180904		55.760,00-	ACCRUED INTEREST PAYMENT DEBIT REF NONREF	

## Exhibit 10: Intercompany transfers between E.R.G. Realty Inc. and Purdue pursuant to a loan

The final loan repayment of \$1,428,841.64 includes \$3,841.64 of interest as shown below.<sup>1</sup>  
The \$9 misclassified telephone charge mentioned on slide 194 is included to reconcile with the October 2018 principal repayment of \$1,425,009.

Doc.Type : KR ( Vendor invoice ) Normal document					
Doc. Number	1900000055	Company Code	550	Fiscal Year	2018
Doc. Date	02.10.2018	Posting Date	02.10.2018	Period	10
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	LICEA100218				
Doc. Currency	USD				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	7010011	PURDUE PHARMA LP		GEN			1.428.841,64-	REPAY LOAN PLUS INTEREST DUE
2	40	102550	ERG Realty Inc.		GEN			1.425.000,00	
3	40	103090	Accrued Interest Inc		GEN			3.841,64	

Doc.Type : SA ( G/L account document ) Normal document					
Doc. Number	100177118	Company Code	208	Fiscal Year	2018
Doc. Date	05.11.2018	Posting Date	31.10.2018	Period	10
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	LT 1018				
Doc. Currency	USD				
Doc. Hdr Text	Adj JE				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	102550	ERG Realty Inc.		GEN			1.425.009,00-	To adj for Loan Repayment plus interest
2	40	103090	Accrued Interest Inc		GEN			1.425.000,00	To adj for Loan Repapment plus interest
3	40	700010	Interest Income	2000208	GEN			9,00	To adj for Loan Repapment plus interest

G/L Account	102550	ERG Realty Inc.							
Company Code	208								

	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/>	8	2018/08	SA		CWS	102550	GEN		275.000,00-	USD
<input type="checkbox"/>	10	2018/10	SA		LT 1018	102550	GEN	To adj for Loan Repayment plus interest	1.425.009,00-	USD
*									1.700.009,00-	USD

<sup>1</sup>\$1,428,841.64 - \$3,841.64 = \$1,425,000.00

## Exhibit 10: Intercompany transfers between E.R.G. Realty Inc. and Purdue pursuant to a loan

The entries for the 2008 principal repayment and interest payment appear in SAP as follows:

G/L Account		102512	Pharma Technologies Inc.										
Company Code		208											
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/> 208	100035311	31.03.2008	31.03.2008	3	2008/03	SA		DEPOSITS	102512	GEN	ERG Realty, Inc; ck #590	50.000,00-	USD
<input type="checkbox"/> 208	100039935	18.06.2008	18.06.2008	6	2008/06	SA		6/10/2008 MISC.	102512	GEN	"ERG Realty, Inc; ck #592"	75.000,00-	USD
<input type="checkbox"/> 208	100047412	22.12.2008	22.12.2008	12	2008/12	SA		12/17/2008 BANK	102512	GEN	"ERG Realty, Inc; ck # 1002"	75.000,00-	USD
*												200.000,00-	USD

G/L Account		101040	A/R Clearing (Trade Accounts Receivable)										
Company Code		208											
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/> 208	100039935	18.06.2008	18.06.2008	6	2008/06	SA		6/10/2008 MISC.	101040	GEN	"ERG Realty, Inc; ck #591"	57.608,22-	USD
<input type="checkbox"/> 208	100035311	31.03.2008	31.03.2008	3	2008/03	SA		DEPOSITS	101040	GEN	ERG Realty, Inc; ck #589; interest	57.591,78-	USD
<input type="checkbox"/> 208	100043947	24.09.2008	24.09.2008	9	2008/09	SA		9/19/2008 MISC.	101040	GEN	"ERG Realty, Inc; ck #594; Interest 6/1/2008 - 8/3	56.408,22-	USD
<input type="checkbox"/> 208	100047412	22.12.2008	22.12.2008	12	2008/12	SA		12/17/2008 BANK	101040	GEN	"ERG Realty, Inc; ck # 1001; Interest 9/1/2008 - 1	55.721,91-	USD
*												227.330,13-	USD

## **Exhibit 1P: Intercompany transfers between various IACs and Purdue for accounting, HR, and other services**

The October 19, 2018 MDL Presentation states that PPLP provided certain IACs accounting, HR, and other services. Per discussion with Purdue and TXP, no amounts were ever charged to these entities for such services.



## Exhibit 1Q: Intercompany transfers between foreign IACs and Purdue for finished products

From January 1, 2008 to September 15, 2019, certain foreign IACs purchased \$56.6 million of finished goods from Purdue, including [REDACTED] in freight and [REDACTED] in markups ([REDACTED] markups from 2011 to 2015 and [REDACTED] markups from 2016 to 2019). Markups between 2008-2010 for foreign markets were extrapolated based on costs and markups in the US Market for those individual products. In 2011, pricing was consolidated and streamlined to ensure that costs were sufficiently covered by product sales.

IAC	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
MUNDIPHARMA DC B.V.	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 899,768	\$ 1,665,224	\$ 1,418,696	\$ 3,983,688
Mundipharma Laboratories GmbH	1,970,427	1,714,390	1,945,014	2,125,956	2,513,596	2,210,809	17,858,921	7,989,780	5,624,451	3,620,237	2,227,170	1,335,646	51,136,397
MUNDIPHARMA LATAM GMBH	-	-	-	-	-	-	-	-	203,239	273,617	242,015	161,927	880,798
MUNDIPHARMA MEA GMBH	-	-	-	-	-	-	-	-	293,932	49,899	35,667	2,228	381,725
MUNDIPHARMA NEAR EAST GMBH	-	-	-	-	-	-	-	-	83,687	52,455	27,083	84,649	247,874
MUNDIPHARMA RESEARCH LIMITED	-	-	-	-	-	-	-	727	-	-	-	-	727
Purdue Pharma Canada	-	-	-	9,325	3,694	-	-	351	-	-	-	-	13,370
<b>Total</b>	<b>\$ 1,970,427</b>	<b>\$ 1,714,390</b>	<b>\$ 1,945,014</b>	<b>\$ 2,135,280</b>	<b>\$ 2,517,290</b>	<b>\$ 2,210,809</b>	<b>\$ 17,858,921</b>	<b>\$ 7,990,859</b>	<b>\$ 6,205,309</b>	<b>\$ 4,895,976</b>	<b>\$ 4,197,159</b>	<b>\$ 3,003,145</b>	<b>\$ 56,644,578</b>

Per discussions with Purdue, there are no manufacturing supply agreements with the Mundipharma entities that support the sales of finished products. There are, however, invoices reflecting the sales of finished products and the terms upon which the sales were made (see slide 207 for additional detail).



## Exhibit 1Q: Intercompany transfers between foreign IACs and Purdue for finished products

SAP provides support for total payments received through Virtual Distribution Co. (SAP company code 999) and G/L account 403000 (Foreign Sales).<sup>1</sup>

G/L Account Company Code		403000 999		Foreign Sales									
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/>	999 92473941	06/10/2019	06/10/2019	6	2019/06	ZD		0000905446	403000	ORF		51,356.16-	USD
<input type="checkbox"/>	999 92473942	06/10/2019	06/10/2019	6	2019/06	ZD		0000905444	403000	ORF		79,004.16-	USD
<input type="checkbox"/>	999 92473943	06/10/2019	06/10/2019	6	2019/06	ZD		0000911037	403000	ORF		2,328.00-	USD
<input type="checkbox"/>	999 92476704	06/13/2019	06/13/2019	6	2019/06	ZD		0000913415	403000	DLM		130.77-	USD
<input type="checkbox"/>	999 92476705	06/13/2019	06/13/2019	6	2019/06	ZD		0000913312	403000	ORM		1,964.00-	USD
<input type="checkbox"/>	999 92476706	06/13/2019	06/13/2019	6	2019/06	ZD		0000915866	403000	ORM		73.65-	USD
<input type="checkbox"/>	999 92476707	06/13/2019	06/13/2019	6	2019/06	ZD		0000917359	403000	ORM		49.10-	USD
<input type="checkbox"/>	999 92477412	06/17/2019	06/17/2019	6	2019/06	ZD		0000901437	403000	ORF		13,350.00-	USD
<input type="checkbox"/>	999 92477413	06/17/2019	06/17/2019	6	2019/06	ZD		0000901436	403000	ORF		31,640.00-	USD
<input type="checkbox"/>	999 92477415	06/17/2019	06/17/2019	6	2019/06	ZD		0000915975	403000	ORF		156,100.00-	USD
<input type="checkbox"/>	999 92478370	06/19/2019	06/19/2019	6	2019/06	ZD		0070001734	403000	GEN		725.00-	USD
<input type="checkbox"/>	999 92478371	06/19/2019	06/19/2019	6	2019/06	ZD		0070001735	403000	GEN		22,620.50-	USD
<input type="checkbox"/>	999 92480419	06/24/2019	06/24/2019	6	2019/06	ZD		0000905984	403000	ORF		151,650.00-	USD
<input type="checkbox"/>	999 92487024	07/08/2019	07/08/2019	7	2019/07	ZD		0000911038	403000	ORF		2,400.00-	USD
<input type="checkbox"/>	999 92487024	07/08/2019	07/08/2019	7	2019/07	ZD		0000911038	403000	ORF		5,830.00-	USD
<input type="checkbox"/>	999 92487024	07/08/2019	07/08/2019	7	2019/07	ZD		0000911038	403000	ORF		7,910.00-	USD
<input type="checkbox"/>	999 92487025	07/08/2019	07/08/2019	7	2019/07	ZD		0000905986	403000	ORF		128,475.00-	USD
<input type="checkbox"/>	999 92490914	07/15/2019	07/15/2019	7	2019/07	ZD		0000910547	403000	ORF		29,250.00-	USD
<input type="checkbox"/>	999 92492399	07/16/2019	07/16/2019	7	2019/07	ZD		0070001736	403000	GEN		45,798.50-	USD
<input type="checkbox"/>	999 92492400	07/16/2019	07/16/2019	7	2019/07	ZD		0070001737	403000	GEN		31,502.65-	USD
<input type="checkbox"/>	999 92492909	07/17/2019	07/17/2019	7	2019/07	ZD		0070001739	403000	GEN		3,955.40-	USD
<input type="checkbox"/>	999 92492915	07/17/2019	07/17/2019	7	2019/07	ZD		0070001738	403000	GEN		1,045.00-	USD
<input type="checkbox"/>	999 92492916	07/17/2019	07/17/2019	7	2019/07	ZD		0070001740	403000	GEN		906.00-	USD
<input type="checkbox"/>	999 92497011	07/25/2019	07/25/2019	7	2019/07	ZD		0070001742	403000	GEN		31,876.04-	USD
<input type="checkbox"/>	999 92498020	07/29/2019	07/29/2019	7	2019/07	ZD		0000916746	403000	ORF		1,149.60-	USD
<input type="checkbox"/>	999 92498020	07/29/2019	07/29/2019	7	2019/07	ZD		0000916746	403000	ORF		6,984.00-	USD
<input type="checkbox"/>	999 92498020	07/29/2019	07/29/2019	7	2019/07	ZD		0000916746	403000	ORF		948.00-	USD
<input type="checkbox"/>	999 92498021	07/29/2019	07/29/2019	7	2019/07	ZD		0000917712	403000	ORF		7,920.00-	USD
<input type="checkbox"/>	999 92498022	07/29/2019	07/29/2019	7	2019/07	ZD		0000912816	403000	ORF		35,432.00-	USD
<input type="checkbox"/>	999 92498022	07/29/2019	07/29/2019	7	2019/07	ZD		0000912816	403000	ORF		5,928.00-	USD
<input type="checkbox"/>	999 92499529	07/31/2019	07/31/2019	7	2019/07	ZD		0070001743	403000	GEN		8,397.33-	USD
<input type="checkbox"/>	999 92500308	08/01/2019	08/01/2019	8	2019/08	ZD		0070001744	403000	GEN		2,655.00-	USD
<input type="checkbox"/>	999 92502667	08/06/2019	08/06/2019	8	2019/08	ZD		0070001745	403000	GEN		1,424.42-	USD
<input type="checkbox"/>	999 92502668	08/06/2019	08/06/2019	8	2019/08	ZD		0070001746	403000	GEN		2,107.38-	USD
<input type="checkbox"/>	999 92502671	08/06/2019	08/06/2019	8	2019/08	ZD		0070001747	403000	GEN		7,147.70-	USD
<input type="checkbox"/>	999 92510894	08/22/2019	08/22/2019	8	2019/08	ZD		0000926078	403000	DLM		4,224.50-	USD
<input type="checkbox"/>	999 92511701	08/26/2019	08/26/2019	8	2019/08	ZD		0000911344	403000	ORF		89,245.44-	USD
<input type="checkbox"/>	999 92511709	08/26/2019	08/26/2019	8	2019/08	ZD		0000915553	403000	ORF		11,230.00-	USD
<input type="checkbox"/>	999 92516690	09/04/2019	09/04/2019	9	2019/09	ZD		0070001749	403000	GEN		14,537.90-	USD
<input type="checkbox"/>	999 92516694	09/04/2019	09/04/2019	9	2019/09	ZD		0070001748	403000	ORF		7,940.00-	USD
<input type="checkbox"/>	999 92521222	09/12/2019	09/12/2019	9	2019/09	ZD		0070001750	403000	GEN		1,125.00-	USD
<input type="checkbox"/>	999 92521228	09/12/2019	09/12/2019	9	2019/09	ZD		0070001751	403000	GEN		6,975.08-	USD
<input type="checkbox"/>	*											56,644,577.90-	USD

<sup>1</sup>Screenshot does not include all entries – abbreviated version shown.

## Exhibit 1Q: Intercompany transfers between foreign IACs and Purdue for finished products

SAP provides support for total payments received through Virtual Distribution Co. (SAP company code 999) and G/L account 403000 (Foreign Sales) in 2008.<sup>1</sup>

G/L Account		403000		Foreign Sales									
Company Code		999											
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/>	999 90712875	23.09.2008	23.09.2008	9	2008/09	ZD		0000319132	403000	OXY		11.190,00-	USD
<input type="checkbox"/>	999 90714533	29.09.2008	29.09.2008	9	2008/09	ZD		0000310589	403000	OXY		37.200,00-	USD
<input type="checkbox"/>	999 90714533	29.09.2008	29.09.2008	9	2008/09	ZD		0000310589	403000	OXY		32.760,00-	USD
<input type="checkbox"/>	999 90714533	29.09.2008	29.09.2008	9	2008/09	ZD		0000310589	403000	OXY		31.040,00-	USD
<input type="checkbox"/>	999 90714533	29.09.2008	29.09.2008	9	2008/09	ZD		0000310589	403000	OXY		15.460,00-	USD
<input type="checkbox"/>	999 90723910	30.10.2008	30.10.2008	10	2008/10	ZD		0000331120	403000	OXY		1.522,00-	USD
<input type="checkbox"/>	999 90723910	30.10.2008	30.10.2008	10	2008/10	ZD		0000331120	403000	OXY		9.660,00-	USD
<input type="checkbox"/>	999 90723910	30.10.2008	30.10.2008	10	2008/10	ZD		0000331120	403000	OXY		3.710,00-	USD
<input type="checkbox"/>	999 90724382	03.11.2008	03.11.2008	11	2008/11	ZD		0000331119	403000	MSC		960,30-	USD
<input type="checkbox"/>	999 90724382	03.11.2008	03.11.2008	11	2008/11	ZD		0000331119	403000	MSC		1.351,35-	USD
<input type="checkbox"/>	999 90727245	12.11.2008	12.11.2008	11	2008/11	ZD		0000331121	403000	OXY		75.375,00-	USD
<input type="checkbox"/>	999 90727245	12.11.2008	12.11.2008	11	2008/11	ZD		0000331121	403000	OXY		130.800,00-	USD
<input type="checkbox"/>	999 90727245	12.11.2008	12.11.2008	11	2008/11	ZD		0000331121	403000	OXY		38.944,00-	USD
<input type="checkbox"/>	999 90727246	12.11.2008	12.11.2008	11	2008/11	ZD		0070000576	403000	GEN		3.868,00-	USD
<input type="checkbox"/>	999 90727247	12.11.2008	12.11.2008	11	2008/11	ZD		0070000577	403000	GEN		5.112,54-	USD
<input type="checkbox"/>	999 90727248	12.11.2008	12.11.2008	11	2008/11	ZD		0070000578	403000	GEN		5.022,80-	USD
<input type="checkbox"/>	999 90727249	12.11.2008	12.11.2008	11	2008/11	ZD		0070000579	403000	GEN		1.130,44-	USD
<input type="checkbox"/>	999 90727904	13.11.2008	13.11.2008	11	2008/11	ZD		0070000575	403000	GEN		7.180,85-	USD
<input type="checkbox"/>	999 90728276	17.11.2008	17.11.2008	11	2008/11	ZD		0000326475	403000	SNS		93.994,20-	USD
<input type="checkbox"/>	999 90729878	20.11.2008	20.11.2008	11	2008/11	ZD		0000321627	403000	SNS		7.138,80-	USD
<input type="checkbox"/>	999 90729879	20.11.2008	20.11.2008	11	2008/11	ZD		0000323885	403000	OXY		22.320,00-	USD
<input type="checkbox"/>	999 90729879	20.11.2008	20.11.2008	11	2008/11	ZD		0000323885	403000	OXY		15.120,00-	USD
<input type="checkbox"/>	999 90729879	20.11.2008	20.11.2008	11	2008/11	ZD		0000323885	403000	OXY		58.200,00-	USD
<input type="checkbox"/>	999 90729879	20.11.2008	20.11.2008	11	2008/11	ZD		0000323885	403000	OXY		27.055,00-	USD
<input type="checkbox"/>	999 90729879	20.11.2008	20.11.2008	11	2008/11	ZD		0000323885	403000	OXY		2.283,00-	USD
<input type="checkbox"/>	999 90729880	20.11.2008	20.11.2008	11	2008/11	ZD		0000335926	403000	SNS		1.189,80-	USD
<input type="checkbox"/>	999 90730340	21.11.2008	21.11.2008	11	2008/11	ZD		0000325695	403000	SNS		72.577,80-	USD
<input type="checkbox"/>	999 90732177	01.12.2008	01.12.2008	12	2008/12	ZD		0070000583	403000	GEN		4.863,34-	USD
<input type="checkbox"/>	999 90732178	01.12.2008	01.12.2008	12	2008/12	ZD		0070000584	403000	GEN		2.364,54-	USD
<input type="checkbox"/>	999 90735276	11.12.2008	11.12.2008	12	2008/12	ZD		0000322480	403000	OXY		291,76-	USD
<input type="checkbox"/>	999 90735276	11.12.2008	11.12.2008	12	2008/12	ZD		0000322480	403000	OXY		1.294,00-	USD
<input type="checkbox"/>	999 90735276	11.12.2008	11.12.2008	12	2008/12	ZD		0000322480	403000	OXY		2.848,80-	USD
<input type="checkbox"/>	999 90735276	11.12.2008	11.12.2008	12	2008/12	ZD		0000322480	403000	OXY		2.442,24-	USD
<input type="checkbox"/>	999 90735276	11.12.2008	11.12.2008	12	2008/12	ZD		0000322480	403000	OXY		2.269,50-	USD
<input type="checkbox"/>	999 90735277	11.12.2008	11.12.2008	12	2008/12	ZD		0000324377	403000	OXY		753,75-	USD
<input type="checkbox"/>	999 90735277	11.12.2008	11.12.2008	12	2008/12	ZD		0000324377	403000	OXY		2.374,00-	USD
<input type="checkbox"/>	999 90735277	11.12.2008	11.12.2008	12	2008/12	ZD		0000324377	403000	OXY		781,50-	USD
<input type="checkbox"/>	999 90735277	11.12.2008	11.12.2008	12	2008/12	ZD		0000324377	403000	OXY		1.941,00-	USD
<input type="checkbox"/>	999 90735277	11.12.2008	11.12.2008	12	2008/12	ZD		0000324377	403000	OXY		5.673,75-	USD
<input type="checkbox"/>	999 90735716	15.12.2008	15.12.2008	12	2008/12	ZD		0000328661	403000	OXY		53.154,00-	USD
<input type="checkbox"/>	999 90735716	15.12.2008	15.12.2008	12	2008/12	ZD		0000328661	403000	OXY		14.448,00-	USD
<input type="checkbox"/>	999 90735716	15.12.2008	15.12.2008	12	2008/12	ZD		0000328661	403000	OXY		1.661,80-	USD
*												1.970.426,62-	USD

<sup>1</sup>Screenshot does not include all entries – abbreviated version shown.

## Exhibit 1Q: Intercompany transfers between foreign IACs and Purdue for finished products

SAP provides support for total payments received through Virtual Distribution Co. (SAP company code 999) and G/L account 403000 (Foreign Sales) in 2019.<sup>1</sup>

G/L Account Company Code		403000 999		Foreign Sales									
CoCd	DocumentNo	Posting Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/>	999 92473941	06/10/2019	06/10/2019	6	2019/06	ZD		0000905446	403000	ORF		51,356.16-	USD
<input type="checkbox"/>	999 92473942	06/10/2019	06/10/2019	6	2019/06	ZD		0000905444	403000	ORF		79,004.16-	USD
<input type="checkbox"/>	999 92473943	06/10/2019	06/10/2019	6	2019/06	ZD		0000911037	403000	ORF		2,328.00-	USD
<input type="checkbox"/>	999 92476704	06/13/2019	06/13/2019	6	2019/06	ZD		0000913415	403000	DLM		130.77-	USD
<input type="checkbox"/>	999 92476705	06/13/2019	06/13/2019	6	2019/06	ZD		0000913312	403000	ORM		1,964.00-	USD
<input type="checkbox"/>	999 92476706	06/13/2019	06/13/2019	6	2019/06	ZD		0000915866	403000	ORM		73.65-	USD
<input type="checkbox"/>	999 92476707	06/13/2019	06/13/2019	6	2019/06	ZD		0000917359	403000	ORM		49.10-	USD
<input type="checkbox"/>	999 92477412	06/17/2019	06/17/2019	6	2019/06	ZD		0000901437	403000	ORF		13,350.00-	USD
<input type="checkbox"/>	999 92477413	06/17/2019	06/17/2019	6	2019/06	ZD		0000901436	403000	ORF		31,640.00-	USD
<input type="checkbox"/>	999 92477415	06/17/2019	06/17/2019	6	2019/06	ZD		0000915975	403000	ORF		156,100.00-	USD
<input type="checkbox"/>	999 92478370	06/19/2019	06/19/2019	6	2019/06	ZD		0070001734	403000	GEN		725.00-	USD
<input type="checkbox"/>	999 92478371	06/19/2019	06/19/2019	6	2019/06	ZD		0070001735	403000	GEN		22,620.50-	USD
<input type="checkbox"/>	999 92480419	06/24/2019	06/24/2019	6	2019/06	ZD		0000905984	403000	ORF		151,650.00-	USD
<input type="checkbox"/>	999 92487024	07/08/2019	07/08/2019	7	2019/07	ZD		0000911038	403000	ORF		2,400.00-	USD
<input type="checkbox"/>	999 92487024	07/08/2019	07/08/2019	7	2019/07	ZD		0000911038	403000	ORF		5,830.00-	USD
<input type="checkbox"/>	999 92487024	07/08/2019	07/08/2019	7	2019/07	ZD		0000911038	403000	ORF		7,910.00-	USD
<input type="checkbox"/>	999 92487025	07/08/2019	07/08/2019	7	2019/07	ZD		0000905986	403000	ORF		128,475.00-	USD
<input type="checkbox"/>	999 92490914	07/15/2019	07/15/2019	7	2019/07	ZD		0000910547	403000	ORF		29,250.00-	USD
<input type="checkbox"/>	999 92492399	07/16/2019	07/16/2019	7	2019/07	ZD		0070001736	403000	GEN		45,798.50-	USD
<input type="checkbox"/>	999 92492400	07/16/2019	07/16/2019	7	2019/07	ZD		0070001737	403000	GEN		31,502.65-	USD
<input type="checkbox"/>	999 92492909	07/17/2019	07/17/2019	7	2019/07	ZD		0070001739	403000	GEN		3,955.40-	USD
<input type="checkbox"/>	999 92492915	07/17/2019	07/17/2019	7	2019/07	ZD		0070001738	403000	GEN		1,045.00-	USD
<input type="checkbox"/>	999 92492916	07/17/2019	07/17/2019	7	2019/07	ZD		0070001740	403000	GEN		906.00-	USD
<input type="checkbox"/>	999 92497011	07/25/2019	07/25/2019	7	2019/07	ZD		0070001742	403000	GEN		31,876.04-	USD
<input type="checkbox"/>	999 92498020	07/29/2019	07/29/2019	7	2019/07	ZD		0000916746	403000	ORF		1,149.60-	USD
<input type="checkbox"/>	999 92498020	07/29/2019	07/29/2019	7	2019/07	ZD		0000916746	403000	ORF		6,984.00-	USD
<input type="checkbox"/>	999 92498020	07/29/2019	07/29/2019	7	2019/07	ZD		0000916746	403000	ORF		948.00-	USD
<input type="checkbox"/>	999 92498021	07/29/2019	07/29/2019	7	2019/07	ZD		0000917712	403000	ORF		7,920.00-	USD
<input type="checkbox"/>	999 92498022	07/29/2019	07/29/2019	7	2019/07	ZD		0000912816	403000	ORF		35,432.00-	USD
<input type="checkbox"/>	999 92498022	07/29/2019	07/29/2019	7	2019/07	ZD		0000912816	403000	ORF		5,928.00-	USD
<input type="checkbox"/>	999 92499529	07/31/2019	07/31/2019	7	2019/07	ZD		0070001743	403000	GEN		8,397.33-	USD
<input type="checkbox"/>	999 92500308	08/01/2019	08/01/2019	8	2019/08	ZD		0070001744	403000	GEN		2,655.00-	USD
<input type="checkbox"/>	999 92502667	08/06/2019	08/06/2019	8	2019/08	ZD		0070001745	403000	GEN		1,424.42-	USD
<input type="checkbox"/>	999 92502668	08/06/2019	08/06/2019	8	2019/08	ZD		0070001746	403000	GEN		2,107.38-	USD
<input type="checkbox"/>	999 92502671	08/06/2019	08/06/2019	8	2019/08	ZD		0070001747	403000	GEN		7,147.70-	USD
<input type="checkbox"/>	999 92510894	08/22/2019	08/22/2019	8	2019/08	ZD		0000926078	403000	DLM		4,224.50-	USD
<input type="checkbox"/>	999 92511701	08/26/2019	08/26/2019	8	2019/08	ZD		0000911344	403000	ORF		89,245.44-	USD
<input type="checkbox"/>	999 92511709	08/26/2019	08/26/2019	8	2019/08	ZD		0000915553	403000	ORF		11,230.00-	USD
<input type="checkbox"/>	999 92516690	09/04/2019	09/04/2019	9	2019/09	ZD		0070001749	403000	GEN		14,537.90-	USD
<input type="checkbox"/>	999 92516694	09/04/2019	09/04/2019	9	2019/09	ZD		0070001748	403000	ORF		7,940.00-	USD
<input type="checkbox"/>	999 92521222	09/12/2019	09/12/2019	9	2019/09	ZD		0070001750	403000	GEN		1,125.00-	USD
<input type="checkbox"/>	999 92521228	09/12/2019	09/12/2019	9	2019/09	ZD		0070001751	403000	GEN		6,975.08-	USD
*												3,003,145.14-	USD

<sup>1</sup>Screenshot does not include all entries – abbreviated version shown.

## Exhibit 1Q: Intercompany transfers between foreign IACs and Purdue for finished products

Per discussions with Purdue, SAP company code 999 (Virtual Distribution Co.) is an internal SAP accounting code that consolidates invoices from various customers. The invoices are then grouped and settled via combined wire transfer. The transactions are swept through journal entry (monthly sweep entry) and charged to each applicable PPLP company. For example, sales to foreign IACs relating to a March 12, 2019 payment were recognized as follows:

Company Code	Account Number	Account Description	DR	CR
999	403000	Foreign Sales		\$ (9,370)
999	101015	AR I/C (SD and Manual Billings)	\$ 9,370 <sup>1</sup>	
999	101015	Invoice 0000884963	\$ 9,370	
999	101015	Invoice 0000882418	24,880	
999	101015	Invoice 0000877620	66,785	
999	101015	Invoice 0000882538	36,180	
999	101015	PD WT 3/12/19		\$ (137,215)
999	101045	A/R Clrng (NonTrade)	\$ 137,190	
999	660080	Bank Service Charge	25	
208	100010	Cash Concentration	\$ 137,190	
208	102999	Virtual Company		\$ (137,190)

999: Virtual Distribution Co.

208: Purdue Pharma L.P.

<sup>1</sup>November 11, 2018 \$9,370 foreign sale invoice paid as part of the March 12, 2019 \$137,215 payment.

## Exhibit 1Q: Intercompany transfers between foreign IACs and Purdue for finished products

These entries appear in SAP as follows:

Doc.Type : ZD ( Customer invoice ) Normal document				
Doc. Number	92373531	Company Code	999	Fiscal Year 2018
Doc. Date	18.11.2018	Posting Date	18.11.2018	Period 11
Calculate Tax	<input type="checkbox"/>			
Ref.Doc.	0000884963			
Doc. Currency	USD			

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	01	122973	Mundipharma Laborato					9.370,00	11/28 em [REDACTED] AP./TD
2	50	403000	Foreign Sales		ORF			9.370,00-	

Customer	122973	<input type="checkbox"/>	Mundipharma Laboratories GmbH	G/L Acc	101015
CoCode	999		St. Alban Rheinweg 74		
Virtual Distribution Co.	Basel		Doc. No.	92373531	
Line Item 1 / Invoice / 01					
Amount	9.370,00		USD		
Tax code	<input type="checkbox"/>				

## Exhibit 1Q: Intercompany transfers between foreign IACs and Purdue for finished products

These entries appear in SAP as follows:

Customer		122973	
Company Code		999	
Name		Mundipharma Laboratories GmbH	
City		Basel	

ment	Ref.key 2	Reference	Typ	Pstng Date	Doc. Date	Net due dt	Amt in loc.cur.	Clrng doc.	RCd	Arrear	Text
<input type="checkbox"/>		PD WT 3/12/19	DZ	13.03.2019	12.03.2019	12.03.2019	137.215,00-	1400168604		1	
<input type="checkbox"/> 3/12/19-sv		0000882538	ZD	18.11.2018	18.11.2018	18.03.2019	36.180,00	1400168604		5-	11/28 em AP./TD
<input type="checkbox"/> 3/12/19-sv		0000884963	ZD	18.11.2018	18.11.2018	18.03.2019	9.370,00	1400168604		5-	11/28 em AP./TD
<input type="checkbox"/> 3/12/19-sv		0000882418	ZD	18.11.2018	18.11.2018	18.03.2019	24.880,00	1400168604		5-	11/28 em AP./TD
<input type="checkbox"/> 3/12/19-sv		0000877620	ZD	18.11.2018	18.11.2018	18.03.2019	66.785,00	1400168604		5-	11/28 em AP./TD
							0,00				

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	101045	A/R Clrng (NonTrade)		GEN			137.190,00	
2	40	660080	Bank Service Charges	2100999	GEN			25,00	Bank Service Charge
3	15	122973	Mundipharma Laborato					137.215,00-	

G/L account document	
Overall No.	0100179022208 19 Doc. Currency USD

CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy
Itm	PK	Account	Account short text	Assignment	Tx	Amount	Text
109	100016253	2019 SA	27.03.2019	17.03.2019	CWS	USD	
208	100179022	2019 SA	27.03.2019	17.03.2019	CWS	USD	
24	40	100010	Cash Concentration	20190327		137.190,00	CH1704835013503332001 MUNDIPHARMA LABORATORIES GMB
132	50	102999	Virtual Company	20190327		137.190,00-	
999	100171092	2019 SA	27.03.2019	17.03.2019	CWS	USD	
1	50	101045	A/R Clrng (NonTrade)	20190327		137.190,00-	CH1704835013503332001 MUNDIPHARMA LABORATORIES GMB
2	40	102208	Purdue Pharma L.P.	20190327		137.190,00	



## Exhibit 1Q: Intercompany transfers between foreign IACs and Purdue for finished products

Sales information on a detailed level, including the IAC to whom the finished products were sold and the respective amounts, are obtained by querying the sales data in SAP company code 999 (Virtual Distribution Co.) using SAP Business Warehouse ("SAP BW"). The query results can then be analyzed to obtain totals by product and customer, and can be traced back to SAP via the billing document number.

For example, a portion of the query results on sales to foreign IACs in 2008 are shown below,<sup>1</sup> along with the pivot table calculating aggregate sales which tie back to total sales of finished product for 2008 (highlighted) on the previous slides.

Filter		Table										
Billing doc. date		Company Cod	Dist Company	Product	Company cod	Company Name	Billing document	Billing doc. d	Plant Name	Sold to Name	Ship to name	Subtotal 2
Billing document		999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90644964	12/9/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 3,496.88
Billing type		999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90644965	12/9/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 2,733.85
Company Code		999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90644966	12/9/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 1,903.13
Created on		999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90644967	12/9/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 1,310.00
Key Figures		999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90644968	12/9/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 1,676.37
Material		999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90644969	12/9/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 3,159.67
Plant		999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90644970	12/9/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 1,866.75
Profit Center		999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90645694	1/30/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 2,445.58
Sales Organization	999 999	999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90676647	5/22/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 3,344.20
Ship-To Party		999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90676648	5/22/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 964.08
Sold-to party		999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90676649	5/22/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 7,000.53
		999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90676650	5/22/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 1,058.90
		999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90685667	6/25/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 2,010.88
		999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90685668	6/25/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 3,304.64
		999	Virtual Distribution	Gen Non-Product Sp	#	Not assigned	90690820	7/15/2008	Purdue Pharmaceuticals L.P.	Mundipharma Laboratories GmbH		\$ 2,738.03

Row Labels	Sales	Cost of Products	Cost of Freight
<b>Mundipharma Laboratories GmbH</b>	<b>\$ 1,970,426.62</b>	<b>\$ 2,465,952.07</b>	<b>\$ 73,253.22</b>
Gen Non-Product Spec	\$ 73,253.22	\$ -	\$ 73,253.22
MS Contin	\$ 14,011.10	\$ 11,395.54	
Oxycontin	\$ 1,478,538.50	\$ 2,194,164.03	
Senokot S	\$ 404,623.80	\$ 260,392.50	
<b>Grand Total</b>	<b>\$ 1,970,426.62</b>	<b>\$ 2,465,952.07</b>	<b>\$ 73,253.22</b>

<sup>1</sup>Some columns have been hidden for ease of presentation.

## Exhibit 1Q: Intercompany transfers between foreign IACs and Purdue for finished products

A portion of the query results on sales to foreign IACs in 2019 are shown below,<sup>1</sup> along with the pivot table calculating aggregate sales which tie back to total sales of finished product under SAP company code 999 for 2019 (highlighted) on slides 203 and 206.

Filter		Table											
		Company Code	Company Name	Profit Center Name	Company Name 2	Billing document	Billing doc. date	Material Name	Plant Name	Sold-to-Party Name	Ship-to-Party Name	Subtotal 2	Cost
Billing doc. date		999	Virtual Distributio	Dilaudid Mundi	Purdue Pharma LP	92434709	3/21/2019	Dilaudid 2 mg 1	Purdue Pharmaceut	MUNDIPHARMA NEAR EAST GMB		\$ 724.20	\$ 724.20
Billing document		999	Virtual Distributio	Dilaudid Mundi	Purdue Pharma LP	92434710	3/21/2019	Dilaudid 2 mg 1	Purdue Pharmaceut	MUNDIPHARMA NEAR EAST GMB		\$ 1,207.00	\$ 1,207.00
Billing type		999	Virtual Distributio	Dilaudid Mundi	Purdue Pharma LP	92476704	6/13/2019	Dilaudid 4 mg 1	Purdue Pharmaceut	MUNDIPHARMA NEAR EAST GMB		\$ 130.77	\$ 130.77
Company Code		999	Virtual Distributio	Dilaudid Mundi	Purdue Pharma LP	92510894	8/22/2019	Dilaudid 2 mg 1	Purdue Pharmaceut	MUNDIPHARMA NEAR EAST GMB		\$ 4,224.50	\$ 4,224.50
Created on		999	Virtual Distributio	Gen Non-Product Spe	Not assigned	92430108	3/12/2019	FREIGHT	Purdue Pharmaceut	MUNDIPHARMA NEAR EAST GMB		\$ 1,000.00	\$ 0.00
Key Figures		999	Virtual Distributio	Gen Non-Product Spe	Not assigned	92430110	3/12/2019	FREIGHT	Purdue Pharmaceut	MUNDIPHARMA DC B.V.		\$ 3,492.54	\$ 0.00
Material		999	Virtual Distributio	Gen Non-Product Spe	Not assigned	92430111	3/12/2019	FREIGHT	Purdue Pharmaceut	MUNDIPHARMA DC B.V.	MUNDIPHARMA KOREA LTD	\$ 12,320.18	\$ 0.00
Plant		999	Virtual Distributio	Gen Non-Product Spe	Not assigned	92439066	4/1/2019	FREIGHT	Purdue Pharmaceut	MUNDIPHARMA MEA GMBH		\$ 1,000.00	\$ 0.00
Profit Center		999	Virtual Distributio	Gen Non-Product Spe	Not assigned	92462045	5/14/2019	FREIGHT	Purdue Pharmaceut	Mundipharma Laboratories GmbH	MUNDIPHARMA COLOMBIA SAS	\$ 8,526.35	\$ 0.00
Sales Organization	999 999	999	Virtual Distributio	Gen Non-Product Spe	Not assigned	92462046	5/14/2019	FREIGHT	Purdue Pharmaceut	Mundipharma Laboratories GmbH	MUNDIPHARMA COLOMBIA SAS	\$ 2,949.21	\$ 0.00
Ship-To Party		999	Virtual Distributio	Gen Non-Product Spe	Not assigned	92462047	5/14/2019	FREIGHT	Purdue Pharmaceut	Mundipharma Laboratories GmbH	MUNDIPHARMA BRASIL PRODUTOS	\$ 5,184.37	\$ 0.00
Sold-to party		999	Virtual Distributio	Gen Non-Product Spe	Not assigned	92462048	5/14/2019	FREIGHT	Purdue Pharmaceut	Mundipharma Laboratories GmbH	MUNDIPHARMA DE MEXICO S DE R.L. DE	\$ 5,939.32	\$ 0.00
		999	Virtual Distributio	Gen Non-Product Spe	Not assigned	92462049	5/14/2019	FREIGHT	Purdue Pharmaceut	Mundipharma Laboratories GmbH		\$ 2,668.50	\$ 0.00
		999	Virtual Distributio	Gen Non-Product Spe	Not assigned	92462050	5/14/2019	FREIGHT	Purdue Pharmaceut	Mundipharma Laboratories GmbH	MUNDIPHARMA COLOMBIA SAS	\$ 5,899.33	\$ 0.00
		999	Virtual Distributio	Gen Non-Product Spe	Not assigned	92462051	5/14/2019	FREIGHT	Purdue Pharmaceut	Mundipharma Laboratories GmbH	MUNDIPHARMA DE MEXICO S DE R.L. DE	\$ 8,153.87	\$ 0.00
		999	Virtual Distributio	Gen Non-Product Spe	Not assigned	92462052	5/14/2019	FREIGHT	Purdue Pharmaceut	MUNDIPHARMA DC B.V.	NARCOTICS CONTROL DIVISION	\$ 5,677.90	\$ 0.00
		999	Virtual Distributio	Gen Non-Product Spe	Not assigned	92462053	5/14/2019	FREIGHT	Purdue Pharmaceut	MUNDIPHARMA DC B.V.	MUNDIPHARMA DISTRIBUTION GMBH	\$ 3,837.40	\$ 0.00

Year	2019
Sold-to-Name	Sales
MUNDIPHARMA DC B.V.	\$ 1,418,696.40
Mundipharma Laboratories GmbH	\$ 1,335,646.11
MUNDIPHARMA LATAM GMBH	\$ 161,926.51
MUNDIPHARMA MEA GMBH	\$ 2,227.50
MUNDIPHARMA NEAR EAST GMBH	\$ 84,648.62
<b>Grand Total</b>	<b>\$ 3,003,145.14</b>

<sup>1</sup>Some columns have been hidden for ease of presentation.

## **Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements**

On December 15, 2005, PPLP and PALP entered into a license agreement expenses agreement ("LAEA").

### **LICENSE AGREEMENT EXPENSES AGREEMENT**

This AGREEMENT ("Agreement"), made as of December 15, 2005, by and between Pharma Associates L.P., a Delaware limited partnership ("PALP"), and Purdue Pharma L.P., a Delaware limited partnership ("PPLP").

WHEREAS, PPLP, as successor in interest to The Purdue Pharma Company, assigned, transferred and conveyed to PALP all of PPLP's rights under various license agreements for the manufacture, distribution, use and/or sale of oxycodone preparations ("License Agreements") but retained all of PPLP's obligations under the License Agreements; and

WHEREAS, PALP accepted such assignment, transfer and conveyance and agreed to reimburse PPLP for all of PPLP's costs and expenses, as determined by PPLP, that either arise out of or are allocable to the License Agreements (the "License Agreement Expenses");

## **Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements**

The LAEA detailed the calculation of annual payments due by PALP to PPLP. Pursuant to the following provisions in the LAEA, PALP was entitled to its costs plus a \$50,000 profit:

1. The amount of the License Agreement Expenses payable by PALP to PPLP each taxable year shall be deemed to be equal to the following amount:

(a) the sum of

- (i) the amount of all royalties accrued by PALP for such taxable year under all such rights assigned, transferred and conveyed to PALP under the License Agreements and
- (ii) the amount of any adjustment to PALP's income for such taxable year pursuant to section 481 of the Internal Revenue Code of 1986, as amended,

(b) less the sum of

- (i) PALP's accrued expenses for the taxable year other than the License Agreement Expenses ("Other Expenses") for such taxable year and
- (ii) \$50,000.

## Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

Between January 1, 2008 and September 15, 2019, \$621.7 million in foreign IAC royalties was received by PALP, PPLP, and Purdue Transdermal Technologies ("PTT") through G/L account 700530 (Foreign Income Royalty).

Company	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
Pharma Associates L.P. (PALP)	\$ (62,563,773)	\$ (66,755,870)	\$ (73,040,536)	\$ (78,196,084)	\$ (66,261,934)	\$ (32,972,225)	\$ (32,995,881)	\$ (13,959,680)	\$ (19,989,856)	\$ (15,280,326)	\$ (14,913,594)	\$ (10,789,229)	\$ (487,718,987)
Plus Revenue	(3,194,463)	-	-	-	-	-	-	-	-	-	-	-	(3,194,463)
Less Expenses	(957,689)	188,736	152,888	153,341	141,892	105,263	105,477	115,249	94,875	125,341	95,835	46,459	367,668
Net to PPLP from PALP	(66,715,925)	(66,567,134)	(72,887,648)	(78,042,743)	(66,120,042)	(32,866,962)	(32,890,404)	(13,844,430)	(19,894,981)	(15,154,985)	(14,817,759)	(10,742,769)	(490,545,782)
PPLP from IACs (other than PALP)	(8,905,540)	(9,381,367)	(11,748,950)	(13,170,417)	(17,698,845)	(13,561,427)	(12,626,432)	(24,054,993)	(16,320,965)	-	-	-	(127,468,937)
Purdue Transdermal Tech (PTT)	-	-	-	-	-	(1,931,435)	(845,702)	(952,575)	26,822	-	-	-	(3,702,890)
<b>Total</b>	<b>\$ (75,621,465)</b>	<b>\$ (75,948,501)</b>	<b>\$ (84,636,599)</b>	<b>\$ (91,213,160)</b>	<b>\$ (83,818,887)</b>	<b>\$ (48,359,824)</b>	<b>\$ (46,362,538)</b>	<b>\$ (38,851,998)</b>	<b>\$ (36,189,124)</b>	<b>\$ (15,154,985)</b>	<b>\$ (14,817,759)</b>	<b>\$ (10,742,769)</b>	<b>\$ (621,717,608)</b>

Note: The amounts above for 2010, 2016, and 2017 reconcile to The October 19, 2018 MDL Presentation when excluding revenue received from [REDACTED] (discussed in a subsequent slide) and deductions under the LAEA.



## Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

SAP contains support for all payments from January 1, 2008 to September 15, 2019 for SAP company codes 304 (PALP), 208 (PPLP) and 241 (PTT) through G/L account 700530 (Royalty Income Foreign) (i.e., gross payments prior to PALP expense deductions and income from

██████████).<sup>1, 2</sup>

G/L Account		700530		Royalty Income Foreign												
Company Code		*														
	CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	Order	
<input type="checkbox"/>	208	100179961	05/31/2019	06/05/2019	5	2019/05	SA	9001208	RC 0519	700530	GEN	EST ROYALTY INCOME MDC ADF	765,964.50-	USD	140	
<input type="checkbox"/>	208	100179961	05/31/2019	06/05/2019	5	2019/05	SA	9001208	RC 0519	700530	GEN	EST ROYALTY INCOME MBBV Japan	386,955.66-	USD	128	
<input type="checkbox"/>	208	100179961	05/31/2019	06/05/2019	5	2019/05	SA	9001208	RC 0519	700530	GEN	EST ROYALTY INCOME MLG ADF	215,460.75-	USD	134	
<input type="checkbox"/>	208	100179961	05/31/2019	06/05/2019	5	2019/05	SA	9001208	RC 0519	700530	GEN	EST ROYALTY INCOME Latam GmBH	14,166.66-	USD	300	
<input type="checkbox"/>	208	100179961	05/31/2019	06/05/2019	5	2019/05	SA	9001208	RC 0519	700530	GEN	2018 Latam GmBH	24.96	USD	300	
<input type="checkbox"/>	208	100179961	05/31/2019	06/05/2019	5	2019/05	SA	9001208	RC 0519	700530	GEN	4Q18 MBBV Japan	3,516.24	USD	128	
<input type="checkbox"/>	304	100002691	06/30/2019	06/28/2019	6	2019/06	SA	9001304	LI 619	700530	GEN	EST ROYALTY INCOME MBBV Japan	386,955.66-	USD	128	
<input type="checkbox"/>	304	100002691	06/30/2019	06/28/2019	6	2019/06	SA	9001304	LI 619	700530	GEN	EST ROYALTY INCOME MLG ADF	215,460.75-	USD	134	
<input type="checkbox"/>	304	100002691	06/30/2019	06/28/2019	6	2019/06	SA	9001304	LI 619	700530	GEN	EST ROYALTY INCOME MDC ADF	765,964.50-	USD	140	
<input type="checkbox"/>	304	100002691	06/30/2019	06/28/2019	6	2019/06	SA	9001304	LI 619	700530	GEN	EST ROYALTY INCOME Latam GmBH	14,166.66-	USD	300	
<input type="checkbox"/>	304	100002693	06/30/2019	07/01/2019	6	2019/06	SA	9001304	RC 0619	700530	GEN	1Q 19 MDC ADF	344,636.18-	USD	140	
<input type="checkbox"/>	208	100180320	06/30/2019	07/08/2019	6	2019/06	SA	9001208	RC 0619	700530	GEN	EST ROYALTY INCOME MDC ADF	765,964.50-	USD	140	
<input type="checkbox"/>	208	100180320	06/30/2019	07/08/2019	6	2019/06	SA	9001208	RC 0619	700530	GEN	EST ROYALTY INCOME MBBV Japan	386,955.66-	USD	128	
<input type="checkbox"/>	208	100180320	06/30/2019	07/08/2019	6	2019/06	SA	9001208	RC 0619	700530	GEN	EST ROYALTY INCOME MLG ADF	215,460.75-	USD	134	
<input type="checkbox"/>	208	100180320	06/30/2019	07/08/2019	6	2019/06	SA	9001208	RC 0619	700530	GEN	EST ROYALTY INCOME Latam GmBH	14,166.66-	USD	300	
<input type="checkbox"/>	208	100180320	06/30/2019	07/08/2019	6	2019/06	SA	9001208	RC 0619	700530	GEN	1Q 19 MDC ADF	344,636.18-	USD	140	
<input type="checkbox"/>	304	100002705	07/31/2019	07/31/2019	7	2019/07	SA	9001304	LI 719	700530	GEN	EST ROYALTY INCOME MBBV Japan	386,955.66-	USD	128	
<input type="checkbox"/>	304	100002705	07/31/2019	07/31/2019	7	2019/07	SA	9001304	LI 719	700530	GEN	EST ROYALTY INCOME MLG ADF	215,460.75-	USD	134	
<input type="checkbox"/>	304	100002705	07/31/2019	07/31/2019	7	2019/07	SA	9001304	LI 719	700530	GEN	EST ROYALTY INCOME MDC ADF	765,964.50-	USD	140	
<input type="checkbox"/>	304	100002705	07/31/2019	07/31/2019	7	2019/07	SA	9001304	LI 719	700530	GEN	EST ROYALTY INCOME Latam GmBH	14,166.66-	USD	300	
<input type="checkbox"/>	304	100002711	07/31/2019	08/02/2019	7	2019/07	SA	9001304	RC 0719	700530	GEN	1Q 19 MBBV ADF Japan	56,409.46	USD	128	
<input type="checkbox"/>	208	100180684	07/31/2019	08/07/2019	7	2019/07	SA	9001208	RC 0719	700530	GEN	EST ROYALTY INCOME MDC ADF	765,964.50-	USD	140	
<input type="checkbox"/>	208	100180684	07/31/2019	08/07/2019	7	2019/07	SA	9001208	RC 0719	700530	GEN	EST ROYALTY INCOME MBBV Japan	386,955.66-	USD	128	
<input type="checkbox"/>	208	100180684	07/31/2019	08/07/2019	7	2019/07	SA	9001208	RC 0719	700530	GEN	EST ROYALTY INCOME MLG ADF	215,460.75-	USD	134	
<input type="checkbox"/>	208	100180684	07/31/2019	08/07/2019	7	2019/07	SA	9001208	RC 0719	700530	GEN	EST ROYALTY INCOME Latam GmBH	14,166.66-	USD	300	
<input type="checkbox"/>	208	100180684	07/31/2019	08/07/2019	7	2019/07	SA	9001208	RC 0719	700530	GEN	1Q 19 MBBV ADF Japan	56,409.46	USD	128	
<input type="checkbox"/>	304	100002715	08/21/2019	08/21/2019	8	2019/08	SA	9001304	RC 0819	700530	GEN	1Q 19 MLG	368,129.76	USD	134	
<input type="checkbox"/>	304	100002719	08/31/2019	08/31/2019	8	2019/08	SA	9001304	LI 819	700530	GEN	EST ROYALTY INCOME MBBV Japan	386,955.66-	USD	128	
<input type="checkbox"/>	304	100002719	08/31/2019	08/31/2019	8	2019/08	SA	9001304	LI 819	700530	GEN	EST ROYALTY INCOME MLG ADF	215,460.75-	USD	134	
<input type="checkbox"/>	304	100002719	08/31/2019	08/31/2019	8	2019/08	SA	9001304	LI 819	700530	GEN	EST ROYALTY INCOME MDC ADF	765,964.50-	USD	140	
<input type="checkbox"/>	304	100002719	08/31/2019	08/31/2019	8	2019/08	SA	9001304	LI 819	700530	GEN	EST ROYALTY INCOME Latam GmBH	14,166.66-	USD	300	
<input type="checkbox"/>	304	100002720	08/31/2019	09/06/2019	8	2019/08	SA	9001304	RC 0819	700530	GEN	2Q 19 MLG	298,660.77	USD	134	
<input type="checkbox"/>	304	100002720	08/31/2019	09/06/2019	8	2019/08	SA	9001304	RC 0819	700530	GEN	2Q 19 MBBV Japan	109,046.42-	USD	128	
<input type="checkbox"/>	304	100002720	08/31/2019	09/06/2019	8	2019/08	SA	9001304	RC 0819	700530	GEN	April/May/Q1add'l 19 MDC	20,332.89-	USD	140	
<input type="checkbox"/>	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	EST ROYALTY INCOME MDC ADF	765,964.50-	USD	140	
<input type="checkbox"/>	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	EST ROYALTY INCOME MBBV Japan	386,955.66-	USD	128	
<input type="checkbox"/>	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	EST ROYALTY INCOME MLG ADF	215,460.75-	USD	134	
<input type="checkbox"/>	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	EST ROYALTY INCOME Latam GmBH	14,166.66-	USD	300	
<input type="checkbox"/>	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	1Q 19 MLG	368,129.76	USD	134	
<input type="checkbox"/>	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	2Q 19 MBBV Japan	109,046.42-	USD	128	
<input type="checkbox"/>	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	April/May/Q1add'l 19 MDC	20,332.89-	USD	140	
<input type="checkbox"/>	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	2Q 19 MLG	298,660.77	USD	134	
<input type="checkbox"/>													644,593,636.62-	USD		

<sup>1</sup>Screenshot does not include all entries – abbreviated version shown.

<sup>2</sup>\$22.9 million of the \$644.6 million reflected herein is the result of "double-counting" of royalties in PPLP's and PALP's books and records for 2018 and 2019--i.e., both PPLP and PALP recognized the same \$14.9 million and \$10.8 million in royalties for 2018 and 2019, respectively, in their books and records. After accounting for this "double-counting," as well as the ██████████ and expenses adjustments, this SAP data reconciles with the \$621.7 million total amount reflected in the previous slide."



## Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

SAP contains support for all payments during 2008 for SAP company codes 304 (PALP), 208 (PPLP) and 241 (PTT) through G/L account 700530 (Royalty Income Foreign) (i.e., gross payments prior to PALP expense deductions and income from [REDACTED]).<sup>1</sup>

G/L Account		700530		Royalty Income Foreign											
Company Code		*													
	CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	Order
<input type="checkbox"/>	304	100000602	02.12.2008	02.12.2008	12	2008/12	SA	9001304	AMB 1208 04	700530	GEN	Est. Royalty Income Singapore	4.583,00-	USD	281
<input type="checkbox"/>	304	100000602	02.12.2008	02.12.2008	12	2008/12	SA	9001304	AMB 1208 04	700530	GEN	Est. Royalty Income Malaysia	500,00-	USD	380
<input type="checkbox"/>	304	100000602	02.12.2008	02.12.2008	12	2008/12	SA	9001304	AMB 1208 04	700530	GEN	Est. Royalty Income Philippines	11.167,00-	USD	340
<input type="checkbox"/>	304	100000602	02.12.2008	02.12.2008	12	2008/12	SA	9001304	AMB 1208 04	700530	GEN	Est. Royalty Income New Zealand	18.333,00-	USD	280
<input type="checkbox"/>	304	100000602	02.12.2008	02.12.2008	12	2008/12	SA	9001304	AMB 1208 04	700530	GEN	Est. Royalty Income Latin America	35.583,00-	USD	300
<input type="checkbox"/>	304	100000602	02.12.2008	02.12.2008	12	2008/12	SA	9001304	AMB 1208 04	700530	GEN	Est. Royalty Income Israel	6.583,00-	USD	132
<input type="checkbox"/>	304	100000602	02.12.2008	02.12.2008	12	2008/12	SA	9001304	AMB 1208 04	700530	GEN	Est. Royalty Income Poland	83,00-	USD	400
<input type="checkbox"/>	304	100000602	02.12.2008	02.12.2008	12	2008/12	SA	9001304	AMB 1208 04	700530	GEN	Est. Targin Royalty - Germany MLG	156.083,00-	USD	144
<input type="checkbox"/>	304	100000603	03.12.2008	03.12.2008	12	2008/12	SA	9001304	AMB 1208 05	700530	GEN	MLG TARGIN 4Q08 ADJ	0,33-	USD	144
<input type="checkbox"/>	304	100000610	22.12.2008	22.12.2008	12	2008/12	SA	9001304	AMB 1208 12	700530	GEN	MAG 3Q08 ROYALTY PYMT IRELAND 12.08.08	10.325,62	USD	120
<input type="checkbox"/>	304	100000610	22.12.2008	22.12.2008	12	2008/12	SA	9001304	AMB 1208 12	700530	GEN	MAG 3Q08 ROYALTY PYMT CYPRUS 12.08.08	600,42	USD	320
<input type="checkbox"/>	304	100000610	22.12.2008	22.12.2008	12	2008/12	SA	9001304	AMB 1208 12	700530	GEN	MAG 3Q08 ROYALTY PYMT ARAB STATES 12.05.08	494,53	USD	360
<input type="checkbox"/>	304	100000611	23.12.2008	23.12.2008	12	2008/12	SA	9001304	AMB 1208 13	700530	GEN	NO ROYALTIES PER KIM PEETZ EMAIL 4.14.08	999,67	USD	400
<input type="checkbox"/>	304	100000617	31.12.2008	06.01.2009	12	2008/12	SA	9001304	AMB 1208 16	700530	GEN	MUNDI GES AUSTRIA ROYALTY ADJ 4Q08	13.631,35-	USD	122
<input type="checkbox"/>	304	100000617	31.12.2008	06.01.2009	12	2008/12	SA	9001304	AMB 1208 16	700530	GEN	MUND PHARMA BV NETHERLANDS ROYALTY ADJ 4Q08	44.191,96-	USD	117
<input type="checkbox"/>	304	100000619	31.12.2008	07.01.2009	12	2008/12	SA	9001304	AMB 1208 18	700530	GEN	MAS 4Q08 ROYALTY ADJ NORWAY	13.749,78-	USD	121
<input type="checkbox"/>	304	100000621	31.12.2008	09.01.2009	12	2008/12	SA	9001304	AMB 1208 20	700530	GEN	NORPHARMA 4Q08 FRANCE ROYALTY ADJ	172.389,52-	USD	118
<input type="checkbox"/>	304	100000621	31.12.2008	09.01.2009	12	2008/12	SA	9001304	AMB 1208 20	700530	GEN	NORPHARMA 4Q08 DENMARK ROYALTY ADJ	128.565,03-	USD	142
<input type="checkbox"/>	304	100000621	31.12.2008	09.01.2009	12	2008/12	SA	9001304	AMB 1208 20	700530	GEN	NORPHARMA 4Q08 SPAIN ROYALTY ADJ	55.407,89	USD	124
<input type="checkbox"/>	304	100000621	31.12.2008	09.01.2009	12	2008/12	SA	9001304	AMB 1208 20	700530	GEN	NORPHARMA 4Q08 ITALY ROYALTY ADJ	46.916,05-	USD	123
<input type="checkbox"/>	304	100000621	31.12.2008	09.01.2009	12	2008/12	SA	9001304	AMB 1208 20	700530	GEN	NORPHARMA 4Q08 BELGIUM ROYALTY ADJ	25.565,43-	USD	127
<input type="checkbox"/>	304	100000621	31.12.2008	09.01.2009	12	2008/12	SA	9001304	AMB 1208 20	700530	GEN	MAB SWEDEN 4Q08 ROYALTY ADJ	67.946,56-	USD	129
<input type="checkbox"/>	304	100000621	31.12.2008	09.01.2009	12	2008/12	SA	9001304	AMB 1208 20	700530	GEN	MUNDI GMBH GERMANY 4Q08 ROYALTY ADJ	294.899,37-	USD	144
<input type="checkbox"/>	304	100000622	31.12.2008	12.01.2009	12	2008/12	SA	9001304	AMB 1208 21	700530	GEN	MOY 4Q08 ROYALTY ADJ FINLAND	43.371,52-	USD	139
<input type="checkbox"/>	304	100000622	31.12.2008	12.01.2009	12	2008/12	SA	9001304	AMB 1208 21	700530	GEN	NAPP UK 4Q08 ROYALTY ADJ	485.087,63	USD	141
<input type="checkbox"/>	304	100000623	31.12.2008	12.01.2009	12	2008/12	SA	9001304	AMB 1208 22	700530	GEN	MAG 4Q08 ROYALTY IRELAND ADJ	19.676,80-	USD	120
<input type="checkbox"/>	304	100000623	31.12.2008	12.01.2009	12	2008/12	SA	9001304	AMB 1208 22	700530	GEN	MAG 4Q08 ROYALTY CYPRUS ADJ	2.860,90-	USD	320
<input type="checkbox"/>	304	100000624	31.12.2008	13.01.2009	12	2008/12	SA	9001304	AMB 1208 23	700530	GEN	MMG 4Q08 ROYALTY EASTERN EUROPE ADJ	206.166,34-	USD	114
<input type="checkbox"/>	304	100000628	31.12.2008	16.01.2009	12	2008/12	SA	9001304	AMB 1208 26	700530	GEN	MBEV 4Q08 JAPAN ROYALTY ADJ	705.540,32-	USD	128
<input type="checkbox"/>	304	100000632	31.12.2008	22.01.2009	12	2008/12	SA	9001304	AMB 1208 31	700530	GEN	LADENBURG 4Q08 ADJ ISRAEL	12.774,33-	USD	132
<input type="checkbox"/>	304	100000632	31.12.2008	22.01.2009	12	2008/12	SA	9001304	AMB 1208 31	700530	GEN	MLG DECEMBER 2008 CANADA ADJ	1.003.621,17	USD	140
<input type="checkbox"/>	304	100000632	31.12.2008	22.01.2009	12	2008/12	SA	9001304	AMB 1208 31	700530	GEN	MLG 4Q08 SWITZERLAND ADJ	96.516,45-	USD	260
<input type="checkbox"/>	304	100000632	31.12.2008	22.01.2009	12	2008/12	SA	9001304	AMB 1208 31	700530	GEN	MLG 4Q08 NEW ZEALAND ADJ	2.056,80-	USD	280
<input type="checkbox"/>	304	100000632	31.12.2008	22.01.2009	12	2008/12	SA	9001304	AMB 1208 31	700530	GEN	MLG 4Q08 AUSTRALIA ADJ	233.319,07	USD	133
<input type="checkbox"/>	304	100000632	31.12.2008	22.01.2009	12	2008/12	SA	9001304	AMB 1208 31	700530	GEN	MLG 4Q08 KOREA ADJ	56.276,26-	USD	134
<input type="checkbox"/>	304	100000632	31.12.2008	22.01.2009	12	2008/12	SA	9001304	AMB 1208 31	700530	GEN	MLG 4Q08 LATIN AMERICA ADJ	5.895,86	USD	300
<input type="checkbox"/>	304	100000632	31.12.2008	22.01.2009	12	2008/12	SA	9001304	AMB 1208 31	700530	GEN	MLG 4Q08 PHILIPPINES ADJ	7.159,60-	USD	340
<input type="checkbox"/>	304	100000632	31.12.2008	22.01.2009	12	2008/12	SA	9001304	AMB 1208 31	700530	GEN	MLG 4Q08 SINGAPORE ADJ	44.690,03	USD	281
<input type="checkbox"/>	304	100000632	31.12.2008	22.01.2009	12	2008/12	SA	9001304	AMB 1208 31	700530	GEN	MLG 4Q08 MALAYSIA ADJ	6.924,01-	USD	380
<input type="checkbox"/>	304	100000632	31.12.2008	22.01.2009	12	2008/12	SA	9001304	AMB 1208 31	700530	GEN	MLG 4Q08 TARGIN OXN ADJ	160.713,45	USD	144
<input type="checkbox"/>	208	100052075	31.12.2008	26.05.2009	12	2008/12	SA	9001208	TNH 1208 49	700530	GEN	Reclass of Japan Royalty	1.119.902,62-	USD	128
<input type="checkbox"/>	304	100000725	31.12.2008	26.05.2009	12	2008/12	SA	9001304	TNH 1208 49	700530	GEN	Reclass of Japan Royalty	1.119.902,62	USD	128
<input type="checkbox"/>	*												71.469.313,33-	USD	

<sup>1</sup>Screenshot does not include all entries – abbreviated version shown.

## Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

SAP contains support for all payments from January 1, 2019 to September 15, 2019 for SAP company codes 304 (PALP), 208 (PPLP) and 241 (PTT) through G/L account 700530 (Royalty Income Foreign) (i.e., gross payments prior to PALP expense deductions and income from [REDACTED]).<sup>1,2</sup>

G/L Account		700530		Royalty Income Foreign														
Company Code		*																
CoCd	DocumentNo	Posting Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	Order				
	208	100179961	05/31/2019	06/05/2019	5	2019/05	SA	9001208	RC 0519	700530	GEN	EST ROYALTY INCOME MDC ADF	765,964.50-	USD	140			
	208	100179961	05/31/2019	06/05/2019	5	2019/05	SA	9001208	RC 0519	700530	GEN	EST ROYALTY INCOME MBBV Japan	386,955.66-	USD	128			
	208	100179961	05/31/2019	06/05/2019	5	2019/05	SA	9001208	RC 0519	700530	GEN	EST ROYALTY INCOME MLG ADF	215,460.75-	USD	134			
	208	100179961	05/31/2019	06/05/2019	5	2019/05	SA	9001208	RC 0519	700530	GEN	EST ROYALTY INCOME Latam GmBH	14,166.66-	USD	300			
	208	100179961	05/31/2019	06/05/2019	5	2019/05	SA	9001208	RC 0519	700530	GEN	2018 Latam GmBH	24.96	USD	300			
	208	100179961	05/31/2019	06/05/2019	5	2019/05	SA	9001208	RC 0519	700530	GEN	4Q18 MBBV Japan	3,516.24	USD	128			
	304	100002691	06/30/2019	06/28/2019	6	2019/06	SA	9001304	LT 619	700530	GEN	EST ROYALTY INCOME MBBV Japan	386,955.66-	USD	128			
	304	100002691	06/30/2019	06/28/2019	6	2019/06	SA	9001304	LT 619	700530	GEN	EST ROYALTY INCOME MLG ADF	215,460.75-	USD	134			
	304	100002691	06/30/2019	06/28/2019	6	2019/06	SA	9001304	LT 619	700530	GEN	EST ROYALTY INCOME MDC ADF	765,964.50-	USD	140			
	304	100002691	06/30/2019	06/28/2019	6	2019/06	SA	9001304	LT 619	700530	GEN	EST ROYALTY INCOME Latam GmBH	14,166.66-	USD	300			
	304	100002693	06/30/2019	07/01/2019	6	2019/06	SA	9001304	RC 0619	700530	GEN	1Q 19 MDC ADF	344,636.18-	USD	140			
	208	100180320	06/30/2019	07/08/2019	6	2019/06	SA	9001208	RC 0619	700530	GEN	EST ROYALTY INCOME MDC ADF	765,964.50-	USD	140			
	208	100180320	06/30/2019	07/08/2019	6	2019/06	SA	9001208	RC 0619	700530	GEN	EST ROYALTY INCOME MBBV Japan	386,955.66-	USD	128			
	208	100180320	06/30/2019	07/08/2019	6	2019/06	SA	9001208	RC 0619	700530	GEN	EST ROYALTY INCOME MLG ADF	215,460.75-	USD	134			
	208	100180320	06/30/2019	07/08/2019	6	2019/06	SA	9001208	RC 0619	700530	GEN	EST ROYALTY INCOME Latam GmBH	14,166.66-	USD	300			
	208	100180320	06/30/2019	07/08/2019	6	2019/06	SA	9001208	RC 0619	700530	GEN	1Q 19 MDC ADF	344,636.18-	USD	140			
	304	100002705	07/31/2019	07/31/2019	7	2019/07	SA	9001304	LT 719	700530	GEN	EST ROYALTY INCOME MBBV Japan	386,955.66-	USD	128			
	304	100002705	07/31/2019	07/31/2019	7	2019/07	SA	9001304	LT 719	700530	GEN	EST ROYALTY INCOME MLG ADF	215,460.75-	USD	134			
	304	100002705	07/31/2019	07/31/2019	7	2019/07	SA	9001304	LT 719	700530	GEN	EST ROYALTY INCOME MDC ADF	765,964.50-	USD	140			
	304	100002705	07/31/2019	07/31/2019	7	2019/07	SA	9001304	LT 719	700530	GEN	EST ROYALTY INCOME Latam GmBH	14,166.66-	USD	300			
	304	100002711	07/31/2019	08/02/2019	7	2019/07	SA	9001304	RC 0719	700530	GEN	1Q 19 MBBV ADF Japan	56,409.46	USD	128			
	208	100180684	07/31/2019	08/07/2019	7	2019/07	SA	9001208	RC 0719	700530	GEN	EST ROYALTY INCOME MDC ADF	765,964.50-	USD	140			
	208	100180684	07/31/2019	08/07/2019	7	2019/07	SA	9001208	RC 0719	700530	GEN	EST ROYALTY INCOME MBBV Japan	386,955.66-	USD	128			
	208	100180684	07/31/2019	08/07/2019	7	2019/07	SA	9001208	RC 0719	700530	GEN	EST ROYALTY INCOME MLG ADF	215,460.75-	USD	134			
	208	100180684	07/31/2019	08/07/2019	7	2019/07	SA	9001208	RC 0719	700530	GEN	EST ROYALTY INCOME Latam GmBH	14,166.66-	USD	300			
	208	100180684	07/31/2019	08/07/2019	7	2019/07	SA	9001208	RC 0719	700530	GEN	1Q 19 MBBV ADF Japan	56,409.46	USD	128			
	304	100002715	08/21/2019	08/21/2019	8	2019/08	SA	9001304	RC 0819	700530	GEN	1Q 19 MLG	368,129.76	USD	134			
	304	100002719	08/31/2019	08/31/2019	8	2019/08	SA	9001304	LT 819	700530	GEN	EST ROYALTY INCOME MBBV Japan	386,955.66-	USD	128			
	304	100002719	08/31/2019	08/31/2019	8	2019/08	SA	9001304	LT 819	700530	GEN	EST ROYALTY INCOME MLG ADF	215,460.75-	USD	134			
	304	100002719	08/31/2019	08/31/2019	8	2019/08	SA	9001304	LT 819	700530	GEN	EST ROYALTY INCOME MDC ADF	765,964.50-	USD	140			
	304	100002719	08/31/2019	08/31/2019	8	2019/08	SA	9001304	LT 819	700530	GEN	EST ROYALTY INCOME Latam GmBH	14,166.66-	USD	300			
	304	100002720	08/31/2019	09/06/2019	8	2019/08	SA	9001304	RC 0819	700530	GEN	2Q 19 MLG	298,660.77	USD	134			
	304	100002720	08/31/2019	09/06/2019	8	2019/08	SA	9001304	RC 0819	700530	GEN	2Q 19 MBBV Japan	109,046.42-	USD	128			
	304	100002720	08/31/2019	09/06/2019	8	2019/08	SA	9001304	RC 0819	700530	GEN	April/May/Quadd'l 19 MDC	20,332.89-	USD	140			
	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	EST ROYALTY INCOME MDC ADF	765,964.50-	USD	140			
	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	EST ROYALTY INCOME MBBV Japan	386,955.66-	USD	128			
	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	EST ROYALTY INCOME MLG ADF	215,460.75-	USD	134			
	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	EST ROYALTY INCOME Latam GmBH	14,166.66-	USD	300			
	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	1Q 19 MLG	368,129.76	USD	134			
	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	2Q 19 MBBV Japan	109,046.42-	USD	128			
	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	April/May/Quadd'l 19 MDC	20,332.89-	USD	140			
	208	100181019	08/31/2019	09/09/2019	8	2019/08	SA	9001208	RC 0819	700530	GEN	2Q 19 MLG	298,660.77	USD	134			
	*											21,578,457.26-	USD					

<sup>1</sup>Total 2019 activity in account 700530 for SAP company codes 304, 208 and 241 equals \$21.6 million (\$10.8 million x 2). Per Purdue, the royalty income from 304 is mirrored on 208's accounting records starting in 2017 (PALP was taken out of the Purdue reporting group) to recognize royalty income in PPLP's accounting records.

<sup>2</sup>Screenshot does not include all entries – abbreviated version shown.

## Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

Per discussions with Purdue and TXP, expected royalties are first recorded under account 700530 (steps 1, 2, and 3) and adjusted via a true up/down to recognize actual royalties received (i.e., the \$344,636.18 adjustment). Per SAP, the estimated royalty and corresponding adjustment can be seen through intercompany accounts between individual IACs and PPLP and are settled to cash in account 103080 (Accrued Royalty Income) (steps 4 and 5). Below is an example of a 2019 royalty that was settled to cash (i.e., 3 months of royalties).

G/L Account  
Company Code

700530  
304

Royalty Income Foreign

①

CoCd	DocumentNo	Posting Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	Order
<input type="checkbox"/> 304	100002691	30.06.2019	28.06.2019	6	2019/06	SA	9001304	LT 619	700530	GEN	EST ROYALTY INCOME MBSV Japan	386.955,66-	USD	128
<input type="checkbox"/> 304	100002691	30.06.2019	28.06.2019	6	2019/06	SA	9001304	LT 619	700530	GEN	EST ROYALTY INCOME MLG ADF	215.460,75-	USD	134
<input type="checkbox"/> 304	100002691	30.06.2019	28.06.2019	6	2019/06	SA	9001304	LT 619	700530	GEN	EST ROYALTY INCOME MDC ADF	765.964,50-	USD	140
<input type="checkbox"/> 304	100002691	30.06.2019	28.06.2019	6	2019/06	SA	9001304	LT 619	700530	GEN	EST ROYALTY INCOME Latam GmBH	14.166,66-	USD	300
<input type="checkbox"/> 304	100002693	30.06.2019	01.07.2019	6	2019/06	SA	9001304	RC 0619	700530	GEN	1Q 19 MDC ADF	344.636,18-	USD	140

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number100002691Company Code304Fiscal Year2019

Doc. Date28.06.2019Posting Date30.06.2019Period06

Calculate Tax☐

Ref.Doc.☐ LT 619Overall No.0100180142208 19

Doc. CurrencyUSD

Doc. Hdr TextAdj JE

②

Account number102754Mundipharma DC B.V.

Company code304Pharma Associates L.P.

Business area

Fiscal year2019

All documents in currency\*Display currencyUSD

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
2	40	102728	Mundi Bradenton BV		GEN			386.955,66	EST ROYALTY INCOME MBSV Japan
6	40	102754	Mundipharma DC B.V.		GEN			765.964,50	EST ROYALTY INCOME MDC ADF
4	40	102755	Mundi Labs GmbH		GEN			215.460,75	EST ROYALTY INCOME MLG ADF
8	40	102762	Mundi Latam GmbH		GEN			14.166,66	EST ROYALTY INCOME Latam GmBH
1	50	700530	Royalty Inc. Foreign	9001304	GEN	128		386.955,66-	EST ROYALTY INCOME MBSV Japan
3	50	700530	Royalty Inc. Foreign	9001304	GEN	134		215.460,75-	EST ROYALTY INCOME MLG ADF
5	50	700530	Royalty Inc. Foreign	9001304	GEN	140		765.964,50-	EST ROYALTY INCOME MDC ADF
7	50	700530	Royalty Inc. Foreign	9001304	GEN	300		14.166,66-	EST ROYALTY INCOME Latam GmBH

Doc.Type : SA ( G/L account document ) Normal document

Doc. Number100002693Company Code304Fiscal Year2019

Doc. Date01.07.2019Posting Date30.06.2019Period06

Calculate Tax☐

Ref.Doc.☐ RC 0619

Doc. CurrencyUSD

Doc. Hdr TextRoy Inc Ex US

④

G/L Account103080Accrued Royalty Income

Company Code304

⑤

CoCd	DocumentNo	Posting Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/> 304	100002647	24.02.2019	25.02.2019	2	2019/02	SA		CWS	103080	GEN	ROYALTIES 1-2Q18 OXYCONTIN LATAM . ASIA AS PER SEP	870.851,27-	USD
<input type="checkbox"/> 304	100002660	17.03.2019	27.03.2019	3	2019/03	SA		CWS	103080	GEN	MUNDIPHARMA DC BV ADF ROYALTY EUR 1292408,94 EX: 1	1.458.612,73-	USD
<input type="checkbox"/> 304	100002662	27.03.2019	28.03.2019	3	2019/03	SA		CWS	103080	GEN	ROYALTIES 3-4Q18 OXYCONTIN LATAM . ASIA AS PER SEP	1.051.527,54-	USD
<input type="checkbox"/> 304	100002679	27.05.2019	28.05.2019	5	2019/05	SA		CWS	103080	GEN	4Q18 ADF ROYALTY MUNDIPHARMA BRADENTON BV EX: 109.	1.428.634,00-	USD
<input type="checkbox"/> 304	100002679	27.05.2019	28.05.2019	5	2019/05	SA		CWS	103080	GEN	PAYM. ADVISE FROM 21.05.2019 PAYME NT DOCUMENT 200	122.129,44-	USD
<input type="checkbox"/> 304	100002689	16.06.2019	17.06.2019	6	2019/06	SA		CWS	103080	GEN	MUNDIPHARMA DC BV 1Q19 ADF ROYALTY EX: 1.1267 /OCM	2.642.529,56-	USD
*								CWS 1				7.574.284,54-	USD
<input type="checkbox"/> 304	100002693	30.06.2019	01.07.2019	6	2019/06	SA		RC 0619	103080	GEN	1Q 19 MDC ADF	2.642.529,56	USD
*								RC 0619				2.642.529,56	USD

<sup>1</sup>Screenshots do not include all entries – abbreviated versions shown.

<sup>2</sup>CWS is one of the designations in SAP for payments made to cash.

## Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

Per discussions with Purdue and TXP, royalty settlements to PPLP from PALP are recorded through intercompany account 102208-304. From January 1, 2008 to September 15, 2019, \$628.5 million of total activity can be observed with \$499.3 million in cash settlements to PPLP from PALP.<sup>1,2</sup>

Account 102208-304	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Totals
Prior Year Cumulative Balance	\$ (1,689,693)	\$ (2,533,635)	\$ (9,810,288)	\$ (10,397,775)	\$ (10,821,606)	\$ (6,985,733)	\$ 756,945	\$ (175,273)	\$ 2,447,071	\$ 202,801	\$ 2,277,358	\$ 775,354	
Debits	67,754,486	107,612,663	72,654,886	79,851,415	75,142,460	49,072,392	33,382,608	36,799,914	22,459,675	53,615,280	19,517,278	10,659,687	628,522,743
Credits	(68,598,427)	(114,889,316)	(73,242,373)	(80,275,246)	(71,306,587)	(41,329,713)	(34,314,826)	(34,177,571)	(24,703,944)	(51,540,723)	(21,019,282)	(13,613,798)	(629,011,807)
Ending Cumulative Balance	\$ (2,533,635)	\$ (9,810,288)	\$ (10,397,775)	\$ (10,821,606)	\$ (6,985,733)	\$ 756,945	\$ (175,273)	\$ 2,447,071	\$ 202,801	\$ 2,277,358	\$ 775,354	\$ (2,178,757)	

Royalties Adjusting Entries	\$ 2,510,311	\$ 50,101,057	\$ 846,708	\$ 339,386	\$ 4,603,872	\$ 8,604,759	\$ 1,054,666	\$ 8,416,508	\$ 5,862,662	\$ 32,495,280	\$ 6,181,523	\$ 2,843,275	\$ 123,860,007
Cash to PPLP	65,176,000	57,507,500	71,796,000	79,130,000	70,530,000	40,461,000	32,319,000	28,120,000	12,120,000	21,120,000	13,325,755	7,726,707	499,331,961
Consolidating Entries	-	-	-	9,114	-	3,910	8,942	-	-	-	-	-	21,967
Intercompany Interest	68,174	4,106	2,179	3,097	8,588	2,722	-	-	-	-	-	-	88,864
Other Charges	-	-	10,000	369,819	-	-	-	263,407	4,477,013	-	10,000	89,705	5,219,944
Total Debits	\$ 67,754,486	\$ 107,612,663	\$ 72,654,886	\$ 79,851,415	\$ 75,142,460	\$ 49,072,392	\$ 33,382,608	\$ 36,799,914	\$ 22,459,675	\$ 53,615,280	\$ 19,517,278	\$ 10,659,687	\$ 628,522,743

Royalties Adjusting Entries	\$ (68,483,735)	\$ (114,022,766)	\$ (73,129,543)	\$ (79,841,292)	\$ (71,213,468)	\$ (41,153,051)	\$ (34,092,760)	\$ (20,909,674)	\$ (20,112,363)	\$ (50,938,969)	\$ (20,999,282)	\$ (13,524,093)	\$ (608,420,996)
Cash from PPLP	(61,000)	(35,000)	(40,000)	(10,000)	(20,000)	-	-	-	(25,000)	(15,000)	(10,000)	-	(216,000)
Consolidating Entries	(32,500)	(35,109)	(15,620)	(19,542)	-	(173,941)	(222,066)	(15,409)	(8,000)	(16,328)	-	-	(538,515)
Intercompany Interest	(17,691)	(17,513)	(47,210)	(34,558)	(73,119)	(2,722)	-	-	-	-	-	-	(192,813)
Other Charges	(3,501)	(778,928)	(10,000)	(369,854)	-	-	-	(13,252,488)	(4,558,582)	(570,426)	(10,000)	(89,705)	(19,643,483)
Total Credits	\$ (68,598,427)	\$ (114,889,316)	\$ (73,242,373)	\$ (80,275,246)	\$ (71,306,587)	\$ (41,329,713)	\$ (34,314,826)	\$ (34,177,571)	\$ (24,703,944)	\$ (51,540,723)	\$ (21,019,282)	\$ (13,613,798)	\$ (629,011,807)

<sup>1</sup>Additional miscellaneous activity includes miscategorized entries that are reversed out through corresponding credits to the intercompany account, as well as a charge related to a security bond.

<sup>2</sup>"As explained on Slide 214, PALP was to net only \$50,000 in profit each year. To this end, these "adjusting expenses" were made to ensure that PALP only retained \$50,000 in profit from the royalties, less the expenses it incurred."

## Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

Per SAP and between 2008-2019, PALP recognized \$487.7 million in royalties through account 700530 (Royalty Income Foreign) and received \$505.4 million in cash, settled through account 103080 (Accrued Royalty Income). PALP subsequently transferred \$499.3 million to PPLP through intercompany transactions (intercompany account 102208-304).

Per discussions with Purdue and TXP, the variance between foreign royalties on PALP's books and the respective cash settlements is due to timing discrepancies between when the royalties are recognized through the income statement (700530) and when they are settled in cash and recognized on the balance sheet (103080).<sup>1</sup> Additionally, the variance between cash settlements on PALP's books (103080) and cash settlements to PPLP through the intercompany account (102208-304) is due to both timing discrepancies and the use of approximation and rounding by Purdue when preparing the intercompany transfers.







G/L Account 700530 - 304 (PALP)	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Grand Total
Foreign Royalties	\$ (62,563,773)	\$ (66,755,870)	\$ (73,040,536)	\$ (78,196,084)	\$ (66,261,934)	\$ (32,972,225)	\$ (32,995,881)	\$ (13,959,680)	\$ (19,989,856)	\$ (15,280,326)	\$ (14,913,594)	\$ (10,789,229)	\$ (487,718,987)
G/L Account 103080 - 304 (PALP)	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Grand Total
Cash Settlements	\$ (65,183,335)	\$ (57,531,136)	\$ (71,831,495)	\$ (79,397,879)	\$ (70,570,966)	\$ (40,618,986)	\$ (32,447,141)	\$ (28,216,935)	\$ (12,009,196)	\$ (20,957,300)	\$ (14,478,006)	\$ (12,126,891)	\$ (505,369,268)
102208 - 304 (PALP) InterCo.	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Grand Total
Cash Settlements To PPLP	\$ (65,176,000)	\$ (57,507,500)	\$ (71,796,000)	\$ (79,130,000)	\$ (70,530,000)	\$ (40,461,000)	\$ (32,319,000)	\$ (28,120,000)	\$ (12,120,000)	\$ (21,120,000)	\$ (13,325,755)	\$ (7,726,707)	\$ (499,331,961)
Difference - Cash Settlements	\$ 7,335	\$ 23,636	\$ 35,495	\$ 267,879	\$ 40,966	\$ 157,986	\$ 128,141	\$ 96,935	\$ (110,804)	\$ (162,700)	\$ 1,152,251	\$ 4,400,185	\$ 6,037,306

<sup>1</sup>The variance in the total amounts reflected above is primarily caused by differences arising from cash- vs. accrual-basis accounting. That is, royalties recognized on PALP's income statement on an accrual basis before January 1, 2008 may not be reflected in the above, but any corresponding cash settlements to PPLP after January 1, 2008 would nevertheless be recognized on its balance sheet on a cash-settled basis after January 1, 2008. Similarly, the Report accounts for royalties recognized on PALP's income statement on an accrual basis before September 15, 2019, but it does not account for any corresponding cash settlements on its balance sheet after September 15, 2019."



## Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

According to PALP's accounting records in SAP, PALP recognized cash settlements of \$12.1 million between January 2019 and September 15, 2019 through G/L account 103080 (Accrued Royalty Income) which reconciles to the prior slide.<sup>1</sup>

Account number	103080	Accrued Royalty Inc.		
Company code	304	Pharma Associates L.P.		
Business area				
Fiscal year	2019			
All documents in currency	*	Display currency	USD	
<div></div>				
Period	Debit	Credit	Balance	Cumulative balance
Balance Carry...				
1				
2	870,851.27	870,851.27		
3	2,510,140.27	2,510,140.27		
4				
5	1,603,767.58	1,603,767.58		
6	2,642,529.56	2,642,529.56		
7	1,104,457.52	1,104,457.52		
8	3,448,149.30	3,448,149.30		
9				
10				
11		2,728,889.74	2,728,889.74-	2,728,889.74-
12				2,728,889.74-
13				2,728,889.74-
14				2,728,889.74-
15				2,728,889.74-
16				2,728,889.74-
Total	12,179,895.50	14,908,785.24	2,728,889.74-	2,728,889.74-

<sup>1</sup>May 2019 \$1.6 million entry includes \$53,004.14 adjustment not made to cash. Therefore, \$14,908,785.24 - \$2,728,889.74 - \$53,004.14 = \$12,126,891.36



## Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

According to PALP's accounting records in SAP, PALP made cash settlements to PPLP totaling \$7.7 million through intercompany account 102208-304 between January 2019 and September 15, 2019.<sup>1</sup> The remaining \$2.9 million of debit activity not settled to cash is related to adjusting entries made to ensure PALP records only \$50,000 of net profit, as explained on slide 213.

G/L Account		102208		Purdue Pharma L.P.									
Company Code		304											
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/> 304	100002660	03/17/2019	03/27/2019	3	2019/03	SA		CWS	102208	GEN		1,937,241.23	USD
<input type="checkbox"/> 304	100002677	04/30/2019	05/01/2019	4	2019/04	SA		CWS	102208	GEN		1,357,371.39	USD
<input type="checkbox"/> 304	100002709	07/31/2019	08/01/2019	7	2019/07	SA		CWS	102208	GEN		1,731,177.66	USD
*								CWS				5,025,790.28	USD
<input type="checkbox"/> 304	100002680	05/31/2019	05/28/2019	5	2019/05	SA		LMT 519	102208	GEN		89,704.88	USD
<input type="checkbox"/> 304	100002682	05/31/2019	05/28/2019	5	2019/05	SA		LMT 519	102208	GEN		53,004.14	USD
*								LMT 519				142,709.02	USD
<input type="checkbox"/> 304	100002699	06/30/2019	07/09/2019	6	2019/06	SA		LT 619	102208	GEN	Adj for June WT from 304 ██████████ Bank to 208 Cha <sup>2</sup>	2,700,916.46	USD
*								LT 619				2,700,916.46	USD
<input type="checkbox"/> 304	100002667	03/31/2019	04/05/2019	3	2019/03	SA		RC 0319	102208	GEN	TO ADJ FOR PAYMENTS BY 208 FOR 304	1,357,371.39	USD
<input type="checkbox"/> 304	100002669	03/31/2019	04/05/2019	3	2019/03	SA		RC 0319	102208	GEN	TO ADJ FOR PAYMENTS BY 208 FOR 304	1,432,899.87	USD
*								RC 0319				2,790,271.26	USD
**												10,659,687.02	USD

<sup>1</sup>\$5,025,790.28 + \$2,700,916.46 = \$7,726,706.74 , which reconciles to slide 220.

<sup>2</sup>Per Purdue, PPLP changed banks from Chase to Signature in June 2019. \$2.7 million entry settled to cash through new [REDACTED] G/L account 100065.

## Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

In almost all years, accounting entries were made such that PALP's income (after PPLP reimbursed its expenses and collected royalties) amounted to \$50,000. In SAP, this is shown as the difference between accumulated account balances in G/L account 700530 (Foreign Royalty Income) and G/L account 800100 (Foreign Other Expenses). The accumulated balance in each account as well as the resulting \$50,000 income for 2019 are illustrated below.

Pharma Associates L.P. U.S.A.				G/L Account Balances				Time 15:24:12	Date 11/22/2019
Carryforward Periods 00-00 2019 Reporting Periods 01-09 2019								RFSSLD00/ELLISRO	Page 1
CoCd	G/L acct	Short Text	Crcy BusA	Balance Carryforward	Balance,prev.periods	Debit rept.period	Credit report per.	Accumulated balance	
304	608410	Management Fee	USD	0.00	0.00	11,251.00	0.00	11,251.00	
304	608491	Other Legal Expenses	USD	0.00	0.00	15,000.00	0.00	15,000.00	
304	690300	TXP Direct Cost Asse	USD	0.00	0.00	2,039.61	168.71	1,870.90	
304	700010	Interest Income	USD	0.00	0.00	0.00	31,462.42	31,462.42-	
304	700070	Purchase Discount	USD	0.00	0.00	0.00	200.00	200.00 <sup>1</sup>	
304	700530	Royalty Inc. Foreign	USD	0.00	0.00	3,510,262.50	15,682,038.70	12,171,776.20-	
304	800100	Foreign Other Exp.	USD	0.00	0.00	14,915,587.98	2,790,271.26	12,125,316.72	
*304			USD	0.00	0.00	18,454,141.09	18,504,141.09	50,000.00-	

<sup>1</sup>\$12,171,776.20 - \$12,125,316.72 = \$46,459.28 shown on slide 214 under "Less Expenses" for 2019.

## Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

Per discussions with Purdue and TXP, in 2008 PALP recognized additional income from [REDACTED] (3rd party company), reflected in G/L account 680000 (Other Co-Development Income), that was also passed on to Purdue.

G/L Account Balances

Pharma Associates L.P.				G/L Account Balances		Time 16:40:02		Date	11.07.2019
U.S.A.						RFSSLD00/SILVAFE		Page	1
Carryforward Periods 00-00 2008 Reporting Periods 01-12 2008									
CoCd	G/L acct	Short Text	Crcy	BusA	Balance Carryforward	Balance,prev.periods	Debit rept.period	Credit report per.	Accumulated balance
304	608410	Management Fee	USD		0,00	0,00	15.000,00	0,00	15.000,00
304	608450	External Accounting	USD		0,00	0,00	19.000,00	0,00	19.000,00
304	608491	Other Legal Expenses	USD		0,00	0,00	149.500,00	109.500,00	40.000,00
304	660040	Interest Interco	USD		0,00	0,00	37.677,57	87.896,20	50.218,63-
304	680000	Co-Development Inc.	USD		0,00	0,00	277.722,00	3.472.185,00	3.194.463,00-
304	690100	InterCo Charge/Credi	USD		0,00	0,00	19.986,60	2.750,78	17.235,82
304	700500	Export Income	USD		0,00	0,00	843.777,94	843.777,94	0,00
304	700530	Royalty Inc. Foreign	USD		0,00	0,00	12.230.290,08	74.794.063,42	62.563.773,34-
304	800000	Misc. Charge/Expense	USD		0,00	0,00	1.471,00	0,00	1.471,00
304	800100	Foreign Other Exp.	USD		0,00	0,00	68.050.012,71	1.334.087,56	66.715.925,15
*304			USD		0,00	0,00	81.644.437,90	80.644.260,90	1.000.177,00

Pharma Associates L.P.				G/L Account Balances		Time 16:40:02		Date	11.07.2019
U.S.A.						RFSSLD00/SILVAFE		Page	2
Carryforward Periods 00-00 2008 Reporting Periods 01-12 2008									
TOTALS FROM ALL COMPANY CODES									
CoCd	Crcy	BusA	Balance Carryforward	Balance,prev.periods	Debit rept.period	Credit report per.	Accumulated balance		
304	USD		0,00	0,00	81.644.437,90	80.644.260,90	1.000.177,00		
*	USD		0,00	0,00	81.644.437,90	80.644.260,90	1.000.177,00		

## Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

Per SAP, between 2008 and 2019, \$161.2 million in cash settlements for royalties from multiple foreign IACs was recognized on PPLP's books and \$3.3 million in similar cash settlements for royalties was recognized on PTT's books through G/L account 103080 (Accrued Royalty Income). Analysis of the intercompany accounts for these additional IACs would entail additional work requiring a substantial amount of time, as PPLP and PTT received transfers from a large number of IACs, which would require a review of each individual intercompany account. Additionally, many of the intercompany accounts with foreign IACs contain significant other activity that would be onerous and time consuming to individually identify.

G/L Account 103080 Cash													
Settlements	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Grand Total
Purdue Pharma L.P	\$ (11,676,459)	\$ (11,254,251)	\$ (12,644,731)	\$ (12,681,862)	\$ (25,289,370)	\$ (15,163,527)	\$ (14,582,883)	\$ (19,493,163)	\$ (25,818,289)	\$ (6,341,253)	\$ (6,302,205)	\$ -	\$ (161,247,994)
Purdue Transdermal Tech	-	-	-	-	-	(1,600,665)	(415,400)	(1,102,696)	(224,371)	-	-	-	(3,343,132)
Total	\$ (11,676,459)	\$ (11,254,251)	\$ (12,644,731)	\$ (12,681,862)	\$ (25,289,370)	\$ (16,764,193)	\$ (14,998,284)	\$ (20,595,859)	\$ (26,042,660)	\$ (6,341,253)	\$ (6,302,205)	\$ -	\$ (164,591,127)

## Exhibit 1R: Intercompany transfers between foreign IACs and Purdue for selling Oxycontin and other products under license agreements

AlixPartners has reviewed several Oxycontin license agreements between PPLP and Mundipharma DC B.V. dated January 1, 2017 (by country/region), as well as several Oxycontin OTR agreements between the same parties dated January 1, 2018. In addition, AlixPartners reviewed two agreements between PPLP and Mundipharma Laboratories GmbH dated January 1, 2018. The tables below summarize the countries and regions mentioned in the various license agreements.

Regions Mentioned in Agreements with Mundipharma DC B.V. Dated January 1, 2016					
Arab States	Cyprus	Germany	Jordan	Norway	South Africa
Austria	Denmark	Hong Kong	Kuwait	Phillipines	Spain
Belgium	Egypt	Iceland	Lebanon	Poland	Sweden
Cen. & East Europe	Finland	Ireland	Netherlands	Saudi Arabia	Switzerland
China	France	Italy	New Zealand	Singapore	United Kingdom

Regions Mentioned in Agreements with Mundipharma DC B.V. Dated January 1, 2018					
Australia	India <sup>1</sup>	Lebanon	Philippines	Thailand	
Canada	Korea	Malaysia	Singapore	Vietnam	

Regions Mentioned in Agreements with Mundipharma Laboratories GmbH Dated January 1, 2018	
	Brazil
	Mexico

<sup>1</sup>The India agreement is not dated; it only contains a blank space for the day and month with the year 2017 printed thereafter.



## **Exhibit 2: Intercompany Transfers Between Rhodes and IACs**



## **Exhibit 2: Intercompany transfers between Rhodes and IACs**

- A. Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients
- B. Intercompany transfers between Mundipharma's LAM region and Rhodes Pharma for finished dosage products
- C. Intercompany transfers between Rhodes Pharma and Mundipharma Laboratories GMBH for theophylline

## **Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients**

From January 1, 2008 to September 15, 2019, Rhodes Tech sold API to various IACs:

- Bard Pharmaceuticals Limited (“Bard,” a subsidiary of Napp Pharmaceuticals Limited), oxycodone hydrochloride from 2008 to 2019 and naloxone HCl dihydrate from 2016 to 2017;
- The P.F. Laboratories Inc. (“P.F. Labs”), oxycodone hydrochloride from 2008 to 2012;
- Napp Pharmaceuticals Limited (“Napp”), oxycodone hydrochloride in 2008;
- Purdue Pharma Inc. (Canada), oxycodone hydrochloride from 2008 to 2019 and methylphenidate hydrochloride from 2015 to 2019;
- Rafa Laboratories Limited, oxycodone hydrochloride from 2009 to 2019 and naloxone HCl dihydrate in 2015;
- Modi Mundipharma Private Limited, oxycodone hydrochloride in 2011 and from 2017 to 2018; and
- Mundipharma Research Limited, oxycodone hydrochloride in 2009.

## Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

Based on discussions with Rhodes, there is no formal agreement between Rhodes Tech and any of the IACs regarding the price of API per kilogram or minimum quantity of kilograms ordered per year. According to Rhodes, the prices at which Rhodes Tech sold API to the IACs were determined on the basis of historical market prices.

In the case of Bard, Rhodes Tech and Bard negotiated an annual price based on the price charged by [REDACTED] (a 3rd party) to Bard for oxycodone hydrochloride, while the price for naloxone HCI dihydrate was negotiated independently. There is no minimum quantity of kilograms ordered per year. For all other IACs, there is no formal agreement. In the example shown below, in 2018 Bard and Rhodes Tech negotiated a price of £975 per kilogram for Oxycodone API.

[REDACTED]

---

**From:** [REDACTED]  
**Sent:** Monday, November 06, 2017 3:00 PM  
**To:** [REDACTED]  
**Cc:** [REDACTED]  
**Subject:** 2018 Budget

Hi [REDACTED],

We confirm the proposed 2018 API price as discussed.

- Oxycodone API £[REDACTED] / kilo

Very best regards,  
[REDACTED]

## Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

Bard and Rhodes Tech negotiated the following prices for 2016 through 2019 for API. Documentation supporting negotiated prices for periods prior to 2016 is not available.

[REDACTED]

---

**From:** [REDACTED]  
**Sent:** Thursday, November 01, 2018 11:26 AM  
**To:** [REDACTED]  
**Cc:** [REDACTED]  
**Subject:** RE: API

For the call today, here is some history for your reference  
Regards  
[REDACTED]

API - Selling Price	2016	2017	2018	2019 Proposed
Oxycodone	£ [REDACTED]	£ [REDACTED]	£ [REDACTED]	£ [REDACTED]
Naloxone	€ [REDACTED]	€ [REDACTED]	€ [REDACTED]	€ [REDACTED]
Morphine	N/A	N/A	N/A	


-----Original Appointment-----

**From:** [REDACTED]  
**Sent:** Monday, October 29, 2018 4:18 PM  
**To:** [REDACTED]  
**Subject:** API  
**When:** Thursday, November 01, 2018 4:30 PM-5:00 PM (UTC+00:00) Dublin, Edinburgh, Lisbon, London.  
**Where:** TC

Hi [REDACTED]  
In [REDACTED] absence we are happy to discuss API's  
Regards  
[REDACTED]

## Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

The following email supports discussions with Rhodes that the price paid by Bard to Rhodes Tech was based on the [REDACTED] contract price (i.e., the 5th bullet point).



## Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

This excerpt from a [REDACTED] contract illustrates that the prices paid by Bard to Rhodes Tech is consistent with the prices Bard agreed to pay to [REDACTED].

### SCHEDULE 3 MINIMUM QUANTITIES & PRICES

#### 1. During the Contract Year 1 April 2016 to 31 March 2017:

1.1 Subject as provided in paragraph 4 of this Schedule 3, the Customer shall purchase a combined minimum quantity of [REDACTED] of Products to Specifications [REDACTED] and/or [REDACTED] during this Contract Year.

1.2 The price for such Product during this Contract Year shall be as follows:

For [REDACTED] of such Product - £ [REDACTED]/kg for all volume purchased.

For any additional volumes over [REDACTED] - £ [REDACTED]/kg – for such additional volumes only.

#### 2. During the Contract Year 1 April 2017 to 31 March 2018:

2.1 Subject as provided in paragraph 4 of this Schedule 3, the Customer shall purchase a combined minimum quantity of [REDACTED] of Products to Specifications [REDACTED] and/or [REDACTED] during this Contract Year.

2.2 The price for such Product during this Contract Year shall be as follows:

For [REDACTED] of such Product - £ [REDACTED]/kg for all volume purchased.

For any additional volumes over [REDACTED] - £ [REDACTED]/kg – for such additional volumes only.

#### 3. During the Contract Year 1 April 2018 to 31 March 2019:

3.1 Subject as provided in paragraph 4 of this Schedule 3, the Customer shall purchase a combined minimum quantity of [REDACTED] of Products to Specifications [REDACTED] and/or [REDACTED] during this Contract Year.

3.2 The price for such Product during this Contract Year shall be as follows:

For [REDACTED] of such Product - £ [REDACTED]/kg for all volume purchased.

For any additional volumes over [REDACTED] - £ [REDACTED]/kg – for such additional volumes only.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed the day and year first above written.

On behalf of

[REDACTED]

By: [REDACTED]

Title: *General Manager*

*21st SEP 2016*

On behalf of

BARD PHARMACEUTICALS  
LIMITED

By: [REDACTED]

Title: *Production Director*

*21 Sept 2016*



## Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

From January 1, 2008 to September 15, 2019, Rhodes Tech recognized API sales of \$140.7 million to the various IACs.

IAC	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
Bard Pharmaceuticals Limited	\$ 3,272,801	\$ 6,136,635	\$ 11,728,748	\$ 13,036,566	\$ 12,050,500	\$ 5,929,003	\$ 11,509,219	\$ 10,433,153	\$ 14,564,696	\$ 19,868,598	\$ 11,363,893	\$ 9,399,676	\$ 129,293,487
The P.F. Laboratories Inc.	3,567,370	28,835	652,692	579,415	55,046	-	-	-	-	-	-	-	4,883,358
Napp Pharmaceuticals Limited	1,931,723	-	-	-	-	-	-	-	-	-	-	-	1,931,723
Purdue Pharma Inc. (Canada)	171,358	434,200	53,329	214,961	215,135	210,547	53,754	131,508	238,031	129,414	53,244	106,310	2,011,791
Rafa Laboratories Limited	-	20,937	194,089	194,353	290,632	193,385	182,075	198,843	270,422	234,463	231,899	150,782	2,161,880
Modi-Mundi Pharma Pvt. Ltd.	-	-	-	39,189	-	-	-	-	-	-	29,675	-	68,864
Mundipharma Research Limited	-	391,934	-	-	-	-	-	-	-	-	-	-	391,934
<b>Total</b>	<b>\$ 8,943,253</b>	<b>\$7,012,542</b>	<b>\$12,628,858</b>	<b>\$14,064,482</b>	<b>\$12,611,313</b>	<b>\$6,332,936</b>	<b>\$11,745,047</b>	<b>\$10,763,503</b>	<b>\$15,073,149</b>	<b>\$20,232,476</b>	<b>\$11,678,712</b>	<b>\$9,656,767</b>	<b>\$140,743,038</b>

Note: Figures above represent amounts invoiced to the various IACs in the respective periods. Actual payments differ slightly in timing, and amounts may differ slightly due to foreign exchange fluctuation for amounts paid in currencies other than USD.

## Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

Prior to 2009, sales of API to the various IACs from Rhodes Tech were processed as journal entries in SAP (i.e., no invoices were generated in SAP; manual invoices were created).<sup>1</sup> An example of such a journal entry from 2008 is illustrated below, debited to account 101015 (Accounts Receivable Intercompany (SD and Manual Billings)) under Bard's customer number (134034) and credited to account 402000 (Sales – Other) in Rhodes Tech's (SAP company code 227) accounting records in SAP.

**Document Overview - Display**

Doc.Type : DR ( Customer invoice ) Normal document  
 Doc. Number 1800000011 Company Code 227 Fiscal Year 2008  
 Doc. Date 17.11.2008 Posting Date 26.11.2008 Period 11  
 Calculate Tax ☐  
 Doc. Currency USD

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	01	134034	BARD PHARMACEUTICALS					1.632.899,55	Inv. #1117080XY: Oxycodone Hydrochloride USP
2	50	402000	Sales Other		OXR			1.632.899,55-	Inv. #1117080XY: Oxycodone Hydrochloride USP

**Display Document: Line Item 001**

Customer 134034 BARD PHARMACEUTICALS G/L Acc 101015  
 CoCode 227 CAMBRIDGE SCIENCE PARK  
 Rhodes Technologies CAMBRIDGE Doc. No. 1800000011

Line Item 1 / Invoice / 01  
 Amount 1.632.899,55 USD  
 Tax code

Additional Data  
 Disc. base 1.632.899,55 Disc. amount 0,00 USD  
 Payt Terms N30 Days/percent 30 0,000 % 0 0,000 % 0  
 Bline Date 17.11.2008 Invoice Ref. / / 0  
 Prmt Block  
 Payment Ref.  
 Clearing 22.12.2008 / 100012364  
 Assignment pd wt 12/22/08.td  
 Text Inv. #1117080XY: Oxycodone Hydrochloride USP Long text

**Master records**

Long Text	ChAc	DelI	Pstg block	Crtn.block	Plan.block	G/L Acct
AR Intercompany (SD and Manual Billings)	PURD	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	101015

<sup>1</sup>There was one sale to P. F. Labs for \$985,000 processed in SAP's accounts payable module in June 2008 for which SAP automatically generated an invoice. This amount was debited to account 101016 (Accounts Receivable (Manual A/R Billings)) under P.F. Labs' customer number (1265) and credited to account 402000 (Sales – Other) on Rhodes Tech's books (SAP company code 227).

## Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

In December 2010, the outstanding balance of receivables under account 101015 (Accounts Receivable Intercompany (SD and Manual Billings)) in Rhodes Tech's accounting records (SAP company code 227) was transferred to account 103040 (Accounts Receivable - Other) and subsequently settled in a single cash payment.

**Document Overview - Display**

Doc.Type : DA ( Customer document ) Normal document  
 Doc. Number 1600000024 Company Code 227 Fiscal Year 2010  
 Doc. Date 10.12.2010 Posting Date 13.12.2010 Period 12  
 Calculate Tax ☐  
 Ref.Doc. PD WT 12/10/10  
 Doc. Currency USD  
 Doc. Hdr Text act 134034 90934570,90933

Item	FK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	103040	AR Other		GEN			3.117.911,42	
2	15	134034	BARD PHARMACEUTICALS					3.174.454,50-	
3	40	700520	Realized FX	9001227	GEN			56.543,08	

**Document Overview - Display**

Doc.Type : SA ( G/L account document ) Normal document  
 Doc. Number 100023810 Company Code 227 Fiscal Year 2010  
 Doc. Date 16.12.2010 Posting Date 15.12.2010 Period 12  
 Calculate Tax ☐  
 Doc. Currency USD  
 Doc. Hdr Text CTW 12102010 to 12152010

Item	FK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
17	50	100010	Cash Concentration		GEN			115.000,00-	FUNDING to SVC PHARMA, LP
18	50	100010	Cash Concentration		GEN			103.972,76-	CONTROL DISBURSEMENT ACCOUNT FUNDING
19	50	100010	Cash Concentration		GEN			45.000,00-	FUNDING to RHODES TECHNOLOGIES, INC. (247)
20	50	100010	Cash Concentration		GEN			7.000,00-	FUNDING to SVC PHARMA, INC.
21	50	100010	Cash Concentration		GEN			1.915,25-	CONTROL DISBURSEMENT ACCOUNT FUNDING
22	50	100530	Misc. Cash Clearing		GEN			26,20-	MISCELLANEOUS BANK DEPOSIT
23	40	100010	Cash Concentration		GEN			13.000.000,00	12/14/2010 MIC MONEY MARKET
24	40	100400	Temp. Invest. Chase		GEN			12.997.974,17-	12/14/2010 MIC / SHORT-TERM INVESTMENT
25	40	100010	Cash Concentration		GEN			3.117.911,42	12/10/2010
26	40	100010	Cash Concentration		GEN			970.000,00	12/10/2010 BANK ERROR / WASH TRANSACTION
27	40	700030	Misc. Income	9000227	GEN			970.000,00	12/10/2010 BANK ERROR / WASH TRANSACTION
28	40	100010	Cash Concentration		GEN			927.000,00	12/14/2010 BANK ERROR / WASH TRANSACTION
29	40	700030	Misc. Income	9000227	GEN			927.000,00	12/14/2010 BANK ERROR / WASH TRANSACTION
30	40	100010	Cash Concentration		GEN			160.000,00	12/13/2010 BANK ERROR / WASH TRANSACTION
31	40	700030	Misc. Income	9000227	GEN			160.000,00	12/13/2010 BANK ERROR / WASH TRANSACTION
32	40	100010	Cash Concentration		GEN			24.227,07	12/10/2010
33	50	100450	BGA Money Market		GEN			13.000.000,00-	12/14/2010 MIC MONEY MARKET
34	50	100010	Cash Concentration		GEN			12.997.974,17-	12/14/2010 MIC / SHORT-TERM INVESTMENT
35	50	103040	AR Other		GEN			3.117.911,42-	12/10/2010

## Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

Invoices for API sales to the IACs from Rhodes Tech were processed in SAP beginning in 2009.<sup>1</sup> As an example, invoices for Bard in 2009 are shown below in SAP on Rhodes Tech's books (SAP company code 227).<sup>2</sup>

By partner - Items List of Billing Documents

Subtotal

By partner - Items List of Billing Documents

Payer

0000134034  
BARD PHARMACEUTICALS  
CAMBRIDGE

Billing date

01.01.2009 to 31.12.2009

Billing Doc.	Item S	Created by	BILL	Σ	Net Value	Curr.	SOrg.	DstC	COT	Payer	Name of the payer	Address	Material	Description	Plant	Batch	Billed qty	SU	BlCat	Billing Date	DocCa	Ret
					11.642.440,1	USD																
					2.752.902,56	USD																
90833237	10	CELENTAM	ZS1		428.664,24	USD	227	GB	Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD	RI01	52-09XYK	193,092	KG	L	20.11.2009	N	
90833238	10	CELENTAM	ZS1		1.013.616,48	USD	227	GB	Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD	RI01	51-09XYK	456,584	KG	L	18.11.2009	N	
90802606	10	CELENTAM	ZS1		1.310.621,84	USD	227	GB	Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD	RI01		978,076	KG	L	06.08.2009	N	
					8.889.537,56	USD																
90833839	10	BACKGROUND	ZF2		997.949,94	USD	227	GB	Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD	RI01		449,527	KG	L	30.11.2009	M	
90833265	10	CELENTAM	ZF2		1.442.280,72	USD	227	GB	Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD	RI01		649,676	KG	L	25.11.2009	M	
90832118	10	BACKGROUND	ZF2		428.664,24	USD	227	GB	Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD	RI01	52-09XYK	193,092	KG	L	20.11.2009	M	
90831437	10	BACKGROUND	ZF2		1.013.616,48	USD	227	GB	Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD	RI01	51-09XYK	456,584	KG	L	18.11.2009	M	
90804890	10	BACKGROUND	ZF2		1.525.075,62	USD	227	GB	Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD	RI01		686,971	KG	L	20.08.2009	M	
90803280	10	BACKGROUND	ZF2		2.171.328,72	USD	227	GB	Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD	RI01		978,076	KG	L	06.08.2009	M	
90801199	10	BACKGROUND	ZF2		1.310.621,84	USD	227	GB	Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD	RI01		978,076	KG	L	06.08.2009	M	

<sup>1</sup>This applies to all IACs with the exceptions of P.F. Labs, Mundipharma Research Limited and Modi Mundipharma Private Limited, for which post-2009 sales were only processed as journal entries (i.e., no invoices were generated in SAP; manual invoices were created).

<sup>2</sup>Total API sales for 2009 of \$6,136,635 reconcile to the chart on Slide 234 by netting returns (the sum of the net value of the first three documents, \$2,752,903) against all other sales documents (the sum of the net value of all other documents, \$8,889,538). The totaled amount of \$11,642,440 should be disregarded as it is only a sum of the absolute values of all billing documents, including returns.



## Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

API sales from Rhodes Tech to Bard from 2018 are shown below in SAP on Rhodes Tech's (SAP company code 227) accounting records in SAP.<sup>1</sup>

By partner - Items List of Billing Documents

Subtotal

By partner - Items List of Billing Documents

Payer

0000134034  
BARD PHARMACEUTICALS  
CAMBRIDGE

Billing date

01.01.2018 to 31.12.2018

Billing Doc.	Item S	Created by	BLIT	Σ	Net Value	Curr.	SOrg.	DChl	DstC	SDst	COT	Payer	Name of the payer	Address	Material	Description	Prod.hier.	Plant	Batch	Billed qty	SU	S	I
					11.363.893,22	USD																	
92375061	10	BACKGROUND	ZF2		88.910,08	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01		69,461	KG		f
92375062	10	BACKGROUND	ZF2		960.915,20	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01		750,715	KG		f
92364811	10	BACKGROUND	ZF2		107.539,20	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01		84,015	KG		f
92364812	10	BACKGROUND	ZF2		257.029,12	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01		200,804	KG		f
92364810	10	BACKGROUND	ZF2		293.698,56	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01		229,452	KG		f
92349636	10	BACKGROUND	ZF2		320.067,84	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01	27-18XYK	250,053	KG		f
92336203	10	BACKGROUND	ZF2		479.654,40	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01		374,730	KG		f
92336202	10	BACKGROUND	ZF2		639.581,44	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01		499,673	KG		f
92318359	10	BACKGROUND	ZF2		21.990,40	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01	11-18XYK	17,180	KG		f
92318357	10	BACKGROUND	ZF2		91.589,12	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01	21-18XYK	71,554	KG		f
92318358	10	BACKGROUND	ZF2		756.185,60	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01		590,770	KG		f
92307564	10	BACKGROUND	ZF2		38.138,85	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01	11-18XYK	28,251	KG		f
92307563	10	BACKGROUND	ZF2		269.863,65	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01	23-18XYK	199,899	KG		f
92307565	10	BACKGROUND	ZF2		337.176,00	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01	11-18XYK	249,760	KG		f
92307566	10	BACKGROUND	ZF2		494.074,35	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01		365,981	KG		f
92291145	10	BACKGROUND	ZF2		80.168,40	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01		59,384	KG		f
92291148	10	BACKGROUND	ZF2		127.230,75	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01	21-18XYK	94,245	KG		f
92291149	10	BACKGROUND	ZF2		148.217,85	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01		109,791	KG		f
92291146	10	BACKGROUND	ZF2		215.549,10	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01		159,666	KG		f
92291147	10	BACKGROUND	ZF2		242.875,80	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01	21-18XYK	179,908	KG		f
92291144	10	BACKGROUND	ZF2		270.935,55	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01	17-18XYK	200,693	KG		f
92271815	10	BACKGROUND	ZF2		108.124,20	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01		80,092	KG		f
92271817	10	BACKGROUND	ZF2		269.358,75	USD	227	EX	GB		Z4	134034	BARD PHARMACEUTICALS	156580	054000	OXYCODONE HCL USP PWD		RI01	6-18XYK	199,525	KG		f

<sup>1</sup>Screenshot does not include all entries – abbreviated version shown.

## Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

Once invoicing began to be processed in SAP, API sales were debited to account 101015 (Accounts Receivable Intercompany (SD and Manual Billings)) under the respective IAC's customer number and credited either to account 402000 (Sales – Other) or 403000 (Foreign Sales) on Rhodes Tech's books (SAP company code 227). The example below shows the earliest non-returned sale for Bard (customer 134034) from 2009. In this instance, upon receipt of payment, the amount was debited to 101045 (Accounts Receivable Clearing (Non-Trade)) and any realized FX gains or losses were recognized in account 700520 (Realized FX).

**Document Overview - Display**

Doc.Type : ZD ( Customer invoice ) Normal document
Doc. Number 90803280 Company Code 227 Fiscal Year 2009
Doc. Date 06.08.2009 Posting Date 06.08.2009 Period 08
Calculate Tax <input type="checkbox"/>
Ref.Doc. 0000372423
Doc. Currency USD

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	01	134034	BARD PHARMACEUTICALS					2.171.328,72	9/23/09 wire received for \$3,660,222.90.td
2	50	403000	Foreign Sales		OXR			2.171.328,72-	

**Document Overview - Display**

Doc.Type : DA ( Customer document ) Normal document
Doc. Number 1600000007 Company Code 227 Fiscal Year 2009
Doc. Date 25.09.2009 Posting Date 29.09.2009 Period 09
Calculate Tax <input type="checkbox"/>
Ref.Doc. PD WT 09/25/09
Doc. Currency USD
Doc. Hdr Text act #134034 various inv

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	101045	A/R Clrng (NonTrade)		GEN			3.660.222,90	
2	15	134034	BARD PHARMACEUTICALS					3.696.404,34-	
3	40	700520	Realized FX	9001227	GEN			36.181,44	



## Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

Continuing with the example from the prior slide, the invoice was settled via a payment from Napp Pharmaceuticals (Bard's parent company) debited to account 100010 (Cash Concentration) and credited to account 101045 (Accounts Receivable Clearing (Non-Trade)).

Document Overview - Display									
<div> </div>									
<div> <div>Doc.Type : SA ( G/L account document ) Normal document</div> <div> <div>Doc. Number 100016548</div> <div>Company Code 227</div> <div>Fiscal Year 2009</div> </div> <div> <div>Doc. Date 01.10.2009</div> <div>Posting Date 30.09.2009</div> <div>Period 09</div> </div> <div> <div>Calculate Tax <input type="checkbox"/></div> <div>Doc. Currency USD</div> <div>Doc. Hdr Text CTW 09252009 to 09302009</div> </div> </div>									
Itm	FK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
19	50	100010	Cash Concentration		GEN			8.200.000,00-	MIC / MONEY MARKET
20	50	102219	Purdue Wilson NC		GEN			5.216.229,31-	FUNDING from P. PHARMACEUTICALS LP (NC)
21	50	102507	SVC Pharma L.P.		GEN			1.080.000,00-	FUNDING from SVC PHARMA LP
22	50	100010	Cash Concentration		GEN			970.000,00-	MIC / MONEY MARKET
23	50	100010	Cash Concentration		GEN			715.328,13-	CONTROL DISBURSEMENT ACCOUNT FUNDING
24	50	100450	BOA Money Market		GEN			700.000,00-	MIC / MONEY MARKET
25	50	100010	Cash Concentration		GEN			250.814,51-	FUNDING to P. PHARMA TECHNOLOGIES, INC.
26	50	100010	Cash Concentration		GEN			248.595,11-	FUNDING to PURDUE PHARMA LP
27	50	100010	Cash Concentration		GEN			108.038,55-	CONTROL DISBURSEMENT ACCOUNT FUNDING
28	50	100010	Cash Concentration		GEN			85.697,59-	CONTROL DISBURSEMENT ACCOUNT FUNDING
29	50	100010	Cash Concentration		GEN			35.000,00-	FUNDING to SVC PHARMA LP
30	50	100010	Cash Concentration		GEN			10.988,99-	CONTROL DISBURSEMENT ACCOUNT FUNDING
31	50	100450	BOA Money Market		GEN			10.000,00-	MIC / MONEY MARKET
32	50	100010	Cash Concentration		GEN			5.000,00-	FUNDING to RHODES TECHNOLOGIES, INC. (247)
33	50	100010	Cash Concentration		GEN			1.438,82-	FUNDING to TXP SERVICES, INC.
34	50	100010	Cash Concentration		GEN			1.069,77-	FUNDING to MUNDIPHARMA LLC
35	50	100010	Cash Concentration		GEN			871,58-	FUNDING to PURDUE PRODUCTS LP
36	50	100530	Misc. Cash Clearing		GEN			146,00-	MISCELLANEOUS BANK DEPOSIT
37	40	100010	Cash Concentration		GEN			3.660.222,90	9/25/2009 NAPP PHARMACEUTICAL PAYMENT for INV #s:
38	40	100010	Cash Concentration		GEN			534.619,79	9/28/2009 BANK ERROR / WASH TRANSACTION
39	40	700030	Misc. Income	9000227	GEN			534.619,79	9/28/2009 BANK ERROR / WASH TRANSACTION
40	40	102109	The PF Laboratories		GEN			26.830,00	9/28/2009 FUNDING to THE P.F. LABORATORIES, INC.
41	50	101045	A/R Clrng (NonTrade)		GEN			3.660.222,90-	9/25/2009 NAPP PHARMACEUTICAL PAYMENT for INV #s:
42	50	700030	Misc. Income	9000227	GEN			534.619,79-	9/28/2009 BANK ERROR / WASH TRANSACTION
43	50	100010	Cash Concentration		GEN			534.619,79-	9/28/2009 BANK ERROR / WASH TRANSACTION
44	50	100010	Cash Concentration		GEN			26.830,00-	9/28/2009 FUNDING to THE P.F. LABORATORIES, INC.

## Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

An example of the journal entries from the latest invoice from 2018 is shown below. Sales were debited to account 101015 (Accounts Receivable Intercompany (SD and Manual Billings)) under Bard's customer number (134034) and credited to account 403000 (Foreign Sales). Balances owed were subsequently transferred to account 103040 (AR – Other) and any realized FX gains or losses were recognized on account 700520 (Realized FX).


Document Overview - Display									
<div> </div>									
<div> <div>Doc.Type : ZD ( Customer invoice ) Normal document</div> <div> <div>Doc. Number 92375062</div> <div>Company Code 227</div> <div>Fiscal Year 2018</div> </div> <div> <div>Doc. Date 20.11.2018</div> <div>Posting Date 20.11.2018</div> <div>Period 11</div> </div> <div> <div>Calculate Tax <input type="checkbox"/></div> <div>Ref.Doc. 0000893328</div> <div>Doc. Currency USD</div> </div> </div>									
Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	01	134034	BARD PHARMACEUTICALS					960.915,20	11-21 emailed inv copy to Walter, Dan & Tony-jk
2	50	403000	Foreign Sales		OKR			960.915,20-	

Document Overview - Display									
<div> </div>									
<div> <div>Doc.Type : DA ( Customer document ) Normal document</div> <div> <div>Doc. Number 1600000176</div> <div>Company Code 227</div> <div>Fiscal Year 2018</div> </div> <div> <div>Doc. Date 28.11.2018</div> <div>Posting Date 29.11.2018</div> <div>Period 11</div> </div> <div> <div>Calculate Tax <input type="checkbox"/></div> <div>Ref.Doc. PD WT 11/28/18</div> <div>Doc. Currency USD</div> <div>Doc. Hdr Text \$954,398.04 Bard</div> </div> </div>									
Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	103040	AR Other		GEN			954.398,04	
2	15	134034	BARD PHARMACEUTICALS					978.334,72-	
3	40	700520	Realized FX	9001227	GEN			23.936,68	

## Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

Continuing with the example from the prior slide, amounts owed were settled in lump sum intercompany payments debited to account 100010 (Cash Concentration) and credited to account 103040 (Accounts Receivable – Other).

Document Overview - Display



Doc.Type : SA ( G/L account document ) Normal document

Doc. Number100061023Company Code227Fiscal Year2018

Doc. Date29.11.2018Posting Date28.11.2018Period11

Calculate Tax☐

Ref.Doc.CWSOverall No.0100061023227 18

Doc. CurrencyUSD

Doc. Hdr TextCTW227 11262018-11282018

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			430,48-	FUNDING XFER TO 006301511162509
2	50	100010	Cash Concentration		GEN			6.238,92-	FUNDING XFER TO 006301511162509
3	40	100010	Cash Concentration		GEN			954.398,04	FX USD INCOMINGFEDCHIPSSDDA [REDACTED] BANK NA
4	40	100010	Cash Concentration		GEN			1.127.879,86	INTER-COMPANY SETTLEMENT: OCTOBER 2018
5	40	100010	Cash Concentration		GEN			1.022.002,24	CORP PAY
6	50	100010	Cash Concentration		GEN			17.470,10-	FUNDING XFER TO 006301511162509
7	40	100040	Chase Control ZBA		GEN			430,48	FUNDING XFER TO 006301511162509
8	40	100040	Chase Control ZBA		GEN			6.238,92	FUNDING XFER TO 006301511162509
9	50	103040	AR Other		GEN			954.398,04-	FX USD INCOMINGFEDCHIPSSDDA [REDACTED] BANK NA
10	40	100040	Chase Control ZBA		GEN			17.470,10	FUNDING XFER TO 006301511162509
11	50	102208	Purdue Pharma L.P.		GEN			1.127.879,86-	
12	50	102250	Rhodes Pharm LP		GEN			1.022.002,24-	

## Exhibit 2A: Intercompany transfers between various IACs and Rhodes Tech for active pharmaceutical ingredients

It is possible to determine that amounts owed to Rhodes by the various IACs for API (as well as owed by Purdue<sup>1</sup>) were periodically settled through lump sum cash payments and netting of intercompany account balances. The chart below shows the cumulative balances, debits, and credits from January 1, 2008 to September 15, 2019 in account 101015 (Accounts Receivable Intercompany (SD and Manual Billings)) on Rhodes Tech's books (SAP company code 227).

Account 101015 Company 227	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Prior Year Cumulative Balance \$	-	\$ 42,892	\$ 1,595,699	\$ -	\$ 53,868	\$ 152,947	\$ 2,485,717	\$ 3,881,890	\$ 1,738,621	\$ 2,290,664	\$ (360,898)	\$ 224,093
Debits	3,487,108	9,796,231	12,436,935	12,277,656	12,726,354	9,609,949	66,460,982	47,534,805	59,234,358	68,582,732	58,782,437	52,362,206
Credits	(3,444,215)	(8,243,425)	(14,032,635)	(12,223,788)	(12,627,275)	(7,277,180)	(65,064,809)	(49,678,075)	(58,682,315)	(71,234,295)	(58,197,446)	(48,341,448)
Ending Cumulative Balance	\$ 42,892	\$ 1,595,699	\$ -	\$ 53,868	\$ 152,947	\$ 2,485,717	\$ 3,881,890	\$ 1,738,621	\$ 2,290,664	\$ (360,898)	\$ 224,093	\$ 4,244,851

<sup>1</sup>For further information on sales of API to Purdue, please refer to Exhibit 3F.

## Exhibit 2B: Intercompany transfers between Mundipharma's LAM region and Rhodes Pharma for finished dosage products

Based on discussions with Rhodes, Rhodes Pharma provided a small amount of finished dosage products to Mundipharma's Latin America, Asia Pacific and Middle East/Africa ("LAM") region in 2016 and 2017. These products were sold at cost plus a [REDACTED] markup.

Product	IAC Purchaser	Date	Quantity	Amount
Oxycodone/APAP 5MG/325MG tablets 100s	Mundipharma Near East GMBH	6/16/2016	[REDACTED]	\$ 1,821
Oxycodone/APAP 5MG/325MG tablets 100s	Mundipharma Near East GMBH	9/28/2016	[REDACTED]	34,140
<b>Total</b>				<b>\$ 35,961</b>

## Exhibit 2B: Intercompany transfers between Mundipharma's LAM region and Rhodes Pharma for finished dosage products

These receivables were recorded and subsequently settled in cash through the following accounting entries in Rhodes Pharma's (SAP company code 250) accounting records in SAP.

Account Number	Account Description	DR	CR
101010	Accounts Receivable (Foreign)	\$ 34,140	
403000	Foreign Sales		\$ (34,140)
101010	Accounts Receivable (Foreign)	\$ 1,821	
403000	Foreign Sales		\$ (1,821)
101045	Accounts Receivable Clearing (Non-Trade)	\$ 35,841	
101010	Accounts Receivable (Foreign)		\$ (35,841)
660080	Bank Service Charges	\$ 25	
102999	Virtual Company	\$ 95	
101010	Accounts Receivable (Foreign)		\$ (120)



## Exhibit 2B: Intercompany transfers between Mundipharma's LAM region and Rhodes Pharma for finished dosage products

These entries appear in SAP as follows (with notation to a cash settlement):

**Document Overview - Display**

Doc.Type : ZD ( Customer invoice ) Normal document  
 Doc. Number 91956909 Company Code 250 Fiscal Year 2016  
 Doc. Date 28.09.2016 Posting Date 28.09.2016 Period 09  
 Calculate Tax ☐  
 Ref.Doc. 0000767456  
 Doc. Currency USD

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	01	139892	MUNDIPHARMA NEAR EAS					34.140,00	8/16/17 rebilled on pplp-9999.td
2	50	403000	Foreign Sales		ORA			34.140,00-	

**Display Document: Line Item 001**

Customer 139892 MUNDIPHARMA NEAR EAST GMBH G/L Acc 101010  
 CoCode 250 PO BOX CH-4020  
 Rhodes Pharmaceuticals LP BASEL Doc. No. 91956909  
 Line Item 1 / Invoice / 01  
 Amount 94.140,00 USD  
 General Ledger Account (1) 1 Entry found  
 G/L account with delete/lock flag in chart of accounts Key words G/L account...

Long Text ChAc DelI Pstg block Crtn.block Plan.block G/L Acct  
 Accounts Receivable Foreign PURD 101010

**Document Overview - Display**

Doc.Type : ZD ( Customer invoice ) Normal document  
 Doc. Number 91899037 Company Code 250 Fiscal Year 2016  
 Doc. Date 16.06.2016 Posting Date 16.06.2016 Period 06  
 Calculate Tax ☐  
 Ref.Doc. 0000767457  
 Doc. Currency USD

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	01	139892	MUNDIPHARMA NEAR EAS					1.820,80	8/16/17 rebilled on pplp-9999.td
2	50	403000	Foreign Sales		ORA			1.820,80-	

**Document Overview - Display**

Doc.Type : DE ( Customer payment ) Normal document  
 Doc. Number 1400008458 Company Code 250 Fiscal Year 2017  
 Doc. Date 31.08.2017 Posting Date 31.08.2017 Period 08  
 Calculate Tax ☐  
 Ref.Doc. FD WT 8/31/17  
 Doc. Currency USD  
 Doc. Mdr Text 435,840.80 PPLP9999 13989

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	101045	A/R Clrng (NonTrade)					35.840,80	
2	15	139892	MUNDIPHARMA NEAR EAS		GEN			35.840,80-	Overpayment

**Document Overview - Display**

Doc.Type : AB ( Accounting document ) Normal document  
 Doc. Number 100021027 Company Code 250 Fiscal Year 2017  
 Doc. Date 05.09.2017 Posting Date 05.09.2017 Period 09  
 Calculate Tax ☐  
 Ref.Doc. Overall No. 0100021027250 17  
 Doc. Currency USD

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	40	660080	Bank Service Charges	2100250	GEN			25,00	Bank Service Charge
2	17	139892	MUNDIPHARMA NEAR EAS					120,00-	
3	40	102999	Virtual Company		GEN			95,00	

## **Exhibit 2C: Intercompany transfers between Rhodes Pharma and Mundipharma Laboratories GMBH for theophylline**

On October 1, 2011, Rhodes Pharma entered into a supply agreement with Mundipharma Laboratories GMBH for theophylline.

**THIS AGREEMENT** is made the      day of              2011 by and between:

**MUNDIPHARMA LABORATORIES GMBH**, a Swiss company, having its principal place of business at St. Alban-Rheinweg 74, Ch-4020 Basel, Switzerland (the "**Seller**"); and

**RHODES PHARMACEUTICALS L.P.**, a Delaware limited partnership, having an address at 498 Washington Street, Coventry, RI 02816, USA (the "**Buyer**").

WHEREAS the Parties wish to enter into an agreement concerning the supply by the Seller of the Products (as hereinafter defined) to the Buyer on the terms hereinafter set forth.

## Exhibit 2C: Intercompany transfers between Rhodes Pharma and Mundipharma Laboratories GMBH for theophylline

According to the supply agreement, Rhodes Pharma agreed to pay prices listed in Schedule 1 subject to periodic negotiated adjustments.

### Schedule 1

#### Product and Price Listing

#### PART A - 2012

#### MUNDIPHARMA LABORATORIES GMBH

#### PRICE LIST

Mundipharma Laboratories GmbH to Rhodes Pharmaceuticals L.P.

#### United States of America

#### Prices Effective 1st January, 2012

PRODUCT DESCRIPTION		MLG EXW SUPPLY PRICE TO RPLP
		2012
<u>SALES TERMS: EXW (Canada)</u> Theophylline Tablets 400mg 100s Theophylline Tablets 600mg 100s	USD USD	

## Exhibit 2C: Intercompany transfers between Rhodes Pharma and Mundipharma Laboratories GMBH for theophylline

From October 1, 2011 to September 15, 2019, Rhodes Pharma paid Mundipharma Laboratories GMBH \$5.3 million for theophylline.

Year	Quantity	Amount
2012		\$ 212,796
2013		506,934
2014		197,148
2015		407,928
2016		1,535,881
2017		518,260
2018		1,368,630
2019		503,510
Total		\$ 5,251,087